---
document_datetime: 2023-09-21 22:04:53
document_pages: 135
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/omblastys-epar-refusal-public-assessment-report_en.pdf
document_name: omblastys-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 136.0252143
conversion_datetime: 2025-12-24 07:14:09.773313
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 December 2022 EMA/CHMP/3393/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Omblastys

International non-proprietary name: iodine (131I) omburtamab

Procedure No. EMEA/H/C/005499/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                  | Omblastys                                                                                                                                                                                                                                                                  |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                      | Y-mAbs Therapeutics A/S Agern Alle 11 DK-2970 Hoersholm DENMARK                                                                                                                                                                                                            |
| Active substance:                               | Iodine ( 131 I) omburtamab                                                                                                                                                                                                                                                 |
| International Non-proprietary Name/Common Name: | iodine ( 131 I) omburtamab                                                                                                                                                                                                                                                 |
| Pharmaco-therapeutic group (ATC Code):          | other therapeutic radiopharmaceuticals, iodine ( 131 I) compounds (V10XA)                                                                                                                                                                                                  |
| Therapeutic indication(s):                      | Omblastys is indicated for the treatment of central nervous system (CNS)/leptomeningeal (LM) metastasis of neuroblastoma in patients, who have previously received CNS-directed multi-modal therapy for their disease, such as chemotherapy, surgery, or radiation therapy |
| Pharmaceutical form(s):                         | Solution for infusion                                                                                                                                                                                                                                                      |
| Strength(s):                                    | 462.5 MBq/mL                                                                                                                                                                                                                                                               |
| Route(s) of administration:                     | Intracerebroventricular use                                                                                                                                                                                                                                                |
| Packaging:                                      | vial (glass)                                                                                                                                                                                                                                                               |
| Package size(s):                                | 1 vial                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................9                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................9        |                                                                                                          |
| 1.2. Legal basis and dossier content..............................................................................9          |                                                                                                          |
| 1.3. Information on Paediatric requirements...................................................................9              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................9                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................9 |                                                                                                          |
| 1.4.2. New active Substance status...............................................................................9           |                                                                                                          |
| 1.5. Protocol assistance                                                                                                     | .............................................................................................10          |
| 1.6. Steps taken for the assessment of the product.......................................................10                  |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ..............................................................................11                         |
| 2.1. Problem statement                                                                                                       | .............................................................................................11          |
| 2.1.1. Disease or condition.........................................................................................11       |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                          | ..................................................................................................12     |
| 2.1.3. Aetiology and pathogenesis                                                                                            | ..............................................................................12                         |
| 2.1.4. Clinical presentation and diagnosis ....................................................................12            |                                                                                                          |
| 2.1.5. Management...................................................................................................12       |                                                                                                          |
| 2.2. About the product                                                                                                       | ..............................................................................................13         |
| 2.3. Type of Application and aspects on development....................................................13                    |                                                                                                          |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................14     |
| 2.4.1. Introduction....................................................................................................14    |                                                                                                          |
| 2.4.2. Omburtamab mAb Active Substance intermediate................................................14                        |                                                                                                          |
| 2.4.3. Sodium Iodide-131 intermediate                                                                                        | .......................................................................18                                |
| 2.4.4. Omburtamab mAb Finished Product intermediate                                                                          | ................................................19                                                       |
| 2.4.5. ( 131 I) omburtamab Finished Medicinal Product.....................................................21                 |                                                                                                          |
| 2.4.6. Discussion and conclusions on chemical, pharmaceutical and biological                                                 | aspects.......26                                                                                         |
| 2.4.7. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................27                                                                                 |
| 2.4.8. Recommendation(s) for future quality development.............................................27                       |                                                                                                          |
| 2.1. Non-clinical aspects                                                                                                    | ............................................................................................27           |
| 2.1.1. Introduction....................................................................................................27    |                                                                                                          |
| 2.1.2. Pharmacology                                                                                                          | .................................................................................................27      |
| 2.1.3. Pharmacokinetics.............................................................................................31       |                                                                                                          |
| 2.1.4. Toxicology                                                                                                            | ......................................................................................................32 |
| 2.1.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................37                                              |
| 2.1.6. Discussion on non-clinical aspects......................................................................38            |                                                                                                          |
| 2.1.7. Conclusion on the non-clinical aspects................................................................40              |                                                                                                          |
| 2.2. Clinical aspects                                                                                                        | ..................................................................................................40     |
| 2.2.1. Introduction....................................................................................................40    |                                                                                                          |
| 2.2.2. Clinical pharmacology                                                                                                 | ......................................................................................41                 |
| 2.2.3. Discussion on clinical pharmacology...................................................................52              |                                                                                                          |
| 2.2.4. Conclusions on clinical pharmacology.................................................................57               |                                                                                                          |
| 2.2.5. Clinical efficacy                                                                                                     | ...............................................................................................57        |
| Propensity score modelling                                                                                                   | .........................................................................................69              |
| 2.2.6. Discussion on clinical efficacy............................................................................79         |                                                                                                          |

<div style=\"page-break-after: always\"></div>

2.2.7. Conclusions on the clinical efficacy  .....................................................................  83

2.2.8. Clinical safety  ..................................................................................................  83

2.2.9. Discussion on clinical safety  ............................................................................  117

2.2.10. Conclusions on the clinical safety  ...................................................................  121

2.3. Risk Management Plan ......................................................................................  121

2.3.1. Safety concerns  .............................................................................................  121

2.3.2. Pharmacovigilance plan  ..................................................................................  122

2.3.3. Risk minimisation measures  ............................................................................  123

2.3.4. Conclusion  ....................................................................................................  127

2.4. Pharmacovigilance  ............................................................................................  127

2.4.1. Pharmacovigilance system  ..............................................................................  127

2.4.2. Periodic Safety Update Reports submission requirements ................................... 127

2.5. Product information ..........................................................................................  127

2.5.1. User consultation  ...........................................................................................  127

2.5.2. Labelling exemptions .....................................................................................  127

2.5.3. Additional monitoring  .....................................................................................  128

3. Benefit-Risk Balance............................................................................  129

3.1. Therapeutic Context .........................................................................................  129

3.1.1. Disease or condition  .......................................................................................  129

3.1.2. Available therapies and unmet medical need  ..................................................... 129

3.1.3. Main clinical studies .......................................................................................  129

3.2. Favourable effects ............................................................................................  130

3.3. Uncertainties and limitations about favourable effects  ........................................... 130

3.4. Unfavourable effects  .........................................................................................  131

3.5. Uncertainties and limitations about unfavourable effects ....................................... 131

3.6. EFFECTS Table  .................................................................................................  132

3.7. Benefit-risk assessment and discussion  ............................................................... 133

3.7.1. Importance of favourable and unfavourable effects  ............................................ 133

3.7.2. Balance of benefits and risks  ...........................................................................  134

3.7.3. Additional considerations on the benefit-risk balance ......................................... 134

3.8. Conclusions .....................................................................................................  134

4. Recommendations ...............................................................................  134

<div style=\"page-break-after: always\"></div>

## List of abbreviations

%ID/g

percent injected dose per gram tissue

131 I

iodine- 131

131 I-omburtamab

iodine- 131 -radiolabeled omburtamab

8H9

laboratory code for omburtamab

AE

adverse event

AESI

adverse events of special interest

ALT

alanine aminotransferase

AM

alveolar macrophages

ASCT

autologous stem cell transplantation

AST

aspartate aminotransferase

AUC

area under the curve

AUC0- ∞

area under the curve from Time 0 to infinity

AUCdata

area under the curve computed using trapezoidal integration of imaging

measurements

AUCtail

area under the curve from the last time point onward

BSA

bovine serum albumin

CD

cluster of differentiation

CDR

complementarity-determining region

CED

convection-enhanced delivery

CE-SDS

capillary electrophoresis sodium dodecyl sulphate polyacrylamide gel

electrophoresis

CFU

colony forming unit

cIEF

capillary isoelectric focusing

CGCCR

Central German Childhood Cancer Registry

CI

confidence interval

CL

clearance

Cmax

maximum concentration

CNS

central nervous system

CNS/LM

central nervous system/leptomeningeal

CPP

critical process parameters

CPV

continued process verification

CQA

critical quality attribute

CSF

cerebrospinal fluid

CSR

clinical study report

CTCAE

common terminology criteria for adverse events

CV%

percent coefficient of variance

Cyno

cynomolgus monkey

DIPG

diffuse intrinsic pontine glioma

DNA

deoxyribonucleic acid

DP

drug product

DPI

drug product intermediate

DS

drug substance

DSRCT

desmoplastic small round cell tumour

E

epithelium

EBV

Epstein Barr virus

EDC

electronic data capture

ELISA

enzyme linked immunosorbent assay

EOS

end of synthesis

EU

endotoxin unit

FAS

full analysis set

FDA

Food and Drug Administration

FEM

Erlenmeyer flasks

G

glial cells

GLP

good laboratory practice

GGT

γ -glutamyltransferase

GMP

good manufacturing practice

Grade 3+

Grade 3 or higher

HC

heavy chain

HCP

host cell protein

HDPE

high density polyethylene

HMW

high molecular weight

HTB119

small cell lung cancer cell line

HTB82

human rhabdomyosarcoma cell line

ICF

informed consent form

IgG

immunoglobulin G

ICH

International Council for Harmonisation

ID

identification

INDA

investigational new drug application

IHC

immunohistochemistry

IND

investigational new drug

INN

international non-proprietary name

INSS

international neuroblastoma staging system

IPC

in process controls

IRB

Institutional Review Board

IRB/PB

Institutional Review Board and Privacy Board

ISE

integrated summary of efficacy

i.t.

intrathecal

i.v.

intravenous

JPA

juvenile pilocytic astrocytoma

ka

association constant

kd

dissociation constant

KD

equilibrium dissociation constant

KM

Kaplan-Meier

LAL

limulus amebocyte lysate

LC

Leydig cells/light chain

LM

leptomeningeal

LMW

low molecular weight

MAA

marketing authorisation application

max

maximum

MCB

master cell bank

MedDRA

Medical Dictionary for Regulatory Activities

min

minimum

MRI

magnetic resonance imaging

MRT

mean residence time

MSK/MSKCC

Memorial Sloan Kettering Cancer Center

MTD

maximum tolerated dose

mu8H9

murine 8H9 monoclonal antibody

MYCN v-myc

myelocytomatosis viral related oncogene

NA

not applicable

NB

neuroblastoma

NC

not collected

NCR

non-critical range

NE

not estimable

NF

national formulary

NHP

nonhuman primate

NLT

not less than

NMB7

human neuroblastoma cell line

NNAS

non-neuroblastoma analysis set

<div style=\"page-break-after: always\"></div>

NNB

non-neuroblastoma

NOR

normal operating range

NT

not tested

OD280

optical density at 280 nm

OLINDA

organ level internal dose assessment

OS

overall survival

PAR

proven acceptable range

PBMC

peripheral blood mononuclear cell

PBS

phosphate-buffered saline

PETG

polyethylene terephthalate glycol

PFS

progression-free survival

Ph. Eur. E

European Pharmacopoeia

Pilocytic Ast

juvenile pilocytic astrocytoma

PK

pharmacokinetics

PI

principal investigator

PNET

primitive neuroectoderm

pPCS

preliminary process control strategy

PPQ

process performance qualification

psi

pounds per square inch

PUP

Protein A ProSep® Ultra Plus

PVDF

polyvinylidene fluoride

qPCR

quantitative polymerase change reaction

QTPP

quality target product profile

RD

radio detector signal from gamma rays of  131 -iodine

Res sd

residual standard deviation of curve fit

rHSA

recombinant human serum albumin

RIT

radioimmunotherapy

Rmax

maximum binding

RMIP

radiochemistry and molecular imaging probes

RMS

rhabdomyosarcoma

ROA

route of administration

ROI

region of interest

RRT

relative retention time

RT

room temperature

RU

response units

S

stroma

SAE

serious adverse event

SAF

safety analysis population

SAL

sterility assurance level

SAP

statistical analysis plan

SD

standard deviation

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

SE-HPLC

size exclusion high performance liquid chromatography

SE-UPLC

size exclusion ultra-performance liquid chromatography

SMQ

standardized MedDRA queries

SOC

system organ class

SPECT

single-photon emission computed tomography

SPR

surface plasmon resonance

t1/2

half-life

t1/2(α)

alpha half-life (distributive half-life)

t1/2(β)

beta half-life (terminal half-life)

TAMC

total aerobic microbial count

TBD

to be determined

TBR

to be reported

TC

total aerobic microbial count

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| TEAE   | treatment-emergent adverse event   |
|--------|------------------------------------|
| TLC    | thin layer chromatography          |
| Tmax   | time of maximum concentration      |
| TOC    | time of dose calibration           |
| TYMC   | total aerobic microbial count      |
| U2OS   | osteosarcoma cell line             |
| U87    | human glioblastoma cell line       |
| ULN    | upper limit of normal              |
| USAN   | United States adopted name         |
| USP    | United States Pharmacopoeia        |
| UV     | ultraviolet                        |
| WBC    | white blood cell                   |
| Vd     | volume of distribution             |
| Y-mAbs | Y-mAbs Therapeutics A/S            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Y-mAbs Therapeutics A/S submitted on 27 April 2021 an application for marketing authorisation to the European Medicines Agency (EMA) for Omblastys, through the centralised procedure falling within the Article 3(1) and point 4 of Annex I of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 November 2019.

Omblastys, was designated as an orphan medicinal product EU/3/17/1839 on 27 February 2017 in the following condition: Treatment of neuroblastoma.

The applicant applied for the following indication:

Omblastys is indicated for the treatment of neuroblastoma with central nervous system (CNS)/leptomeningeal (LM) metastasis.

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0322/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0322/2020 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## 1.4.2. New active substance status

The applicant requested the active substance iodine ( 131 I) omburtamab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.5. Protocol assistance

The applicant received the following protocol assistance on the development relevant for the indication subject to the present application:

| Date        | Reference                        | SAWP co-ordinators                                 |
|-------------|----------------------------------|----------------------------------------------------|
| 18 May 2017 | EMEA/H/SA/3528/1/2017/PA/PED/III | Prof. Brigitte Blöchl-Daum and Dr Alexandre Moreau |

The protocol assistance pertained to the following clinical aspects:

- Adequacy of the historical data to demonstrate unmet medical need and to establish the historical rate of survival in paediatric patients with neuroblastoma CNS/LM metastasis.
- Acceptability of the historical data to serve as valid control for comparison with the  131 I-mu8H9 treated patients.
- Acceptability of the proposed analyses to provide clinical evidence that  131 I-mu8H9 provides substantial improvement over available therapies for the intended patient population.
- Acceptability of the proposed multicentre phase II clinical study design, in particular with regards to the primary and secondary endpoints, inclusion and exclusion criteria, criteria for assessment of efficacy, safety measures and the proposed evaluation of dosimetry.
- Acceptability of the sample size, the appropriateness of the statistical methods and the success criteria for effectiveness for the phase II study.
- Sufficiency of the existing  131 I-mu8H9 clinical data from study 03-133 together with the planned phase II study 101 to support a MAA.
- Proposed level of evidence at the time of the initial MAA versus data to be submitted as a post approval commitment.
- Orphan similarity.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Jan Mueller-Berghaus

Co-Rapporteur:  John Joseph Borg

| The application was received by the EMA on                                                              | 27 April 2021     |
|---------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                | 20 May 2021       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on            | 9 August 2021     |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on         | 23 August 2021    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on            | 19 August 2021    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                | 2 September 2021  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on | 16 September 2021 |

<div style=\"page-break-after: always\"></div>

| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                       | 22 April 2022     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                           | 01 June 2022      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                  | 10 June 2022      |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                   | 23 June 2022      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                           | 13 September 2022 |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                  | 28 September 2022 |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                   | 13 October 2022   |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                           | 18 October 2022   |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                   | 08 November 2022  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a marketing authorisation to Omblastys on | 15 December 2022  |
| The CHMP adopted a report on similarity of Omblastys with Qarziba on                                                                                                                      | 15 December 2022  |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product                                                    | 15 December 2022  |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Neuroblastoma (NB) is a rare paediatric cancer and is the most common solid extra-cranial solid tumour cancer in children. High-risk neuroblastoma is a life-threatening disease that is associated with poor long-term survival. For high-risk patients, 5-year overall survival (OS) rates have improved during the last two decades but are still below 50% (Pinto et al, 2015).

<div style=\"page-break-after: always\"></div>

Neuroblastoma with CNS/LM metastasis is a neuroblastoma, that at initial staging or at relapse, has metastasised to the brain parenchyma and/or the LM, excluding tumours localised to the skull bone.

## 2.1.2. Epidemiology

Neuroblastoma represents about 10% of solid tumours in infants and children under the age of 15 with an annual incidence of about 1/70.000 in children in this class of age (orphanet reference). It is the third most common childhood cancer, after leukaemia and brain tumours, and is the most common solid extracranial tumour in children. Ninety percent of NB is found in children younger than 5 years of age (London, 2005; American Cancer Society, 2021). The median age at diagnosis is 17.3 months, and 40 percent of patients are diagnosed before one year of age. It is rare in people over the age of 10 years.

The  population-based  median  annual  age-standardised  incidence  rate  of  neuroblastoma  per  million children per year in Germany between 1980 and 2015 was 13.2 per million (Berthold et al, 2017). In the  United  States  (US),  800  new  cases  of  neuroblastoma  are  reported  per  year  (American  Cancer Society, 2021).

## 2.1.3. Aetiology and pathogenesis

Little  is  known  about  the events that predispose to the development of neuroblastoma. Certain risk factors  are  associated  with  a  worse  prognosis;  these  include  v-myc  myelocytomatosis  viral  related oncogene (MYCN) amplification, and &gt;18 months of age at diagnosis.

## 2.1.4. Clinical presentation and diagnosis

The final diagnosis of neuroblastoma is based on pathology (tumour biopsy or tumour cytology combined with increased levels of urinary catecholamine metabolites) (Brodeur, 1993). The clinical presentation of CNS/LM neuroblastoma is dependent on the location and nature of the lesion. The diagnosis of CNS/LM neuroblastoma is based on clinical symptoms and imaging.

## 2.1.5. Management

## Treatment options for neuroblastoma with CNS/LM metastasis

Current surgery and radiotherapy techniques for newly diagnosed patients, in conjunction with induction chemotherapy, have reduced the risk of local relapse. However, refractory, or recurrent disease occurs in most patients with high-risk neuroblastoma, and CNS/LM metastasis primarily occurs in the relapsed or recurrent setting (Kramer et al, 2001; Matthay et al, 2003). Conventional systemic treatment for newly diagnosed patients does not adequately prevent or treat the CNS/LM metastasis. Additionally, toxicity limits of high-dose chemotherapy appear to have been reached without further clinical benefit (Modak and Cheung, 2010).

The apparent increase in CNS/LM metastasis that has been observed is possibly related to the better treatment success for the primary disease. It is hypothesised that current treatments for the primary disease are not sufficiently treating micro-metastasis to the CNS. Therefore, the experience with this type of disease manifestation is also limited, since prior to the effective treatment of primary disease patients died by this 'competing risk'.

Various treatment combinations comprise one or more of the following standard options for metastatic CNS/LM neuroblastoma, all with the aim of reducing symptoms, but with modest chance of cure:

<div style=\"page-break-after: always\"></div>

- -Surgical  debulking  of  tumour  when  feasible  prior  to  irradiation,  to  reduce  symptoms, oedema, and haemorrhage, or to correct cerebrospinal fluid (CSF) flow.
- -Focal,  whole  brain  irradiation,  or  craniospinal  irradiation  (where  feasible)  to  alleviate symptoms, obtain disease control, and correct CSF flow in cases of obstruction.
- -Systemic combination chemotherapy (e.g., irinotecan plus temozolomide).
- -Myeloablative therapy and stem cell transplantation.

Data obtained from the Central German Childhood Cancer Registry (CGCCR) which include the majority of neuroblastoma patients enrolled in clinical trials in Germany, show that the treatment modalities for CNS/LM neuroblastoma are not uniform, even on a nationwide level in Germany. While most patients in Germany have received autologous stem cell transplantation, and radiation, around half of the patients have received chemotherapy, and less than that immunotherapy. Irrespective of treatment combinations used, data show only limited effects of current treatments (Kramer et al, 2001; Matthay et al, 2003; Berthold et al, 2017).

## Unmet medical need

With specific treatments for neuroblastoma with CNS/LM metastasis yet to be approved, an area of high unmet medical need persists for patients with this very rare and life-threatening disease.

## 2.2. About the product

Y-mAbs Therapeutics A/S (Y-mAbs) has developed ( 131 I) omburtamab which is proposed by the company for the following indication:

Omburtamab  is indicated for the treatment of neuroblastoma with central nervous system (CNS)/leptomeningeal (LM) metastasis.

Other  names  historically  used  for  the  drug  product  include  burtomab,  mu8H9,  8H9,  and  131 I-8H9. Omburtamab is a murine IgG1κ monoclonal antibody (mAb) secreted by a hybridoma cell line issued from the fusion of Balb/C splenic lymphocytes and SP/2-0 myeloma cells. The secreted mAb recognizes a unique cell membrane neuroblastoma antigen 4Ig-B7-H3 (CD276) that is expressed on a wide range of paediatric and adult solid tumours and expressed as well on CNS/LM neuroblastoma tumour cells. The conjugated iodine-131 emits radiation, resulting in nearby tumour cell DNA damage and cell death. Memorial Sloan Kettering Cancer Center (MSK) initiated the developed of this radioimmunotherapy in 2001. The rights to the commercial development of omburtamab were licensed to Y-mAbs in 2015.

The nonclinical testing of  (131 I) omburtamab relies on published data from studies conducted early in its development at Memorial Sloan Kettering Cancer Center (MSK) (New York, New York). Clinical evidence is derived from patients with paediatric neuroblastoma with CNS/LM metastasis during a single-site trial conducted at MSK (Trial 03-133). This is supplemented by data from an international, multisite clinical trial sponsored by Y-mAbs (Trial 101).

## 2.3. Type of application and aspects on development

Y-mAbs requested CHMP protocol assistance in 2017 for its orphan programme of omburtamab to seek advice related to the clinical data necessary to support a marketing authorisation application (MAA) for ( 131 I) omburtamab for the treatment of relapsed neuroblastoma with CNS/LM metastasis. Additionally, Y-mAbs  requested  to  obtain  feedback  on  specific  clinical  questions  and  endpoints  to  demonstrate significant benefit in relation to the orphan drug designation.

<div style=\"page-break-after: always\"></div>

The feedback from CHMP was considered when designing the Phase 2/3 Trial 101. Furthermore, to accommodate CHMP's comments, the Paediatric Investigational Plan (PIP) initially submitted to EMA in 2017, included a detailed description of how external control data (especially historic control data from the  German  registry)  would  be  defined  to  ensure  adequately  selected  data  as  comparison  for establishment of clinical evidence. The PIP also included a description of the measures to fulfil for the interim analysis of Trial 101 to be included as part of an MAA. The initial PIP decision was granted in 2019. A modification to the PIP was approved in August 2020 and a PIP compliance check was adopted in October 2020.

In  preparation  for  the  MAA  submission in the  EU,  both  an  EMA  MAA  pre-submission  meeting  and a Rapporteur/Co-Rapporteur meeting were conducted during 2020 to discuss the format and content of the planned application.

## 2.4. Quality aspects

## 2.4.1. Introduction

Iodine-131 omburtamab is a radiolabelled murine monoclonal antibody (mAb) that recognises and binds selectively to the B7-H3 antigen expressed on CNS/LM neuroblastoma tumour cells. The iodine-131 emits beta radiation, resulting in DNA damage and tumour cell death.

Consequently, ( 131 I) omburtamab targets and kills the tumour with the combination of antibody binding affinity and beta decay from the radioisotope.

The  manufacturing  of  the  active  substance  ( 131 I)  omburtamab  is  achieved  by  radiolabelling  of omburtamab active substance intermediate using sodium iodide- 131  active substance intermediate.  An additional section describes the finished product intermediate which precedes the radiolabelling step to the finished product

The omburtamab finished product is provided in a sterile, 10 mL, borosilicate, clear, type I glass vial, sealed with an n-butyl rubber septum and secured by an aluminium crimp seal. The strength is defined as 462.5 MBq/mL at the time of administration as a solution for infusion.

## 2.4.2. Omburtamab mAb active substance intermediate

## 2.4.2.1. General information

Omburtamab is a murine IgG1κ monoclonal antibody (mAb) secreted by a hybridoma cell line issued from the fusion of Balb/C splenic lymphocytes and SP/2-0 myeloma cells. It binds to the glycoprotein antigen, 4Ig-B7-H3.

Molecular mass has been determined by intact mass spectrometry to confirm the theoretical molecular mass and the presence of lysine truncated- and glycoform variants. The most abundant variant contains one heavy chain C-terminal lysine and two N-glycans of the G0F type.

## 2.4.2.1. Manufacture, characterisation and process controls

## Manufacturing process and control of critical steps

Omburtamab active substance (AS) intermediate is manufactured at an EU based Contract Manufacturer. Satisfactory demonstration of GMP compliance is provided.

<div style=\"page-break-after: always\"></div>

Omburtamab active substance is a murine monoclonal antibody (IgG1κ mAb) secreted by a hybrid oma cell line SP2/0. A cell culture process including cell expansion and production in a bioreactor with a fedbatch process resulting in a single crude harvest. For the production phase the culture is controlled by temperature,  dissolved  oxygen  and  pH.    Nutrient  supplement  solutions  are  added  to  the  culture  at defined intervals. Production is stopped and harvested at a specified time or if cell viability drops below 50%. The population doubling level (PDL) should not exceed 40 from thawing of the WCB at the end of the production in bioreactor. The purification process starts with the removal of cells and cell debris from the harvested culture by depth filtration. The harvest material is clarified using depth filter. To obtain purified omburtamab active substance solution, all chromatography and filtration steps are performed at room temperature (15°C - 25°C). The purification process consists of the following steps: Protein A affinity  chromatography,  viral inactivation at low pH, anion exchange (AEX) chromatography, cation exchange  (CEX)  chromatography,  Viral  reduction  filtration,  and  tangential  flow  filtration  (TFF).  The omburtamab active substance is microfiltered (0.5 μm/0.2 μm) and stored in polyethylene terephthalate glycol (PETG) bottles. In-process controls (IPCs) performed after each of the purification steps allow the monitoring  of  the  performance  of  each  step  with  respect  to  purity,  yield  and  product  integrity.  No reprocessing is permitted but re-filtration may only be performed if the filter integrity test has failed. Overall, process description is of decent quality. The final control strategy is now provided, and the dossier updated accordingly. This control strategy definite (and not potential) classifications. Critical steps are identified and controlled with specific IPC. Based on criticality, IPCs are either controlled viaacceptance  criteria  (AC),  IPC  limits  and  monitoring.  If  an  acceptance  criterion  is  not  met,  after confirmation of the out-of-specification (OOS), the batch will be rejected. An IPC limit excursion results in an investigation.

The control strategy was considered to be preliminary, and this was raised as a major objection.  The final  commercial  controls  of  critical  steps  and  intermediates  were  provided  following  completion  of validation activities.

## Control of materials

All  raw materials used for the manufacturing process of omburtamab active substance are received, identified,  sampled,  quarantined,  tested,  labelled  and  released  according  to  established  written procedures. All raw materials used in the manufacturing process are free of animal-derived components. Lists of compendial and non-compendial materials used in the upstream process (USP) and downstream process (DSP) are provided. Suppliers of resins and filters are indicated. Chromatographic resins and filters are single use.

Omburtamab is a murine IgG1κ monoclonal antibody (mAb) secreted by a hybridoma cell line issued from  the  fusion  of  Balb/C  splenic  lymphocytes  and  SP/2-0  myeloma  cells.  The  cell  banking  system consists currently of a master cell bank (MCB) only.

An extended cell bank (ExCB) was generated covering a population doubling level (PDL) of +10.8 beyond the end of production and 40.4 from MCB-1 thawing. Both cell banks have been tested for the absence of  adventitious  agents  according  to  (ICH  Q5A(R1).  The  applicant  states  that  MCB-1  and  ExCB-1.1 underwent isoenzyme analysis and phenotypic characterisation to confirm identity, purity and stability of the cell line, according to ICH Q5B and ICH Q5D. The qualification of a future working cell bank (WCB) will be covered by a comparability study with the MCB-1. A new ExCB will be performed on a bioreactor run  produced  from  one  WCB  vial  to  allow  WCB  &amp;  ExCB  viral  and  phenotypic  characterisations.  The protocol for characterisation of future working and extended cell banks is acceptable. The maximum cell culture time is based on Population Doubling Level, and it has been classified as CPP.

<div style=\"page-break-after: always\"></div>

## Process validation and/or evaluation

The manufacturing and validation approach has been conducted for the omburtamab active substance. The preliminary control strategy was built on process experience throughout development (from small scale development studies to clinical manufacturing) and experience with similar processes. Operational and performance parameters were classified into potential critical and noncritical parameters in a risk assessment prior to process validation at full-scale. No formal process characterisation studies were performed. The control strategy is based on critical or key process parameters controls and associated in-process controls. Process validation for omburtamab active substance includes the identification and classification of (critical) quality attributes (CQAs), process risk assessment and a subsequent control strategy. For process verification the applicant proposes stage process validation, which, in principle, is acceptable. Data from process performance qualification (PPQ) runs: PPQ1, PPQ2, and PPQ3 have been included in the current submission. With regard to staging, the process validation the applicant refers to small scale model results and/or prior knowledge, The applicant provided details on the process risk assessment approach, e.g., definition of risk priority number (RPN) threshold. Results of the small-scale studies  (process  characterisation  studies)  supporting  the process  risk  assessment  are provided.  The impact of investigated PP on certain CQAs is e shown. An overview about omburtamab critical quality attributes (CQAs) and the associated justification for the classification has been provided. The panel of CQAs listed is considered sufficient. Characteristics of mAbs such as low molecular weight (LMW) species, fragments, charged variants, glycosylated species were considered in the assessment.

To be able to demonstrate the fill homogeneity into the bottles, samples are taken before the first bottle, in the middle of the repartition and before the last bottle. The content by optical density (OD) and the high molecular weight (HMW) content by size exclusion high performance liquid chromatography (SEHPLC) are performed respectively to confirm the homogeneity of the omburtamab active substance. The downstream process holding times were evaluated for their impact on stability indicating parameters at small scale during consistency to define the holding time for the production scale. Re-filtration studies on omburtamab active substance filtration will be formally evaluated to demonstrate the absence of impact on product quality in case the filtration step would be repeated. These studies were performed at  laboratory  scale  using  representative  parameters  of  the  production  scale.  Omburtamab  active substance is shipped frozen (&lt;-60°C) as per established shipping validation protocol. The omburtamab manufacturing process is shown to effectively and consistently remove process-related impurities (HCP, DNA, protein A, Poloxamer, antifoam) to acceptable safety levels.

## Manufacturing process development

Development of the hybridoma cell line has been described leading to clinical and commercial scale manufacturing process.  Characterisation and process controls, with comparability determined through the scale up activities during development have been described.

## Characterisation

Omburtamab has been characterised by suitable analytical methods. The structure of the antibody has been  confirmed.  Post-translational  modifications  are  sufficiently  characterised.  The  N-glycosylation profile  indicates  that  the  most  abundant  N-glycan  species  observed  is  G0F,  followed  by  G1F. Aglycosylated N-glycans (G0) is also present Omburtamab is a murine IgG1κ monoclonal antibody (mAb) secreted by a hybridoma cell line issued from the fusion of Balb/C splenic lymphocytes and SP/2-0 myeloma cells. The levels of HMW species and fragments are considered acceptable and are controlled by specifications. Biological activity was evaluated by binding activity of omburtamab to B7-H3. The biological characterisation of omburtamab is considered sufficient. It is noted that the intended mode of action  (MoA)  of  Iodine-131  omburtamab  is  that  the  radiolabelled  antibody  recognises  and  binds selectively to the B7-H3 antigen expressed on CNS/LM neuroblastoma tumour cells and the iodine-131 emits radiation, resulting in DNA damage and tumour cell death. Omb urtamab represents a full IgG1κ

<div style=\"page-break-after: always\"></div>

monoclonal antibody and therefore characterisation of all biological properties including binding to Fcgamma receptors, C1Q and Fc-mediated effector functions such as ADCC, ADCP, CDC is expected. With regard  to  ADCC  in  vitro  tumour  killing  ADCC  properties  of  the  five  IgG  antibody  constructs  were investigated  using  neuroblastoma  LAN-1  tumour  cells  as  targets  and  human  peripheral  blood mononuclear  cells  as  effector  cells.  The  murine  construct  representing  omburtamab  had  no  ADCC function with human peripheral blood mononuclear cells. Characterisation of effector function activity was raised as a major objection; the characterisation has been satisfactorily demonstrated.

Process-related impurities such as host cell protein (HCP), host cell DNA (HCD), Protein A, Poloxamer 188, and anti-foam are removed by the process to acceptable limits. HCP, HCD, and ProtA are further controlled by specifications for which the limit for HCP should be tightened. Regarding extractable and leachables, the drug substance container was identified with the highest risk. An extractable study has been performed on the drug substance container using the formulation buffer. No organic extractables above analytical evaluation threshold and 3-fold above blank were detected in the extracts of the drug substance container

## 2.4.2.2. Specification

The release and shelf-life specifications for omburtamab AS include general tests, identity, concentration, potency, purity and impurities. Safety tests are controlled only at AS release.

Specifications cover the relevant Quality Attributes (QA) according to the characterisation.

The  Acceptance  Criteria  were  substantially  tightened  as  requested:  potency  by  surface  plasmon resonance, SE-HPLC, capillary electrophoresis sodium dodecyl sulfate (CE-SDS), HCP, and Bioburden. Capillary isolelectric focusing (cIEF) is implemented as purity parameter and reported with numerical acceptance criteria. Stability specification acceptance criteria were aligned with the revised release.

## Batch analysis

The  batch  release  results  for  omburtamab  drug  substance  batches  were  produced  with  the  to-bemarketed manufacturing process.  The data demonstrate that the acceptance criteria were met at the time of definition.

## Reference materials

One interim reference standard and one primary reference standard have been established since the transfer of the omburtamab active substance manufacturing process. A working reference standard will be established from active substance and qualified against the primary reference standard. A two-tiered reference standard system will be implemented.

## Container closure

Omburtamab  active  substance  is  filled  in  non-pyrogenic  PETG  bottles  closed  with  high-density polyethylene (HDPE) screw caps. Materials are in compliance with relevant guidance documents mainly USP requirement. Considering the scattered guidance provided in European guidance documents, this is considered acceptable.

## 2.4.2.3. Stability

A 24-month shelf life is proposed for omburtamab active substance when stored at the recommended storage condition (-70°C ± 10°C). The batches placed on stability are considered representative. The proposed shelf life is based on 24 months long-term stability data at recommended storage conditions

<div style=\"page-break-after: always\"></div>

and accelerated stability data at 5°C± 3°C for 12 months and stressed stability data at 25°C ± 2°C for 6 months. Overall, the data indicate a good stability profile of omburtamab.

## 2.4.3. Sodium Iodide-131 intermediate

The  applicant  submitted  an  ASMF  (open  part)  of  the  radionuclide  precursor  sodium  [ 131 I]iodide  for radiolabelling.  The  restricted  part  of  the  ASMF  for  the  radionuclide  precursor sodium  [ 131 I]iodide  for radiolabelling is separately submitted by the ASMF holder.:

The ASMF open part covered the following areas: General information, Manufacture, Characterisation, Controls, Reference Standards or Materials, Container Closure System, Stability.  The ASMF restricted part covered additional details on Characterisation, Control and Mnaufacture.

Iodine-131 is obtained by fission of uranium-235.  The purification process ends with the trapping of iodine (I2) in NaOH solution. This trapping occurs by dismutation and gives two oxidation stages (-1 for I -  and +5 for IO 3- ). However, the radiolysis phenomenon due to the high activity of the mother solution results in the reduction of IO 3-  to I -  (generally more than 99%). The stock solution is sodium iodide (NaI) in NaOH aqueous solution.

The oxidation stage [-1] of the iodine in the stock solution is confirmed by the routine radiochemical purity measurements, which indicate that more than 99% of the radioactivity is associated with the 'iodide' chemical form.

The  fission  of  235 U  yields  a  large  number  of  isotopes  which  form  decay  chains.  During  the  process validation,  only  one  other  isotope  of  iodine  was  observed  ( 133 I)  meaning  that  iodine  trapping  and distillation are sufficient to remove all the other radio-contaminants.

Sodium iodide ( 131 I) solution for radiolabelling is only dedicated for the synthesis (radiolabelling) of a molecule to obtain a radio-iodinated clinically relevant active substance.  Hence, the sodium iodide ( 131 I) solution for radiolabelling is not dedicated for use as an active substance in the manufacturing of a finished medicinal product as for e. g. sodium iodide ( 131 I) capsules.

With  the  radionuclide  precursor  sodium  iodide  ( 131 I)  solution  for  radiolabelling,  this  ASMF  does  not describe an active substance but an intermediate dedicated for synthesis (radiolabelling) to obtain a clinically relevant active substance. The specification of the sodium iodide ( 131 I) solution for radiolabelling has more the character of a radiochemical substance than of a pharmaceutical substance. In this context it  is  also  necessary  to  recognise  that  an  ASMF  is  typically  only  used  for  clinically  relevant  active substances and not for intermediates as in this case. However, it was agreed that the detailed description of the manufacturing of a radionuclide using methods of nuclear physics and nuclear chemistry can be provided by ASMF in the marketing authorisation dossier.

With regard to the presented information about the manufacturing of sodium iodide ( 131 I) solution for radiolabelling no concerns are raised. The reason for this is on one side the fact that the sodium iodide ( 131 I) will be further processed to obtain the clinically relevant active substance and is from a chemical point of view only an intermediate in a synthesis sequence and on the other side it is recognised that sodium iodide  ( 131 I)  has  manufactured  for  clinical  use  for  more  than  50  years,  typically  for  thyroid therapy, and a wide practical knowledge about how to manufacture and handle sodium iodide ( 131 I) is widely  available.  Furthermore,  the  pharmacopoeia  provides  for  sodium  iodide  ( 131 I)  solution  for radiolabelling a monograph and the sodium iodide ( 131 I) solution for radiolabelling is in compliance with this monograph.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Omburtamab mAb finished product intermediate

## 2.4.4.1. Description of the product and pharmaceutical development

Manufacture  and  partial  release  testing  of  omburtamab  finished  product  intermediate  is  done  by  a fill/finish  Contract  Manufacturer  (CMO)  in  EU.  Additional  release  testing  is  performed  by  analytical Contract Research Organisations  in EU and Switzerland. Satisfactory demonstration of GMP compliance is provided.

The  omburtamab  finished  product  intermediate  is  available  as  a  solution  ready  for  radio  labelling composed of omburtamab active substance, citric acid/sodium phosphate dibasic buffer and water for injection with a pH of 4.2 ± 0.2. No novel excipients are used.

Omburtamab  is  formulated  into  the  formulation  buffer  at  the  TFF  step  in  the  omburtamab  active substance manufacturing process and is diluted in the omburtamab finished product intermediate fill process (with formulation buffer). All omburtamab finished product intermediate batches manufactured, have been made by dilution of omburtamab active substance, filtration and filling of omburtamab finished product intermediate into Type 1 glass vials without any modification. The batch size has varied according to clinical needs.

The omburtamab finished product intermediate batches manufactured on behalf of Y-mAbs have been filled in vials at the CMO in various batch sizes. This CMO is the chosen manufacturer for commercial supply of omburtamab finished product intermediate.

Compatibility  studies  were  performed  at  the  CMO  to  assess  any  potential  incompatibility  of  the omburtamab finished product intermediate solution with the following material: polyvinylidene fluoride filters (PVDF filters); stainless steel; ultra low density polyethylene (ULDPE bag); Platinum cured silicon tubing.  No  significant  changes  were  seen  between  the  control  sample  and  the  samples  in  the compatibility study. In order to confirm the suitability of the omburtamab finished product intermediate container closure system a preliminary extractable and leachable assessment is provided for the glass vial and the rubber stopper. This includes the patient population and dosing regimen and the fact that the vial is made of Type I borosilicate glass and complies with the requirements of Directive 94/62/EC and Ph. Eur. 3.2.1. No basic qualification or specific extractables data are obtained from the supplier of the rubber stoppers but a product-specific extractable study was executed on the final vial and stopper (see below container closure system section).

The omburtamab finished product intermediate contains no preservatives and is manufactured using an aseptic  process  including  sterilisation  by  filtration.  In-process  controls  have  been  introduced  to  the manufacturing process to demonstrate the capability of the bioburden reducing steps. In addition, media fills have been executed to demonstrate the aseptic processing capability.

## 2.4.4.2. Manufacture of the product and process controls

The manufacturing process for omburtamab finished product intermediate includes thawing and dilution of the omburtamab active substance, mixing, followed by aseptic fill finish into glass vials. The vials are 100% visually inspected for product, particulate matter, closure and container defects. Omburtamab finished product intermediate is shipped frozen (-25°C to -15°C) CMO to warehouse and from warehouse to the designated radiolabelling facility.

The control strategy for the omburtamab finished product intermediate manufacturing process includes numerous  process  controls,  which  are  classified  as  CPP  or  non-CPP.  The  CPPs  defined  for  the  Ab intermediate finished product manufacturing process are considered adequately justified. The majority

<div style=\"page-break-after: always\"></div>

of CPPs is controlled by master batch record instructions. Process sampling points for finished product intermediate testing are indicated.

Periodical revalidation of the aseptic filling line is performed by executing a media fill worst-case process twice per year. Data for the last three worst-case media fill batches covering the omburtamab finished product intermediate process were presented. No contaminated units were observed in the media fill processes.  The  shipment  is  operated  by  an  international  shipping  company  who  has  completed  a performance  qualification  on  mock  finished  product  intermediate  material.  The  mock  shipment  was performed in a warm period of the year as a worst-case scenario and the temperature internal and external  of  the  shipping  container  were  monitored  during  the  shipment.  The  data  indicate  that  the shipping container maintains a temperature in the range of -25°C to -15°C during a shipment.

Process performance and control was demonstrated through three successful consecutive batches of omburtamab finished product intermediate. For the PPQ batches, all results conformed to the predefined acceptance  criteria.  No  deviations  occurred.  A  summary  of  in-process  hold  times  at  15°C  -  25°C observed during process performance qualification is provided.

Excipients are added during the omburtamab active substance manufacturing process and during dilution with formulation buffer in the omburtamab finished product intermediate process. All listed excipients are  of  compendial  degree.  There  are  no  novel  excipients  in  the  omburtamab  finished  product intermediate. No excipients of human or animal origin are used in the manufacture of omburtamab finished product intermediate. According to the applicant the suppliers certify that the excipients are manufactured without the use of raw materials of animal origin and thus pose no risk of TSE.

## 2.4.4.3. Product specification

Five finished product intermediate batches were produced at the fill / finish CMO.

The release and shelf life specifications for omburtamab finished product intermediate include general tests, identity, concentration, potency, purity, impurities and microbial safety tests. The specifications for the finished product intermediate further include tests for visible and sub-visible particles, extractable volume, and container closure integrity.

Specifications cover  the  relevant quality attributes. Acceptance  criteria  (AC) for the following specifications were substantially tightened: potency by surface plasmon resonance, SE-HPLC, CE-SDS. cIEF was implemented as purity parameter and reported with numerical acceptance criteria. Stability specification acceptance criteria were aligned with the revised release AC. Compendial methods were successfully  verified.  It  is  acknowledged  that  since  omburtamab  active  substance  and  omburtamab finished product intermediate are identical in terms of protein identity and formulation and has a similar protein  concentration,  the  assay  verifications  and  validations  performed  on  omburtamab  active substance as described in Section 3.2.S.4.3 also applies to omburtamab finished product intermediate. The acceptance criteria defined at the time of release were met for all finished product intermediate batches manufactured with the to-be-marketed manufacturing process. Product-related impurities in omburtamab finished product intermediate are the same as for the omburtamab active substance. Limits for the product-related impurities are included in the omburtamab finished product intermediate release specification.  With  regard  to  potential  process-related  impurities  an  extractables  and  leachables  risk assessment was carried out to estimate whether potential leachables originating from polymeric singleuse systems and containers pose any risk to the patient's safety. No items used during the omburtamab finished  product  intermediate  manufacturing  were  identified  as  high-risk.  The  omburtamab  finished product intermediate specification is set in accordance with the guidelines described in Q6B. For the definition of limits, it is acknowledged that it is not possible to use statistics for setting release acceptance criteria due to the limited number of lots.

<div style=\"page-break-after: always\"></div>

## Batch analysis

The batch release results for omburtamab finished product intermediate batches demonstrate that the acceptance criteria were met.

## Reference materials

The reference standard used for omburtamab finished product intermediate testing is the same as the reference standard used for omburtamab active substance testing.

## Container closure

The container closure system for omburtamab finished product intermediate 2 mg/mL consists of a sterile, clear 2R Type I glass vial sealed with a 13 mm bromobutyl stopper over sealed with an aluminium seal and white polypropylene cap. The components of the container closure system are in compliance with Ph. Eur. A product specific extractable study has been performed on the  glass vial and stopper, using the formulation buffer (aqueous solution of citric acid and sodium phosphate dibasic, pH 4.2) as extraction solvent. No organic extractables above analytical evaluation threshold and 3-fold above blank were detected in the extracts of the glass vials/stopper combination. The glass vials are colourless, the rubber stoppers are made of bromobutyl rubber and primary packaging is in compliance with respective Ph. Eur. Requirements.

## 2.4.4.4. Stability of the product

A 36-month shelf life was proposed for omburtamab finished product intermediate when stored at the recommended  storage  condition  (-20°C±5°C).  The  batches  placed  on  stability  are  considered representative.  The  proposed  shelf  life  was  revised  to  24  months  long-term  stability  data  at recommended storage conditions and accelerated stability data at 5°C± 3°C for 24 months and stressed stability data at 25°C ± 2°C for 6 months.

Overall, the data indicate a good stability profile of omburtamab  finished product intermediate. Taking the  comparability  data  into  account  it  is  agreed  that  currently  24  months  stability  data  for  three representative  batches  are  available  and  support  the  proposed  shelf  life  of  24  months  for  the omburtamab Finished Product Intermediate.

## 2.4.5. ( 131 I) omburtamab Finished Medicinal Product

## 2.4.5.1. Description of the product and pharmaceutical development

Radiolabelling of the cold omburtamab with iodine-131, sterile manufacturing and release testing of the finished product is performed by radiolabelling facility located in the USA. Satisfactory demonstration of GMP compliance is provided.

All  excipients  used  for  ( 131 I)  omburtamab  drug  product:  sodium  dihydrogen  phosphate,  disodium phosphate,  recombinant  human  serum  albumin,  sodium  chloride,  octanoic  acid,  polysorbate  80, hydrochloric acid, sodium hydroxide, water for injections, are tested per compendial methods.

There are no excipients of human or animal origin and no novel and no non-compendial excipients.

Omburtamab finished product intermediate is radiolabelled with iodine-131.

The  radioactive  active  substance  [ 131 I]Iodo-omburtamab  is  formulated  in  aqueous  solution  with  a radioactive  concentration  (strength)  to  meet    462.5  MBq  /  mL  (12.5  mCi/mL)    at  reference  time. According the SmPC the reference time is defined as the time of use. The shelf-life is declared with 96

<div style=\"page-break-after: always\"></div>

hours and one vial is dedicated for single use. To obtain clarity about the radioactive strength and the actual amount of product (radioactivity) per vial one binding reference time is defined.

According to the SmPC the fill volume of one product single dose vial is constant. Further, the strength of  the  product  is  acknowledged  as  being  the  radioactive  concentration  and  amount  present  at  the reference time.

For recombinant human serum albumin (rHSA), USP, the question was raised whether the rHSA is added as  a  pure  substance  or  as  a  preparation  containing  its  own  excipients.    The  rHSA,  Recombumin,  is formulated with water for injection (Ph. Eur.), sodium chloride (USP/Ph. Eur.), octanoic acid (Ph. Eur.) and Polysorbate 80. These excipients are stated on the SmPC.

The applicant described the complete radiolabelling step which is the synthesis of the clinically relevant active substance  [ 131 I]Iodo-omburtamab  in the finished product  part 'P'. It is clear that in radiopharmaceutical production, the active substance (radiolabelling) synthesis is directly connected to the finished product formulation, in this case the formulation of an injection.

The applicant initially presented a mainly narrative summary of development of the final product, with limited data.  This was raised as a major objection, resolved during the procedure.

## 2.4.5.2. Manufacture of the product and process controls

The radiolabelling of the cold omburtamab with iodine-131, the purification of the [ 131 I]Iodo-omburtamab and its  formulation  in  a  sterile  injection  (finished  product  manufacturing)  and  the  complete  release testing of the finished product is done by the radiolabelling facility. A pre-approval inspection has been performed by FDA with outcome classification 'Voluntary Action Indicated', and COMSTAT shows that the manufacturing site is acceptable for the activities related to Sterile-Filled Small Volume Parenteral Drugs. For market release the in the European Union seated manufacturer Y-mAbs Therapeutics A/S, Denmark,  is  declared.  A  GMP  certificate  covering  the  batch  release  of  aseptically  manufactured radiopharmaceuticals and biotechnological products issued by the Danish Medicinal Agency dated the 10 th  July 2020 is presented..

The ( 131 I)  omburtamab  finished  product is  produced  in  a  continuous  finished  product  manufacturing process  by  sterile  filtration  and  aseptic  filling.  During  this  process,  the  precursor,  the  omburtamab finished product intermediate reacts with a solution of Na[ 131 I]I in a buffered solution and the use of Iodination beads. The product is purified by use of a purification column, immediately formulated in situ , sterile filtered and aseptically filled into a sterile vial and immediately stored at the recommended storage condition of -70 ± 10 °C. ( 131 I) Omburtamab finished product is shipped frozen &lt;-60°C directly from the radiolabelling facility in USA to the hospital that ordered the dose. The individual process steps are described and IPCs are indicated in the process scheme and further described in section control of critical steps below. The preparation of the finished product is the purification of the after radiolabelling obtained [ 131 I]Iodo-omburtamab using a desalting column which works according to the size-exclusion principle letting inorganic ions and small molecules faster moving om the column than proteins with high molecular weight. By this the small molecules and non-reacted [ 131 I]iodine in the chemical form as iodide can be simply separated from the [ 131 I]Iodo-omburtamab, while the [ 131 I]Iodo-omburtamab elutes from the column much slower than the small molecules. As the eluent solution is aqueous phosphate buffer, the active substance [ 131 I]Iodo-omburtamab can be directly eluted in the finished product preparation which is an aqueous phosphate buffer which can be directly sterile filtered in the finished product vial. Because the size exclusion chromatography of proteins with high molecular weight does not allow separation of the radiolabelled proteins from the non-radiolabelled proteins, it is a technical fact that the complete amount of omburtamab whether radiolabelled or not remains in the finished product

<div style=\"page-break-after: always\"></div>

The validation of the aseptic operations as for e.g., the media fill test belongs first of all into the GMP area  and  is  confirmed  with  the  GMP  certificate  which  covers  the  process.  The  stability  of  the manufacturing process is demonstrated by three consecutive process validation batches of [ 131 I]Iodoomburtamab injection which were manufactured at the manufacturing site, which is common established praxis.

For manufacturing a 'sterile fluid pathway' is described, meaning that beginning with the sterile filtration a closed connection from the sterile filter to a rubber stopper closed production vial using a syringe needle is used. This technique facilitates the demand for the cleanroom conditions for the filling area from class 'A' to class 'C'. The disadvantage of this technique is that the rubber stopper of the vial is punctured by at least one needle, and in the case of a necessary ventilation needle by two needles. Furthermore, samples for release testing and retain samples must be withdrawn too. This means the original integrity of the rubber stopper is impaired by multiple insertion of syringe needles. The applicant has presented in the development part studies which show that the punctured rubber stoppers retain integrity. Nevertheless, this does not change the fact that the rubber stoppers are punctured, and this was raised as a Major Objection. The applicant agreed to revise the process, which is presented as a Recommendation to the final opinion. The simple closed vial filling technique derives from the in-house preparation of radiopharmaceuticals in hospitals where the injections are used 'in-house' during few hours. For the classical Positron-Emission-Tomography (PET) Radiopharmaceuticals radiolabelled with the radionuclides Nitrogen-13, Carbon-11 and Fluorine-18 this technique is used and tolerated till today because these radiopharmaceuticals are used during few hours after their manufacturing because of their  fast  radioactive  decay.  In  the  case  of  [ 131 I]Iodo-omburtamab  -  injection  the  background  is completely different. [ 131 I]Iodo-omburtamab is neither dedicated for use in few hours nor dedicated for in-house use. For [ 131 I]Iodo-omburtamab injection a shelf life of 4 days is proposed and the distribution is proposed throughout the world using air transport shipping. From (radio-)pharmaceutical manufacturing technology there is no reason to tolerate a filling method in contradiction to the standards of  sterile  solution  filling  by  impacting  the  original  integrity  of  the  rubber  stopper.  For  the  filling  of radiopharmaceuticals, the use of open-filling in a clean-room class A cabinet by closing of the vials after the filling without puncturing the stoppers is possible by remote controlled equipment to avoid radiation burden to the co-workers at the manufacturing facility. Argumentations that sterility testing and dye intrusion tests show the integrity of the punctured rubber stoppers cannot be accepted because the sterility assurance level (SAL) is defined according to the European pharmacopoeia with 10 -6  meaning that only 1 to 1 million vial is allowed to be not sterile. The applicant describes his efforts to install two manufacturers which will be in the future capable to supply the finished product as usual for injections in glass vials closed with intact non - punctured rubber stoppers.

The technical deficiency in the manufacturing process  can be simply solved by using adequate production equipment from radiopharmaceutical technology and a commitment is made by the applicant that the manufacturing process of the finished product will be shifted from 'closed' filling technique leading to punctured rubber stoppers to 'open' filling technique leading to intact non punctured rubber stoppers at the latest 10 months after the issue of the marketing authorisation should be made (post authorisation measure).  The applicant aims to introduce an alternative radiolabelling facility in the EU as the future finished product filling site to be filed as a variation post approval. A restricted access barrier system (RABS) and dispensing system is in place at this facility, ensuring a satisfactory aseptic filling process.

In-vivo stability  of  iodinated  tyrosine  moieties  could  be  worse  because  the  body  possess  enzymes specialised on the deiodination of iodo-tyrosine moieties in the context of the steering of the thyroid hormones thyroxine. About the in-vivo stability of the radioiodinated omburtamab no data is submitted by the applicant regarding deiodination. As iodine in ortho position to a hydroxyl group in an aromatic system  is  not  perfectly  stable  towards  deiodination,  alternative  processes  were  considered.  para-

<div style=\"page-break-after: always\"></div>

radioiodo- phenylalanine was also developed which can be first radioiodinated and then conjugated with the protein assuring that the protein is not damaged by harsh radiolabelling conditions. The applicant should use for the radiolabelling of omburtamab a method which produce an against deiodination stable [ 131 I]Iodo-omburtamab, as for e. g. by using radioiodinated Phenylalanine-derivatives.  In this context the applicant is invited to provide data in view to the in-vivo stability of  [131I]Iodo-omburtamab, for e. g. in blood plasma.

## 2.4.5.3. Product specification

The  release  and  shelf  life  specifications  for  131 I-omburtamab  finished  product  include  general  tests, radiochemical identity, concentration, strength, potency, radiochemical purity and impurities, radionuclidic identity and purity, protein purity and microbial safety tests.

Specifications are set in accordance with ICH Q6A and Q6B and cover the characteristics to be controlled. Three consecutive process validation batches of  131 I-omburtamab were produced in which the quality of the product has been analysed. Clear references to analytical procedures are added to the specifications. Analytical procedures have been briefly described. Most of the specifications and their limits are founded on pharmacopeia monographs and are in the usual frame for radiopharmaceuticals and does not need to be discussed.

Potential  process-  and  product-related  impurities  that  may  be  present  in  131 I-omburtamab  finished product are described and would be detected by methods used for release testing.

Extractable  samples  were  analysed  for  volatile,  semi-volatile,  non-volatile  organic  compounds  and inorganic elements by HS-GC-FID/MS, GC-FID/MS, LC-DAD/MS, and ICP-MS. No compounds above the AET were observed. The radiochemical purity of  131 Iomburtamab should be aligned to ≥ 90% for the monomer at T0 and at expiry. To ensure the accurate potency of iodine -  131  the radiochemical purity of the [ 131 I]Iodo-omburtamab should be as high as possible. Because of [ 131 I]Iodo-omburtamab injection is  a  therapeutic  radiopharmaceutical  the  reliable  determination  of  the  radioactivity  amount  filled  is essential. The applicant describes the use of a by the German national meterologic institute physikalisch technische bundesanstalt (PTB) calibrated Iodine-131 reference standard in the same geometry and packaging  of  the  finished  product.  Furthermore,  the  applicant  describes  that  the  calibration  and operational tests for the dose calibrators are done according to the pharmacopeia. The radioactivity calibration  of  [ 131 I]Iodo-omburtamab  was  initially  not  sufficiently  assured  and  raised  as  a  Major Objection.  The  described  methods  used  for  calibration  of  the  activimeters  used  at  both  relevant manufacturing sites are acceptable and assure a reliable determination of the radioactivity amount filled per vial.

A risk assessment to evaluate potential nitrosamine impurities in the  131 I-omburtamab finished product is provided. The risk assessment was satisfactory.

## Batch analysis

Three consecutive process validation batches of  131 I-omburtamab were produced in which the quality of the product has been shown to meet the acceptance criteria.

## Reference materials

A list of reference standards or reference materials used for quality control testing of the  131 Iomburtamab final finished product is provided. These materials are primarily used for calibration purposes and their use is justified. Reference standards are always connected to the analytical method they are used for. If an analytical method needs to be changed typically different reference standards are needed too. This is

<div style=\"page-break-after: always\"></div>

in  the  case  for  the  measurement of the radioactive concentration which is detailed described in the discussion of the validation of the method to determine the radioactive concentration.

## Container closure

The container closure system used for the radiolabelled finished product is a pre-assembled, sterile empty vial (Type I borosilicate glass vial), which is closed with a n-butyl rubber elastomer septa and aluminium crimp seal. The glass used for the  sterile empty vial is a USP Type I, borosilicate glass. The closure is a 20 mm butyl rubberstopper. The seal is an aluminium seal. An extractable study has been performed  on  the  final  product  vial,  using  the  final  formulation  buffer  as  extraction  solvent.  No extractable  compounds  were  detected.  The  usual  primary  packaging  material  for  sterile  aqueous solutions is used which would be acceptable in the case that the rubber stopper is not punctured by filling needles using a for a sterile solution non adequate filling process. The filling process is assessed deeply before  in  the  assessment  of  the  manufacturing  process.  Specifications  and  description  of  analytical procedures used (and their validation, where relevant), and compendial confirmation for each element of packaging is provided. The actual used secondary packaging material are sufficiently described.

## 2.4.5.4. Stability of the product

131 I-omburtamab finished product is shipped frozen &lt;-60°C directly from the CMO in the USA  to the hospital that ordered the dose. Therefore it is acknowledged that a certain time is required for shipment and  the  proposed  shelf-life  of  the  final  finished  product  131 I-omburtamab  of  96  hours  at ≤ -60°C, protected from light in a shielded lead container was not initially accepted due to lack of stability data.. To  overcome  the  potential  issues  with  the  limited  shelf-life,  Y-mAbs  proposed  to  transfer  the manufacturing process to a European based CMO. Supportive stability batches were manufactured at a European based CMO, (to be added post-approval). The provided data support the proposed 96 hours shelf-life for  131 I-omburtamab finished product when stored at ≤ -60°C.

When thawed for use, the finished product should be stored below 25°C and must be used within 3 hours.

## 2.4.5.5. Adventitious agents

## TSE compliance

All raw materials used in the manufacture process of omburtamab are received, identified, sampled, quarantined,  tested,  labelled  and  released  according  to  established  written  procedures.  The  whole production process of Omblastys, including the omburtamab fermentation and purification process as well as the radiolabelling process, is free of animal- or human derived materials. The omburtamab master cell bank has been established to grow in chemically-defined serum-free medium and has therefore been produced without materials of animal or human origin. Only during early cultivation of host cells before adaption to the serum-free growing, cells were cultivated in the presence of foetal bovine serum. TSE safety  is  demonstrated  through  the  sourcing  of  the  serum  from  geographical  low  risk  country.  In summary, compliance of the manufacture of Omblastys with TSE-Guideline EMEA 410/01 rev03 has been sufficiently demonstrated.

## Virus safety

The omburtamab monoclonal antibody is produced in a hybridoma cell line derived from the fusion of mouse myeloma cells Sp2/0-Ag14 and splenic lymphocytes from BALB/c mice. No animal- or humanderived reagents are used in the manufacture of the omburtamab active substance or finished product, the corresponding master cell bank or the radiolabelling process of the antibody. The serum is gammairradiated. No more information on the serum is provided which is acceptable because the master cell

<div style=\"page-break-after: always\"></div>

bank has been tested sufficiently and found to be negative for bovine viruses. None of the excipients are of human or animal origin. The omburtamab master cell bank and a corresponding extended cell bank have been tested sufficiently for adventitious viruses as well as retroviruses in accordance with ICH Q5A. As confirmed on certificates of analysis, no viruses except retrovirus-like particles as well as infectious amphotropic/xenotropic retroviruses were detected which is acceptable as hybridoma cells are known to produce such particles. The use of the MCB for omburtamab production is acceptable. The unprocessed bulk harvest is also tested routinely in compliance with ICH Q5A for adventitious viruses including a specific assay for MVM and Vesivirus detection. No viruses may be found by these assays for further processing of the batch. Detection of infectious retroviruses and the counting of retrovirus-like particles is not a routine assay, but has been performed on several batches produced according to the commercial process in line with ICH Q5A. Infectious retroviruses have been found in one of the batches analysed and  retrovirus-like  particles  in  all  tested  batches  which  is  not  unexpected.  The  maximum  number detected  has  been  used  for  calculation  of  the  retrovirus  safety  margin.  The  virus  reduction  for  the parvovirus is considered sufficient. A retrovirus risk assessment was performed demonstrating sufficient clearance for the hybridoma cell-derived retrovirus-like particles (RVLP). In summary, the virus safety of Omblastys has been shown to be suitable at the level of raw materials used in the production processes as well as the excipients, however, the virus reduction capacity of the process was initially demonstrated only to a limited extent and more information and data were provided to confirm a robust virus reduction capacity of the omburtamab purification process.

## 2.4.6. Discussion and conclusions on chemical, pharmaceutical and biological aspects

The dossier is structured in order to reflect the stages of manufacture: omburtamab mAb intermediate active substance, omburtamab mAb intermediate finished product, Sodium Iodide-131 ASMF, and  131 Iomburtamab finished product.

Iodine-131  omburtamab  is  a  radiolabelled  murine  monoclonal  antibody  that  recognises  and  binds selectively to the B7-H3 antigen expressed on CNS/LM neuroblastoma tumour cells. The iodine-131 emits radiation, resulting in DNA damage and tumour cell death.

An ASMF (open part) of the radionuclide precursor sodium [ 131 I]iodide for radiolabelling is submitted by the applicant. The restricted part of the ASMF for the radionuclide precursor sodium [ 131 I]iodide for radiolabelling is separately submitted by the ASMF holder

Omburtamab finished product intermediate is radiolabelled with iodine-131 to produce  131 I-omburtamab Finished product.

While  the  omburtamab determines the biodistribution  of  the  active  substance,  the  strong  β -emitter Iodine-131 with a physical half-life of around 8 days is suitable for therapeutic cancer treatment by irradiation.

In  the  submitted  documentation  the  synthesis  (radiolabelling)  of  the  active  substance  [ 131 I]Iodoomburtamab is not described in its own active substance part 3.2.S. In the manufacturing sequence from  the  active  substance  [ 131 I]Iodo-omburtamab  to  the  finished  product  [ 131 I]Iodo-omburtamab injection (Omblastys) no isolation of the active substance [ 131 I]Iodo-omburtamab is foreseen.

The radionuclide iodine-131 is manufactured at a research reactor and used in the chemical form sodium iodide ( 131 I) solution for radiolabelling. Furthermore, the sodium iodide ( 131 I) solution for radiolabelling is specified in conformity with the corresponding Pharmacopoeia Monograph no. 2121.

<div style=\"page-break-after: always\"></div>

After  radioiodination  obtained  reaction  solution  is  purified  using  size  exclusion  chromatography  to separate  the  [ 131 I]Iodo-omburtamab  /  omburtamab  from  the  smaller  molecules,  i.e.  non-reacted [ 131 I]iodine, buffer salts etc.

A number of major objections on quality were raised during the procedure: control strategy for mAb intermediate was considered to be preliminary; characterisation of effector function activity; initially a mainly narrative summary of development of the final product was presented; radioactivity calibration of  [ 131 I]Iodo-omburtamab  was  initially  not  sufficiently  assured.  These  were  resolved  during  the procedure.

The  former  major  objection  concerning  the  not  state-of-the-art  filling  technology  used  in  the manufacturing process leading to finished product vials where the closing stoppers are impacted in their integrity  from  the  filling  process  with  two  needles  for  filling  and  venting  can  be  solved  with  a recommendation.  The  applicant  agreed  to  revise  the  process,  which  is  now  presented  as  a Recommendation for future quality development.

Overall, it is concluded that the provided quality information is considered sufficient and therefore from quality point of view the application for  131 I-omburtamab could be approvable.

## 2.4.7. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of Omblastys is considered to be acceptable when used in accordance with the conditions defined in the SmPC.

## 2.4.8. Recommendation(s) for future quality development

In  the  context  of  the  obligation  to  take  due  account  of  technical  and  scientific  progress,  the  CHMP recommends the following point for investigation:

The applicant should switch from a 'closed' filling technique leading to punctured rubber stoppers to 'open' filling technique leading to intact non punctured rubber.

## 2.1. Non-clinical aspects

## 2.1.1. Introduction

The nonclinical data package supporting the application to market  131 I-omburtamab relies on information in the published literature from studies conducted early in its development, as well as more recent studies that  have  characterized  its  specificity  of  binding,  biodistribution  and  dosimetry,  and  mechanisms  of radiation-induced toxicity.

## 2.1.2. Pharmacology

## 2.1.2.1. Primary pharmacodynamic studies

The identification of B7-H3 as a potential therapeutic target and its expression in tumour tissue is based on literature. It was demonstrated that Omburtamab bound to human and cynomolgus monkey B7-H3

<div style=\"page-break-after: always\"></div>

with  comparable  high  affinity  (1.1  and  1.6  pM  KD  for  human  and  cynomolgus  monkey  B7-H3, respectively).

Table 1. The binding kinetic information of omburtamab to B7-H3 from different species

| B7H3 (3ug/ml)   |   No.of replicates | Mean ka (M-1 S-1)   | ka SD   | Mean kd (5-1)   | kd SD   | Mean Ko (pM)   | Ko SD (pM)   | Mean Rmax(RU)   |   Rmax SD |   Mean Res sd | Res sd SD   |
|-----------------|--------------------|---------------------|---------|-----------------|---------|----------------|--------------|-----------------|-----------|---------------|-------------|
| cyno            |                  3 | 6.5x10*             | 9.6x10  | 1.0x10-*        | 0.0     | 1.6            | EZ'O         | 210             |      42   |           4.8 | 1.3         |
| human           |                  3 | 8.9x10*             | 5.9x10* | 1.0x10s         | 0.0     | 1.1            | 0.076        | 562             |      59   |           9.3 | 2.5         |
| mouse           |                  3 | Na                  | na      | na              | na      | na             | na           | 5.2             |       2.2 |           3.7 | 1.5         |
| rat             |                  3 | Na                  | na      | nia             | na      | na             | nia          |                 |       3.8 |           6.5 | Z'E         |

No detectable binding was observed with mouse or rat B7-H3. In conclusion the cynomolgus monkey is considered the relevant species.

It was determined whether Omburtamab binds to human tumour tissues including non-small cell lung carcinoma, ovarian cancer, neuroblastoma, medulloblastoma, glioblastoma, sarcoma, liver cancer and melanoma. Positive staining was evident in all tumour types whereas no staining was observed in normal control tissues.

Table 2. Summary of Experimental Design

Table 3. Summary of Histopathologic Scoring with OMBURTAMAB

| Tissue                        | FFPE   | Frozen   | Antibody                   |
|-------------------------------|--------|----------|----------------------------|
| Non-Small Cell Lung Carcinoma | V      | V        | OMBURTAMAB                 |
| Ovarian Cancer                | √      |          | OMBURTAMAB                 |
| Neuroblastoma                 |        | NA       | OMBURTAMAB                 |
| Medulloblastoma               | V      | NA       | OMBURTAMAB                 |
| Glioblastoma                  | V      | √        | OMBURTAMAB                 |
| Sarcoma                       |        |          | OMBURTAMAB                 |
| Melanoma                      |        | ?        | OMBURTAMAB                 |
| Non-Small Cell Lung Carcinoma | V      | V        | Isotype Control Mouse IgG1 |
| Ovarian Cancer                | V      | V        | Isotype Control Mouse IgG1 |
| Neuroblastoma                 | √      |          | Isotype Control Mouse IgG1 |
| Medulloblastoma               | V      |          | Isotype Control Mouse IgG1 |
| Glloblastoma                  | V      | V        | Isotype Control Mouse IgG1 |
| Sarcoma                       | √      | V        | Isotype Control Mouse IgG1 |
| Melanoma                      | V      | V        | Isotype Control Mouse IgG1 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Tissue (FFPE)                 | Distribution   | Staining Incident/lntensity   | Comment                                                            |
|-------------------------------|----------------|-------------------------------|--------------------------------------------------------------------|
| Non-small cell lung carcinoma | diffuse        | 44                            | granular,celsurface, some intracellular                            |
| Ovarian Cancer                | multifocal     | 2/2                           | granular,cellsurface, some intracellular                           |
| Neuroblastoma                 | diffuse        | 43                            | granular, cellsurface some intracelluar                            |
| Medulloblastoma               | diffuse        | 44                            | granular,cell surface, some intracellular                          |
| Glioblastoma                  | multifocal     | 44                            | granular,cellsurface, some intracellular                           |
| Sarcoma                       | mulifocal      | 22                            | granular,cellsurface, some intracellular                           |
| Melanoma                      | diffuse        | 4/4                           | granular,cellsurface, some intracellular                           |
| Liver Cancer                  | diffuse        | 3/3                           | granular,cellsurface, some intracellular                           |
| Liver Normal                  | NA             | 0/0                           | NA                                                                 |
| Tissue (Frozen)               | Distribution   | Staining Incident/lntensity   | Comment                                                            |
| Non-small cell lung carcinoma | diffuse        | 2/3                           | granular,cellsurface some intracellular                            |
| Lung Cancer                   | multifocal     | 22                            | granular,cellsurface some intracellularof glandularepithelialcells |
| Ovarian Cancer                | diffuse        | 43                            | granular,celsurface, some intracellular                            |
| Glioblastoma                  | diffuse        | 3/3                           | granular,cellsurface some intracellular                            |
| Sarcoma                       | diffuse        | 4/4                           | granular,cellsurface some intracellular                            |
| Melanoma                      | multifocal     | 3/3                           | granular, cellsurface some intracellular                           |

In the only GLP compliant tissue cross-reactivity study using a set of approximately forty specified tissues of human origin specific on-target binding to B7-H3, was seen in the epithelium of the skin, prostate, eye,  endometrium, adrenal, fallopian tube, and cervix, as well as in the supporting stroma of most tissues. Potential off-target binding was seen in cytoplasmic staining of the Leydig cells of the testis, in cytoplasmic staining in glial cells of the spinal cord of one donor, and in cytoplasmic staining of alveolar macrophages in the lungs.

Inhibition of tumour growth by 131 I-Omburtamab compared to unlabelled Omburtamab  was demonstrated in two different xenograft models.

The potential effectiveness of  131 I-omburtamab as an antitumor agent in vivo was evaluated in nude mice  with  established  subcutaneous  rhabdomyosarcoma  (HTB82)  or  medulloblastoma  (DAOY)  cell xenografts, instead of the well-established mouse model of neuroblastoma.

Rhabdomyosarcoma tumour volume diminished to less than 50% of initial volume 21 days after injection without any adverse effects; however, tumour growth was noted 50 to 60 days after administration of 131 I-omburtamab.

Figure 1. Antitumor Effect of  131 I-omburtamab on RMS Xenografts

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source:Modaketal,200s.m

Note:3FS isa murine anti-disialoganglioside IgG3 thatbinds to neuroblastoma cells but not RMS cells 3F8=iodine-131murine 3F8monoclonal antibody （I-3F8):8H9=iodine-131murine monoclonal antbody (I-omburtamab):Ig=immunoglobulin;RMS=rhabdomyosarcoma

In  athymic,  subcutaneous  DAOY  xenograft  tumour bearing  nude  mice,  131 I-Omburtamab  appears to inhibit tumour growth when compared to unlabelled omburtamab with a significant effect on survival (percent change in tumour volume was greater in the omburtamab group (97.1% ±22%) than in the 131 I-omburtamab group (30.9% ±19%) at all time points starting on Day 13).

In athymic, subcutaneous DAOY xenograft tumour bearing nude mice,  131 I-Omburtamab inhibits tumour growth when compared to unlabelled Omburtamab with a significant effect on survival as 6 out of 7 animals had to be euthanised due to tumour volume increase.

Table 4. Cause of Death for All Animals on Study per Group

|                                |             | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   |
|--------------------------------|-------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Group                          | Nper group  | Weightloss                  | Tumor Volume> 2.000mm       | Studyend point\"             | Other                       |
| Unlabeled Omburtamab (control) | 7           | 0                           | 6                           | 0                           | 1                           |
| 131jOmburtamab                 | 7(+1 extra) | 0                           | 口                           |                             |                             |

Temminal end point dcfined as the date allanimals trom he unlabcled Omburtamab group were removed trom shudy due totumor swre

Duelopoorheaihposl-njecion

Due to sweing ol the cye.

## 2.1.2.2. Secondary pharmacodynamic studies

No dedicated secondary safety pharmacodynamic studies have been conducted.

## Safety pharmacology programme

In accordance with ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals no stand-alone safety pharmacology studies with  131 I-omburtamab have been conducted.

<div style=\"page-break-after: always\"></div>

## 2.1.2.3. Pharmacodynamic drug interactions

Considering the MoA no pharmacodynamic drug interaction studies have been conducted.

## 2.1.3. Pharmacokinetics

Pharmacokinetic studies to characterise biodistribution and dosimetry of radiolabelled omburtamab were conducted after either intrathecal or intravenous dosing with  125 I-omburtamab in naïve rats or in tumourbearing mice.

According  to  the  Guideline  on  the  non-clinical  requirements  for  radiopharmaceuticals,  in  case  of radiotherapeutics 'the only additional aspect to consider in these cases is that the dosimetry study might be performed in an animal model of disease, if appropriate, to support that the targeted area will be reached adequately'. The in vivo PK studies have been performed in rats (without tumour) and mice bearing medulloblastoma and rhabdomyosarcoma tumours. No in vivo studies have been performed in xenograft animal model with neuroblastoma.

Biodistribution  analyses,  conducted  by  single-photon  emission  computed  tomography  (SPECT)  and computed tomography (CT) imaging, were used to quantify concentration over time in organs of interest, mean residence times (MRT), and organ and whole-body dosimetry estimates.

Figure 2. Blood Kinetics of  125 I-8H9 in nude mice with RMS xenografts

Table 5. Percent Injected Dose/Gram of  125 I-8H9 Distributed in HTB82 Xenografts and Normal Tissues 4, 24, 48 and 172 Hours After Injection

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                 | 4hours（n=7mice） Mean±SD   | 24hours （n=9mice） Mean ± SD   | 48howrs （n=9mice) Mean±SD   | 172hours(n=8mice） Mean±SD   |
|-----------------|---------------------------|-------------------------------|-----------------------------|-----------------------------|
| Adrenal         | 5.0±1.6                   | 1.4± 1.6                      | 1.4±0.5                     | 0++0                        |
| Bladder         | 4.5±1.6                   | 2.6±1.2                       | 2.9±0.8                     | 0.9±0.6                     |
| Blood           | 26.6±2.1                  | 14.1±3.0                      | 10.7±2.1                    | 3.2±0.9                     |
| Brain           | 0.4±0.1                   | 0.3±0.1                       | 0.3±0.1                     | 00+10                       |
| Femur           | 1.2±0.9                   | 1.4±0.5                       | 1.1±0.5                     | 0.4±0.1                     |
| Heart           | 10.3±2.9                  | 4.3±1.9                       | 2.9±0.5                     | 0.9±0.2                     |
| Kidney          | 7.3±3.1                   | 3.9±1.6                       | 3.0±0.7                     | 0.8±0.3                     |
| Large intestine | 20+11                     | 1.7±0.6                       | 1.2±0.3                     | 0.2±0.1                     |
| Liver           | 7.7±1.3                   | 4.0 ± 1.7                     | 2.2±0.3                     | 0.7±0.3                     |
| Lung            | 17.7±7.8                  | 5.7±3.5                       | 5.3±1.1                     | 1.4±0.5                     |
| Muscle          | 0.7±0.2                   | 1.2±0.6                       | 1.1±0.4                     | 0.3±0.1                     |
| Skin            | 3.2±1.6                   | 2.3±1.6                       | 2.5±1.5                     | 0.6±0.4                     |
| Small intestine | 2.8±0.6                   | 1.5±0.4                       | 1.1±0.2                     | 0.3±0.1                     |
| Spine           | 2.8±1.2                   | 2.1±0.8                       | 1.7±0.7                     | 0.5±0.2                     |
| Spken           | 5.5±2.2                   | 5.8±2.4                       | 3.3±0.8                     | 0.5±0.2                     |
| Stomach         | 2.4±1.0                   | 2.4±2.1                       | 1.6±0.7                     | 0.5±0.4                     |
| Tumor           | 7.0±1.8                   | 11.5±3.9                      | 15.1±3.7                    | 5.4±1.2                     |

It  is  noted  that  no  PK  studies  were  performed  regarding  the  antibody  compound.  Such  analysis  is expected including description and validation of the methods to characterise the antibody kinetics as well as potential ADAs. The applicant is asked to provide information regarding the antibody kinetics ( 131 Iomburtamab, free omburtamab) including potential ADA development.

In Sprague Dawley rats, dosimetry estimates indicate that the dose-limiting organ for  131 I-omburtamab in the adult male and female models was the heart wall followed by liver and the kidneys (0.53 and 0.69; 0.51 and 0,61; 0,38 and 0,46 respectively for the organs and animal gender). Effective doses for  131 Iomburtamab in adults were estimated at 0.20 and 0.28 mSv/MBq in males and females, respectively.

In Tumour-Bearing Mice selective tumour uptake was demonstrated at 4 to 172 hours after intravenous administration of 125I-omburtamab. Absorbed doses in tumours ranged from 797 mGy/MBq in small tumours up to 1,157 or 1,216 mGy/MBq in larger tumours. The dose-limiting organ was the skeleton (based on myelosuppression), followed by the liver and kidneys.

The overall pharmacokinetic characteristics of  131 I-omburtamab is driven by its antibody component and being a protein, omburtamab will undergo standard metabolism. Therefore, no dedicated studies to investigating  the  metabolism  of  131 I-omburtamab  are  considered  warranted.  The  applicant  has  not conducted any nonclinical excretion studies with  131 I-omburtamab, which is acceptable for the antibody part as it will undergo normal protein metabolism. It is stated that free iodine-131 will mainly undergo renal clearance which is agreed. Accumulation of free Iodine-131 possibly expected in the thyroid and the gastrointestinal tract has been analysed and clinical measures such as 'Blockade of  131 I-uptake in the thyroid gland is to be ensured by administration of stable iodine e.g., potassium iodide' are indicated in the SmPC to counter act thyroid accumulation. Regarding the gastrointestinal tract only low levels of iodine- 131  were detected by dosimetry in the various compartments.

## 2.1.4. Toxicology

The nonclinical toxicology programme has been conducted early in development at MSK in mice, rats, and Cynomolgus monkeys. Additional studies have been conducted more recently in mice and rats to better understand the radiation-induced toxicity associated with the  131 I-omburtamab treatment and the recovery after exposure.

<div style=\"page-break-after: always\"></div>

Table 6. Overview of Toxicology Studies

<!-- image -->

CED=convection-enhanced delivery.GLP=Good Laboratory Practice;ip.=intrapenitoneal:it =intrathecal; iV.=intravenous,MB =medulloblastoma:MOA =method ofadministration;RMS=rhabdomyosarcoma; SD=SpragueDawley.Us7=humanglioblastoma cell line.

## 2.1.4.1. Single dose toxicity

Study  YMAB-2019-CR14  radiotoxicity,  biodistribution  and  dosimetry  of  radiolabeled  omburtamab derivatives delivered intrathecally to Sprague Dawley Rats

After delivering a single intrathecal dose of  131 I-omburtamab to naïve Sprague Dawley rats (451 ±37.6 μ Ci; 20 μ g mass dose), all animals experienced a transient decrease in white blood cells 1 week after treatment; however, there was no other evidence of treatment-related toxicity in blood count, serum chemistry, or histopathology assessments.

One rat treated with  131 I-Omburtamab was found dead one week after treatment and no cause of death was apparent on post-mortem evaluation. A second rat treated with  131 I-omburtamab was euthanised prematurely due to lab error associated with an erroneous weight measurement. White blood cell counts transiently decreased from baseline values in all treatment groups at week one treatment.

<div style=\"page-break-after: always\"></div>

Table 7. Cause of Death Summary

<!-- image -->

|               | Nper   | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   | Reason for Euthanasia (n)   |
|---------------|--------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Group         | dnoJb  | Found dead                  | Welght loss                 | Other                       | End of Study                |
| 3j-Omburtamab |        | 1\"                          | 0                           |                             | 4                           |

Systemic radiotoxicity, namely myelosuppression in the first few weeks after treatment, was investigated after intravenous or intraperitoneal exposure to  131 I-omburtamab in mice.

## Study YMAB-2019-CR16 Single-Dose Radiotoxicity Study of Iodine- 131  Labelled Omburtamab in Athymic Nude Mice

To determine any radiotoxic effects of intravenous (IV) delivered omburtamab derivatives, mice were dosed IV at two dose levels with  131 I-Omburtamab (n=8 per group at 103.8 ± 1.9 μ Ci and 201.2 ± 5.1 μ Ci, 20 μ g). A control cohort (n=8) was also dosed with unmodified omburtamab (20 μ g). Following dosing, mice were monitored for 8 weeks with twice-weekly bodyweights and clinical observations, biweekly complete blood counts (CBC, one-half of animals per group per week), and serum chemistry at baseline and termination of the study (8 weeks).

There were no unexpected deaths or unscheduled euthanasia of any mice over the 8 weeks of the study. Compared  to  controls,  mice  in  the  131 I-Omburtamab,  groups  experienced  a  transient  decrease  in haematocrit, red blood cell concentration, and white blood cell concentration that rebounded to baseline within 4 weeks post injection.

## Study YMAB-2019-CR11 Efficacy of  131 I-omburtamab in DAOY Xenograft Athymic Nude Mice

In athymic, subcutaneous DAOY xenograft tumor bearing nude mice there appears to be a reversible effect on haematopoietic cells, particularly red and white blood cells. Specifically, a transient decrease in red blood cells and haematocrit was observed.

Table 8. Red Blood Cell concentration

| Group          | Baseline（10\" cells/mm)   | Week2（10cells/mm）   | Week4(10 cells/mm)   |
|----------------|--------------------------|---------------------|----------------------|
| Omburtamab     | 84±09                    | 86±06               | 88±01                |
| i31jOmburtamab | 9.9±0.7                  | 6.0±1.6             | 7.4±0.6              |

Table 9. White Blood Cell Concentration

| Group         | Baseline （10 cells/mm)   | Week2(10²cells/mm)   | Week4(10 cella/mm)   |
|---------------|--------------------------|----------------------|----------------------|
| Omburtamab    | 29±05                    | 43±0.9               | 5.3±13               |
| \"'-Omburtamab | 33±03                    | 0.12±0.06            | 38±1.1               |

Table 10. Haematocrit Values

| Group         | Baseline (%)   | Week2（5)   | Week4(%)   |
|---------------|----------------|------------|------------|
| Omburtamab    | 449±26         | 419:29     | 426±04     |
| 31jOmburtamab | 473±3.7        | 29.7±8.0   | 38.5±33    |

<div style=\"page-break-after: always\"></div>

Study YMAB-2019-CR07 Assessment of radiotoxicity of omburtamab derivatives delivered intraperitoneally into athymic nude mice.

To determine any radiotoxic effects of intraperitoneally delivered Omburtamab derivatives, groups of mice were dosed IP with  131 I-omburtamab. Following dosing, mice were monitored for five weeks with bi-weekly bodyweights and clinical observations, weekly CBC and urinalysis, and serum chemistry every three-weeks. Humane endpoints were defined as follows: greater than 20% decrease in bodyweight from peak weight on-study, greater than 10% weight gain from ascites, any sign of pain or distress. Survival, changes in bodyweight, blood and urine biomarker levels following dosing were compared to baseline measurements for each animal.

Six of the seven animals dosed with  131 I-omburtamab did not survive past day 16. Of the 6 mice dosed with  131 I-omburtamab, only one animal died due to study-specific endpoints. The majority of deaths on study were due to weight loss. The  131 I-omburtamab group had low haematocrit levels (&lt;20%), low red blood cell counts (&lt;5 x10 3 /mm 3 ), and low white blood cell counts (&lt;0.5 x 10 3 /mm 3 ).

## 2.1.4.2. Repeat dose toxicity

Study  YMAB-2019-CR17  Assessment  of  radiotoxicity  of  radiolabelled  omburtamab  following  repeat intrathecal dosing to Sprague Dawley rats

To  determine  any  radiotoxic  effects  of  IT  delivered  omburtamab,  groups  of  rats  (n=6  per  group) underwent repeat dosing (500 μCi, 20 μg) with 131 I-omburtamab for a total of three doses. Doses were separated by 20 days.

Table 11. Summary of Dosing in Study YMAB-2019-CR17

|              |          | Animal Information   | Animal Information   | DosingInformation'   | DosingInformation'   | DosingInformation'   |
|--------------|----------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Group        | Dose No. | NAIF)                | Weight(g)            | Mass(ug)             | Radioactivity (mCD)  | Volume (mL)          |
| Omburtamab   | 1        | 6(3/3)               | 295±19               | 20                   | NA                   | 30                   |
| Omburtamab   | 2        | 6(3/3)               | 354±34               | 20                   | NA                   | 30                   |
| Omburtamab   | 3        | 6(3/3)               | 382±42               | 20                   | NA                   | 30                   |
| l-Omburtamab | 1        | 6(3/3)               | 275±23               | 20                   | 440.7±31.6           | 30                   |
| l-Omburtamab | 2        | 6(3/3)               | 348±34               | 20                   | 460.0±13.6           | 30                   |
| l-Omburtamab | 3        | 6(3/3)               | 387±40               | 20                   | 466.5±14.2           | 30                   |

<!-- image -->

|                  | Main/additional cohort   | Dose No.and Inj.Date   | Punhed radiochemical punty.   | lmmunoreactivity.   |
|------------------|--------------------------|------------------------|-------------------------------|---------------------|
| Omburtamab       | M                        | 1:Oct11.2019           | N/A                           | N/A                 |
| Omburtamab       | M                        | 2.0cl31.2019           | N/A                           | N/A                 |
| Omburtamab       | M                        | 3:NoV21.2019           | N/A                           | N/A                 |
| 1311- Omburtamab | M                        | 1:0ct11,2019           | %66                           | 86.4±2.7            |
| 1311- Omburtamab | M                        | 2:0ct31.2019           | 98.3%                         | 86.2±1.0            |
| 1311- Omburtamab | M                        | 3:Nov21.2019           | %66<                          | 87.0±2.6            |

After  repeated  intrathecal  dosing  of  omburtamab  (20μg mass  dose)  or 131 I-omburtamab  (441467 μCi/dose) in Sprague Dawley rats, three doses given as one treatment every 20 days, deaths were noted in both dosing groups due to paraplegia caused by inflammation from the catheter placement, spontaneous tumor development, or other unknown causes; however, there were no clinically significant

<div style=\"page-break-after: always\"></div>

findings  in  blood  counts,  serum  chemistry,  or  histopathological  evaluations  suggestive  of  systemic radiotoxicity.

|   Subject ID | Group           | Dateofdeath/Date euthanized   | Cause             | Notes                                                           |
|--------------|-----------------|-------------------------------|-------------------|-----------------------------------------------------------------|
|          326 | Omburtamab      | Euthanized -Day 57            | Paraplegia        | Most likely caused by inflammation associated with the catheter |
|          327 | Omburtamab      | Euthanized -Day 50            | Spontaneous tumor | Inguinalmassandabrasions fromself-mutilation                    |
|          347 | 131-Omburtamab  | Found dead - Day 45           | Unknown           | No abnormal findings                                            |
|          348 | 131j-Omburtamab | Found dead - Day 51           | Unknown           | Bladderdistendednormaland erythematous / hemorrhagic            |
|          330 | 131]-Omburtamab | Euthanized-Day53              | Paraplegia        | Most likely caused by inflammation associated with the catheter |

Study 92-01-001 A repeat-dose toxicity study with intrathecal administration of  131 I-omburtamab in cynomolgus monkey

Two monkeys were administered intrathecal injections of  131 I-omburtamab into the cisternal space at doses ranging from approximately 3.6 to 8.3 mCi on each of Days 1, 3, and 6; NHP2 also received injections on Days 8 and 10. NHP2 was preimmunised with  131 I-omburtamab (210 days and 127 days prior to study initiation, using 4.6 and 4.7 mCi, respectively, i.v.). Blood and cerebrospinal fluid (CSF) were obtained throughout the dosing period.

Table 12. Dosing Schedule

| Animal   | Injection Number   | Day   | Dose(mCi)       | ROA   |
|----------|--------------------|-------|-----------------|-------|
| NHPI     |                    | 1     | 7.32            | LL    |
| NHPI     | 2                  | 3     | 8.34            | LV.   |
| NHPI     | 3                  | 6     | 3.62            | LL    |
| NHPI     | 4                  | 8     | Failed attempt\" |       |
| NHPI     | 5                  | 10    | Failed attempt\" |       |
| NHP2     | Pre1               | -210  | 4.4             | L.V.  |
| NHP2     | Pre2               | -127  | 4.77            | LV.   |
| NHP2     | 1                  |       | 7.44            | LL    |
| NHP2     | 2                  | 3     | 8.04            | LL    |
| NHP2     | 3                  | 6     | 7.5             | iL    |
| NHP2     | 4                  | 8     | Not specified   | LL.   |
| NHP2     | 5                  | 10    | Not specified   | LL.   |

Both animals achieved high levels of  131 I-omburtamab radioactivity counts per minute (CPM) in the CSF after intrathecal injections. Lower levels of CPM were detected in the blood after intrathecal injections in both monkeys. In preimmunised NHP2, a monkey anti-mouse antibody response had no effect on CPM measured in the CSF but did result in decreased CPM measured in the serum. On CNS single-photon emission computed tomography (SPECT) scans, there was no focal or ventricular retention at 24 or 72 hours after intrathecal administration.

One monkey died on Day 12 of the study after receiving three of five intended doses. The animal died from surgical complications that arose during the first injection; necropsy findings revealed a brainstem haemorrhage with old and new clots filling the fourth ventricle due to a traumatic cisternal puncture. All other  organ  systems,  including  the  liver,  were  grossly  normal.  Scarring  and  haemorrhaging  at  the injection site were observed under histopathological assessment. The second monkey received all five doses  and  was  euthanised  on  Day  1,301.  No  significant  acute  toxicities  were  observed  during  the

<div style=\"page-break-after: always\"></div>

treatment period and no treatment-related toxicities were observed during the extended follow-up of this animal. At necropsy, all tissues examined appeared grossly normal.

High levels of radioactivity were achieved in the CSF of animals. In general, after i.t. administration, total radioactivity was eliminated from the CNS rapidly and was nearly complete by 48 hours after dosing. Dosing with  131 I-omburtamab had no apparent effect on CBC for either monkey. Dosing was associated with  slight  increases  in  BUN  and  serum  Cr  levels,  which  may  have  resulted  from  a  postprocedural reduction in food intake. In the CSF, a rise in total protein and pleocytosis, predominantly eosinophilia, was observed with  131 I-omburtamab dosing; these lab values resolved or were recovering by Day 16.

## 2.1.4.3. Genotoxicity

According to (ICH) S6(R1), genotoxicity studies are generally not necessary to support marketing of biotechnology-derived pharmaceuticals; therefore, Y-mAbs does not consider genotoxicity testing with 131 I-omburtamab to be warranted.

## 2.1.4.4. Carcinogenicity

Y-mAbs has not conducted carcinogenicity studies with  131 I-omburtamab. As discussed in ICH S6(R1) and  ICH  S9,  standard  carcinogenicity  studies  are  generally  not  necessary  to  support  marketing  of biotechnology products without cause for concern or to support therapeutics intended to treat advanced cancer;  therefore,  Y-mAbs  does  not  consider  carcinogenicity  testing  with 131 I-omburtamab  to  be warranted.

## 2.1.4.5. Reproductive and developmental toxicity

According to ICH S9, generally no fertility or pre- and postnatal toxicity studies are warranted to support the treatment of patients with late-stage or advanced cancer. As the age of the target population of  131 Iomburtamab  is  not  expected  to  allow  pregnancy  to  occur  during  the  treatment  or  the  subsequent exposure period, conduct of embryo-fetal development studies are not considered warranted.

## 2.1.4.6. Local Tolerance

Y-mAbs has not conducted local tolerance studies with  131 I-omburtamab. Local effects at injection sites were evaluated in toxicity studies.

## 2.1.4.7. Other toxicity studies

Not applicable

## 2.1.5. Ecotoxicity/environmental risk assessment

For ( 131 I-omburtamab) consisting of a protein a radionuclide, ERA is only performed for the radionuclide since  the  protein  part  is  considered  as  not  posing  an  environmental  risk.  The  worst-case  calculated PECSURFACEWATER for ( 131 I-omburtamab) was calculated 44.4 Bq/L and compared to the PECSURFACEWATER calculated for the main source of  131 I discharge from patients/hospitals to the environment, which are 131 Iodine  thyroidal  treatment  indications.  The  calculated  environmental  impact  resulting  from 131 I exposure from thyroidal therapies therefore is about 60-fold higher than the one expected from  131 Iomburtamab  therapy  (2740  Bq/L  vs.  44.4  Bq/L)  and  therefore  it  is  acceptable  to  apply  the  same

<div style=\"page-break-after: always\"></div>

conclusion that direct hospital discharge after  131 iodine therapeutic procedures is safe and exposure to medicinal staff and the public will remain under the threshold of 1 mSv/year.

## 2.1.6. Discussion on non-clinical aspects

The nonclinical data package supporting the application to market  131 I-omburtamab relies on information in the published literature from studies conducted early in its development, as well as more recent studies that  have  characterised  its  specificity  of  binding,  biodistribution  and  dosimetry,  and  mechanisms  of radiation-induced toxicity.

## Pharmacodynamic

In pharmacology studies, the binding characteristics of unlabelled omburtamab were evaluated, and the effectiveness of  131 I-omburtamab as an antitumor agent was tested in an in vivo mouse xenograft model bearing omburtamab-reactive tumours. Nonclinical studies have shown that omburtamab specifically targets the membrane of cancer cells on B7-H3 (Cluster of Differentiation [CD] 276) which is a member of the B7 (CD28) and that it has preferential affinity for a spectrum of cancerous tissues with marginal binding to normal tissues and that it does not cross-react with normal human brain tissue.

According to the Guideline on the non-clinical requirements for radiopharmaceuticals 'the selectivity and specificity of the non-radioactive part as well as secondary pharmacodynamics, defined as effects on other than the desired therapeutic targets, should be critically evaluated and documented'. In vitro target/receptor profiling studies with omburtamab performed by the applicant are considered sufficient.

Absence of dedicated secondary safety pharmacodynamic studies is considered acceptable considering that  131 I activity is the driving MoA.

## Pharmacokinetic

In pharmacokinetic (PK) studies conducted in the same xenograft mouse model, tissue distribution and clearance were evaluated with  125 I-omburtamab the difference in radionuclide use is not expected to affect  the  PK  of  the  radiolabelled  antibody,  results  obtained  with  125 I-omburtamab  are  considered relevant to  131 I-omburtamab.

No nonclinical analytical methods were available to summarise and refers to the respective reports for descriptions of the methods used in imaging and dosimetry studies. The applicant proposes to conduct a human pharmacokinetics study employing validated analysis methods to assess the pharmacokinetics of  131 I-omburtamab. Taking this into account and in line with the 3R policy it is considered acceptable to not performing additional non-clinical work.

Stability of the  131 I-omburtamab conjugation is considered of concerns and data on such stability would be important to be collected. Impact of such data may be seen in the context of the benefit-risk of the product and would possibly trigger regulatory action.

## Toxicology

In toxicology studies, the safety and feasibility of dosing were evaluated in several species using either unlabelled or radiolabelled omburtamab (including 124I-omburtamab and  131 I-omburtamab) delivered by  several  different  routes  of  administration  (including  intraperitoneal,  intrathecal  or  intravenous infusion, or by convection-enhanced delivery of the antibody directly into the brain parenchyma or to an implanted tumour).

The nonclinical toxicity programme is considered sparse and is focused on radiation-induced toxicity. The only GLP conform non-clinical study is the tissue cross reactivity study in human tissues. The applicant is asked to justify why toxicity studies were conducted under non-GLP conditions.

<div style=\"page-break-after: always\"></div>

All studies but the cross reactivity one described in the Pharmacology part (D84VS) were not conducted in GLP. Although it is recognised that some studies employing specialised test systems which are often needed for biopharmaceuticals, may not be able to comply fully with GLP (as per ICHS6 and guideline on radiopharmaceuticals).

The main animal model selected to test radiotoxicity was the naïve rat.  131 I-omburtamab dosimetry estimates after intrathecal dosing in indicated that the dose-limiting organ was the heart wall followed by liver and kidney.

No single-dose general toxicity studies evaluating cold (unlabelled) omburtamab monoclonal antibody have been conducted in a species with a similar cross-reactivity profile as for human tissues.

Systemic radiotoxicity was investigated after intravenous or intraperitoneal administration. In several studies, deaths in animals treated with radiolabelled omburtamab were associated with evidence of nonrecoverable myelosuppression such as excessive bodyweight loss with reductions in haematocrit and red and white blood cell counts). Systemic administration of radiolabelled omburtamab causes bone marrow toxicity and non-recovering myelosuppression, which can be expected from radioimmunotherapy.

Absence of clinical or neurotoxicity, as well as absence of histological findings was observed both in rats (after direct infusion into brain parenchyma) and in monkeys (following CED single dose administration of 124I-omburtamab and over a period of 6, 7 and 9 months - Histological analysis - of postoperative examination).  Moreover,  131 I-omburtamab  was  considered  to  be  well  tolerated  in  monkeys  when administered via a non-traumatic cisternal injection.

Omburtamab demonstrated high affinity for B7-H3 antigen from human or monkey but not from mouse or rat indicating that the cynomolgus monkey is the relevant animal model to investigate potential ontarget adverse effects of omburtamab binding. After repeated intrathecal administration in a very limited number  of  cynomolgus  monkeys  (2),  unfortunately  one  animal  died  most  probably  due  to  surgical complications. This leaves just the results of one animal for which no significant acute toxicities were observed during the treatment period and no treatment-related toxicities were observed during the extended follow-up.

Taking into account that omburtamab binds with high affinity to B7-H3 of human or monkey origin the cynomolgus monkey is considered the relevant animal model to investigate potential on-target adverse effects of omburtamab binding and a an adequate GLP-conform toxicity study is expected for a MAA. Such a study should include a control group, 'cold' omburtamab and  131 I-omburtamab. A GLP-conform toxicity study is expected for a MAA. This study should include a control group, 'cold' omburtamab and 131 I-omburtamab.

In general, it is acceptable that genotoxicity testing was not performed with  131 I-omburtamab, but the absence of such studies should be adequately justified. Referring to the (ICH) S6(R1), where it is stated that genotoxicity studies are generally not necessary to support marketing of biotechnology-derived pharmaceuticals is not considered adequate as the MoA is based on the radio nucleotide which is actually genotoxic.  131 I-Omburtamab is a radioimmunotherapeutic for relapsed or refractory paediatric metastatic neuroblastoma. Therefore, in accordance with ICH S9 it is acceptable that no standard carcinogenicity studies were performed with 131 I-Omburtamab. The absence of dedicated reproductive and developmental toxicity studies is considered acceptable considering the age of the target population.

Local tolerance was assessed in other toxicity studies, in particular in such studies reflection the mode of administration. Omburtamab derivatives were administered by direct interstitial infusion or CED into the  brain  parenchyma  to  rats  and  monkeys.  Finding  in  these  studies  were  related  to  infusion  site histological observations such as haemorrhaging, mild neuronal loss, gliosis.

<div style=\"page-break-after: always\"></div>

In a GLP compliant tissue cross-reactivity study using a set of approximately forty specified tissues of human origin specific on-target binding to B7-H3, was seen in the epithelium of the skin, prostate, eye, endometrium, adrenal, fallopian tube, and cervix, as well as in the supporting stroma of most tissues. Potential  off-target  binding  was  seen  in  cytoplasmic  staining  of  the  Leydig  cells  of  the  testis,  in cytoplasmic staining in glial cells of the spinal cord of one donor, and in cytoplasmic staining of alveolar macrophages in the lungs.

## 2.1.7. Conclusion on the non-clinical aspects

From non-clinical point of view, the MAA for  131 I-omburtamab is in general insufficiently characterised. Clinical data may be more informative and complement such deficiency, provided that the stability of the coupled antibody can be demonstrated. Indeed, concerns on non-targeted delivery of [ 131 I]Iodine, which could pose a risk to patient safety, are raised in regard to stability of the  131 I-omburtamanb conjugation for which data would be expected to be collected. Upon analysis of such data impact of it should be considered on the benefit risk of the product.

## 2.2. Clinical aspects

## 2.2.1. Introduction

## GCP aspects

The cClinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

| Study ID   |   No. of study cen- tres / loca- tions | Design                                                                                                                                                                                                | Study Posology                                                                                                                                                                                                                                                                                                                                                                                 | Study Objective                                                        | Subjs by arm entered/ compl.                                                                                  | Duration                                                                                                                                                                                                                  | Gender M/F Median Age                                                        | Diagnosis Incl. criteria                                                        | Primary Endpoint                                                                                                                                                    |
|------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 03- 133    |                                      1 | Phase 1 trial is a two-part, single-arm, open-label, non- randomize d, single- centre efficacy, safety, and dosimetry trial of intracerebr o- ventricular (ICV) administrat ion of 131 I- omburtama b | Part 1 investigated escalating radioactivity of 131 I- omburtamab with the goal of identifying the maximum tolerated dose. Part 2 investigated dosing at the selected dose of 50 mCi (1850 MBq) determined in Part 1. Subjects without objective disease progression (as determined by neurologic or radiographic examination) four weeks after the last intracerebroventricul ar infusion and | Definition of clinical toxicities of intra- thecal 131 I- ombur- tamab | 109 subjects with NB; 37 paediatric subjects with malignanc ies other than NB (included in SAE analysis only) | Cycle of 5 weeks included pre-medi- cation, 131 I- omburta- mab admini- stration (one dosimetry dose administe red during Week 1 and one treatment dose administe red during Week 2). If a subject received an additional | Male 72 67,3% Female 35 32,7% Age Mean - 5,149 SD 2,645 Median 4,709 Min max | Subjects with a histological ly confirmed diagnosis of a NB with CNS/LM disease | Interim analysis OS at 3 years PFS (CNS/LM) at 12 months Follow - up duration Dosi- metry, blood, brain, and CSF dosi- metry radiation PK activity in blood and CSF |

<div style=\"page-break-after: always\"></div>

|     |    |                                                                                                                                                       | without unexpected Grade 3 or 4 toxicity were eligible for a repeat dosing cycle.                                                                                                     |                             |    | cycle of treatment , the subseque nt cycle started with a dosimetry dose >4 weeks after the treatment dose of the previous cycle.              | 0,85 13,03                                                           |                                                         | Freuence and type of severe AE and SAE                                                                                                                                         |
|-----|----|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 101 |  4 | Single- arm, open- label, nonrandom ized trial included a screening period followed by treatment and observatio n periods. 4 periods spanning 3 years | FIRST DOSE 131 I-omburtamab was administered via an indwelling intracerebroventricul ar access device (e.g., Ommaya reservoir) with adequate CSF flow SECOND DOSE 5 weeks after first | Overall survival at 3 years | 50 | Screening - 4 weeks Followed by first dose, Second dose 5 weeks after first dose Follow up at 26 th week Long term follow-up at 6 months for 3 | Male 29 58% Female 21 42% Mean age 4,7 yrs Median 4 yrs Range 0 - 11 | confirmed diagnosis of NB with relapse in the CNS or LM | CNS/LM PFS (primary interim endpoint) will be estimated at 6 months based on the time from first dose of 131 I- ombur- tamab to CNS/LM progress- sion or death from any cause. |

## 2.2.2. Clinical pharmacology

## 2.2.2.1. Pharmacokinetics

The clinical pharmacology programme for  131 I-omburtamab comprised two clinical studies (trial 03-133 and  trial  101)  enrolling  paediatric  subjects  with  neuroblastoma  and  CNS/LM  metastasis.  Clinical pharmacology investigations  included  radiation  dosimetry,  based  on  imaging  and  samples  (CSF  and blood),  and  PK  based  on  radioactivity  counts  data  from  CSF  and  blood  samples  instead  of  proteinquantification-based PK analysis.

The intended posology is two intracerebroventricular doses of 1850 MBq (50 mCi; or the equivalent based on a dose reduction of 33% and 50% for children less than 3 years and 1 year of age, respectively) with a minimum of 4 weeks in between.

It should be noted that the proposed indication is not limited by age group, while in both presented trials the target population were children, please see clinical efficacy discussion.

## Analytical Methods

Radioactivity measurements were conducted using a gamma or well counter according to Kramer et al., Journal of Clinical Oncology, 2007. Biodistribution was assessed by dosimetry using the same methods as for PK, while imaging-based dosimetry was based on whole-body gamma scans. Analytical methods used for quantification of pharmaceuticals must be validated to ensure that the methods are suitable for

<div style=\"page-break-after: always\"></div>

their intended purpose. For  131 I-omburtamab, no data on method validation have been found for the radioactivity measurements performed for dosimetry and analysis of PK of  131 I-omburtamab.

The following PK parameters were tabulated for subjects in trial 03-133 (n=27 in PK population) and trial 101 (n=23 in PK population): CSF volume of distribution (mL), CSF clearance half-life (minutes), CSF maximum (peak) drug concentration (activity) (Cmax) (Bq/mL), CSF time to maximum concentration (activity) (Tmax) (hr), blood Cmax (Bq/mL), blood Tmax (hr), whole body clearance half-life (hr) (Trial 101 only), brain clearance half-life (hr) (Trial 101 only). The following dosimetry endpoints were calculated: CSF  absorbed  dose  (Gy),  CSF  absorbed  dose  per  mCi  (Gy/mCi),  blood  absorbed  dose  (Gy),  blood absorbed dose per mCi (Gy/mCi), brain surface absorbed dose (Gy), brain surface absorbed dose per mCi (Gy/mCi), absorbed doses by ROI (mGy/MBq). Dosimetry data and PK parameters were summarised with descriptive statistics. Absorbed doses by ROI were listed and presented as bar graphs.

## Adsorption, Distribution, Metabolism and Elimination.

Locally administered omburtamab was demonstrated to be primarily absorbed through the arachnoid granulations, where CSF is reabsorbed into the blood.

## Biodistribution

In study 03-133, after a dosimetry dose of 2 mCi, mean absorbed radiation dose measured at brain surface was 0.394 Gy. Mean absorbed radiation doses in the CSF and blood were 0.787 Gy and 0.0469 Gy, respectively. No data are available on absorbed radiation doses after treatment doses.

In study 101, mean absorbed radiation doses measured at brain surface, in CSF and in blood after the dosimetry dose (2mCi) were 0.61 Gy, 1.219 Gy and 0.016 Gy, respectively. After the treatment dose, mean absorbed radiation doses measured at brain surface, in CSF and in blood were 12.77 Gy, 25.54 Gy and 0.360 Gy, respectively. Absorbed doses were higher for the 50 mCi treatment dose than for the 2 mCi dosimetry dose, but similar mean values of absorbed doses were obtained in brain, blood, and CSF if corrected for mCi dose. As anticipated due to the intracerebroventricular route of administration, CSF absorbed a much higher (76-fold) radiation dose than the blood.

<div style=\"page-break-after: always\"></div>

Table 13. Dosimetry and Pharmacokinetic Results from Clinical Trials

<!-- image -->

|                                                   |                                                         |                                                                                                               |                                                   |                                                   | Dosimetry and                                     | Dosimetry and                                     | Dosimetry and                                     |
|---------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Trial ID                                          | Primary Objective                                       | Trial Desigu                                                                                                  | No.ofNB Subjects                                  | Dose                                              | Source                                            | Absorbed dose per mCi (G/mCi)                     | Absorbed dose (G)                                 |
| PedianicNenroblastomaSnbjeclswithCNS/LMMelastases | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases       | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases                                                             | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases | PedianicNenroblastomaSnbjeclswithCNS/LMMelastases |
| 03-1334                                           | Define clinical toxicities of inhathecal 131I-ombutamab | Single-center, single-arm, non- randomized, open-label hial Part l: dose- escalation Part 2: cohort expansion | Safety: 109 Efficacy: 107 PK/dosimetry: 27        | Dose escalation: 10-70 mCi/ treahment dose        | CSF                                               | ON                                                | 0.787 (0.3664)                                    |
| 03-1334                                           | Define clinical toxicities of inhathecal 131I-ombutamab | Single-center, single-arm, non- randomized, open-label hial Part l: dose- escalation Part 2: cohort expansion | Safety: 109 Efficacy: 107 PK/dosimetry: 27        | Dosimehy: 2 mCi                                   | Blood                                             | NC                                                | 0.047 (0.0303)                                    |
| 03-1334                                           | Define clinical toxicities of inhathecal 131I-ombutamab | Single-center, single-arm, non- randomized, open-label hial Part l: dose- escalation Part 2: cohort expansion | Safety: 109 Efficacy: 107 PK/dosimetry: 27        | Expansion phase: 50 mCi/teahment dose4n           | Brain surface                                     | NC                                                | 0.394 (0.1832)                                    |
| 101r                                              | Overall suvival at 3 years                              | Multi-center, single-arm, non- randomized, open-label hial                                                    | Safety: 24 Efficacy: 24 PK/dosimety: 23           | Dosimehy: 2 mCi 50 mCi/hreament dose4             | CSF                                               | 0.580 (0.3322)                                    | 1.219 (0.7248)                                    |
| 101r                                              | Overall suvival at 3 years                              | Multi-center, single-arm, non- randomized, open-label hial                                                    | Safety: 24 Efficacy: 24 PK/dosimety: 23           | Dosimehy: 2 mCi 50 mCi/hreament dose4             | Blood                                             | 0.009 (0.0034)                                    | 0.016 (0.0050)                                    |
| 101r                                              | Overall suvival at 3 years                              | Multi-center, single-arm, non- randomized, open-label hial                                                    | Safety: 24 Efficacy: 24 PK/dosimety: 23           | Dosimehy: 2 mCi 50 mCi/hreament dose4             | Brain surfnce                                     | 0.290 (0.1670)                                    | 0.610 (0.3632)                                    |
| 101r                                              | Overall suvival at 3 years                              | Multi-center, single-arm, non- randomized, open-label hial                                                    | Safety: 24 Efficacy: 24 PK/dosimety: 23           | Dosimehy: 2 mCi 50 mCi/hreament dose4             | Whole body                                        | ON                                                | NC                                                |

Imaging-based dosimetry revealed brain and liver as primary target organs with highest absorbed radiation doses, followed by urinary bladder wall and spleen.

Figure 3. Total Absorbed Treatment Dose by Organ

<!-- image -->

Organ dosimetry was analysed for whole body and regions-of-interest during Cycle 1 only.

<div style=\"page-break-after: always\"></div>

## Volume of distribution

In study 03-133, CSF volume of distribution was 63.2 mL and in study 101, CSF volume of distribution was 28.9 mL, with a relatively high degree of variability (range: 0.6-234 mL).

## Elimination

Referring to radioactivity measurements in CSF, radioactivity left the CSF space with a geometric mean clearance half-life of 237.1 minutes and 127.74 minutes in study 03-133 and study 101, respectively.

The  geometric  mean  whole-body  clearance  half-lives  determined  in  study  101  were  similar  for  the dosimetry dose (47 hours) and treatment dose (41 hours).

## PK of  131 -iodine

The PK properties of free iodine- 131  have been summarised in the EMA Guideline on core SmPC and Package Leaflet for sodium iodide ( 131 I) for therapeutic use. In brief, iodine- 131  is absorbed rapidly from the upper GI tract (90% in 60 minutes). In case the thyroid is not protected, iodine- 131  is predominantly taken up by the thyroid or excreted renally. Urinary excretion is 37-75%, faecal excretion is about 10%, with almost negligible excretion in sweat. The effective half-life of radioiodine is about 12 hours in blood plasma.

## Dose proportionality and time dependency

Sample-based and imaging-based dosimetry revealed similar absorbed radioactive doses in CSF and blood if corrected for mCi/MBq administered to patients. Relationship appears to be dose-proportional (see Table 14).

Table 14. Dosimetry Absorbed Dose Parameters

<!-- image -->

| Parameter                               | Dosimetry      | Treatment        |
|-----------------------------------------|----------------|------------------|
| Full Analysis Set (M)                   | 24             |                  |
| CSF Absorbed Dose(Gy)                   |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 1.219 (0.7248) | 25.541 (16.1072) |
| Median                                  | 1.070          | 18.665           |
| Min -Max                                | 0.29 -2.67     | 6.70 -60.31      |
| CSF Absorbed Dose per mCi (Gy/mCi)      |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 0.580 (0.3322) | 0.563 (0.3309)   |
| Median                                  | 0.500          | 0.495            |
| Min - Max                               | 0.15-1.25      | 0.15-1.25        |
| Blood Absorbed Dose (Gy)                |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 0.016 (0.0050) | 0.360 (0.1232)   |
| Median                                  | 0.020          | 0.320            |
| Min - Max                               | 0.01-0.02      | 0.16-0.57        |
| Blood Absorbed Doseper mCi(Gy/mCi)      |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 0.009 (0.0034) | 0.009 (0.0035)   |
| Median                                  | 0.010          | 0.010            |
| Min-Max                                 | 0.00-0.01      | 0.00-0.01        |
| Brain Suface Absorbed Dose (Gy)         |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 0.610 (0.3632) | 12.770 (8.0541)  |
| Median                                  | 0.540          | 9.330            |
| Min - Max                               | 0.14 - 1.34    | 3.35 - 30.15     |
| BrainSufaceAbsorbed Doseper mCi(Gy/mCi) |                |                  |
| N                                       | 23             | 22               |
| Mean (SD)                               | 0.290 (0.1670) | 0.282 (0.1650)   |
| Median                                  | 0.250          | 0.250            |
| Min - Max                               | 0.07-0.63      | 0.07 -0.62       |

Source:Table14.2.4.1

CSF=cerebrospinal fluid;Max=maximum;Min=minimum;N=Number of subjects;SD=standard deviation.

In both study 03-133 and study 101, sampling and imaging for PK and dosimetry were done during the first cycle only. PK data are only available for the dosimetry dose (2 mCi/74 MBq), PK characteristics after the first and second treatment dose have not been investigated.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics in the target population

## Trial 03-133

Trial 03-133 was an open-label, single-arm, single-site Phase 1 clinical trial in paediatric patients with CNS/LM relapse from a known or confirmed omburtamab-reactive malignancy (i.e., expressing B7-H3 (CD276)). Trial 03-133 included two parts: a Part 1 (dose escalation phase) to evaluate the maximally tolerated dose (MTD) of intracerebroventricular  131 I-omburtamab (dose range 10 - 70 mCi) and a Part 2 (expansion phase) with 50 mCi as treatment dose established during the dose escalation phase. In both parts, subjects entered at Week 1 for the  131 I-omburtamab dosimetry dose (2 mCi/74 MBq) followed by Week 2 for the  131 I-omburtamab treatment dose at the dose levels specified.

Dose reduction was foreseen in patients aged between 1 - 3 years and patients younger than 1 year based on a publication by Bleyer, Cancer Treat Rep 1977 (see Table 15).

Table 15. Treatment Dose Directed by Age

| Age (years)   |   Dosimetr'yDose (mCi)* | Therapeutic DoseReduction   |   Therapeutic Dose (mCi)* |
|---------------|-------------------------|-----------------------------|---------------------------|
|               |                       2 | 50% reduction               |                      25   |
| 1 to ≤3       |                       2 | 339%6reduction              |                      33.5 |
|               |                       2 | No reduction                |                      50   |

2.0 mCi=74 MBq:25.0 mCi=925MBg: 33.5 mCi=1.239 MBq and 50.0 mCi-1,850 MBq.

Thyroid protection was ensured by adequate stable iodide saturation (by use of oral potassium iodide and Cytomel).

Sampling schedule for dosimetry and PK is presented in Table 16.

Table 16. CSF and Blood Sampling and Imaging Scans in Cycle 1 of Trial 03-133

| Timing of   | Dosimetry Dose   | Dosimetry Dose       |
|-------------|------------------|----------------------|
| Sampling    | Blood and CSF    | Whole-BodyGammaScanb |
| Baseline    | X                |                      |
| 1 hr        | X                |                      |
| 2-4 hr      | X                |                      |
| 3-6 hr      |                  | X                    |
| 18-24 hr    | X                | X                    |
| 36-48 hr    | X                |                      |
| 44-49 hr    |                  | X                    |

CSF =cerebrospinal fluid

a: Blood and CSF samples: used both for PK and dosimetry (sample-based) investigations

b:Whole-Body Gamma Scan: data are not available from MSK and imaging-based dosimetry results fromTrial 03-133 are therefore not included in this application

131 I-omburtamab PK CSF and blood parameters are presented in Table 17and Table 18, respectively.

<div style=\"page-break-after: always\"></div>

Table 17. Summary of  131 I-omburtamab Pharmacokinetic CSF Parameters

<!-- image -->

| Summary Statistic   | Tmr (l)   |   Cmax (Bq/mL) | CL ti2 (min)   | Va (mL)         |
|---------------------|-----------|----------------|----------------|-----------------|
| n                   | 27        |             27 | 23             | 23              |
| Mean                | 1.93      |         788497 | 237.0623       | 63.23213        |
| SD                  | 0.718     |         372401 | 162.85092      | 36.607077       |
| Median              | 2.00      |         696340 | 198.7200       | 61.51520        |
| Min. Max            | 1.0.3.3   |         418840 | 67.872.744.978 | 9.5238.146.4286 |

Source:Table14.2.7.1

CLtin=clearancehalf-life;Cmx=maximumconcentration;CSF=cerebrospinalfluid; max=maximum;min=minimum;Tmax=timetomaximumconcentration:Va=yolumeof distribution.

Table 18. Summary of  131 I-omburtamab Pharmacokinetic Blood Parameters

<!-- image -->

| SunmaryStatistic   | Tmu (h)   | Cm (Bq/mL)     |
|--------------------|-----------|----------------|
| 11                 | 27        | 27             |
| Mean               | 24.39     | 7152.662       |
| SD                 | 9.081     | 4383.9355      |
| Median             | 22.00     | 6555.660       |
| Min,Max            | 2.2,46.5  | 307.47.20553.5 |

Source: Table 14.2.7.1

Cmx=maximumconcentration;max=maximum;min=minimum;Tmx=time tomaximum concentration,

The median Tmax in the CSF was 2.0 h with a range of 1.0 to 3.3 h. CSF exposure to  131 I-omburtamab (mean Cmax) was 788497.4 Bq/mL (corresponding to 0.0213 mCi/mL). Mean CL t1/2 and Vd were 237 min and 63 mL, respectively.

Compared to  131 I-omburtamab in the CSF,  131 I-omburtamab was absorbed slowly in the blood, with a median Tmax of 22.0 h (ranging from 2.2 to 46.5 h). This was expected due to the intracerebroventricular administration of  131 I-omburtamab. Systemic exposure to  131 I-omburtamab (mean Cmax of 7152.662 Bq/mL, corresponding to 0.193 μCi/mL) was approximately 110 -fold lower than CSF exposure.

## Trial 101

Trial  101 is  an ongoing, single-arm, open-label, non-randomised, multisite Phase 2/3 clinical trial in paediatric patients who have a histologically confirmed diagnosis of neuroblastoma with relapse in the CNS/LM and who have progression or relapse in the CNS/LM after induction therapy.

Treatment with  131 I-omburtamab in Trial 101 followed a regimen similar to that described for Part 2 of Trial 03-133. The dosimetry and treatment dose levels (2 mCi and 50 mCi, respectively) and reductions based on age, the treatment cycles, the method of administration and thyroid protection treatment are consistent.

It should be noted that the dosimetry dose was used only to assess dosimetry and PK, not to individualise treatment doses, and dosimetry was discontinued as of 01 January 2020. All PK results included in this summary are from subjects enrolled prior to 01 January 2020 and who received both a dosimetry and treatment dose (one treatment cycle).

There was a more frequent sampling schedule in Trial 101 compared to Trial 03-133 and an additional sampling was conducted after the treatment dose (50 mCi) in Trial 101 only. Sampling schedule for dosimetry and PK is presented in Table 19.

<div style=\"page-break-after: always\"></div>

Table 19. CSF and Blood Sampling and Imaging Scans in Cycle 1 of Trial 101

<!-- image -->

|                                    | Dosimetry Dose   | Dosimetry Dose         | TreatmentDose   | TreatmentDose          |
|------------------------------------|------------------|------------------------|-----------------|------------------------|
| Timing of Sampling                 | Blood and CSF    | Whole-Body Gamma Scanb | Blood and CSFa  | Whole-Body Gamma Scanb |
| Baseline                           | X                |                        |                 |                        |
| 30minutes(±5min)                   | X                |                        |                 |                        |
| 1 hr(± 10 mim)                     | X                |                        |                 |                        |
| 4 hr(±10min）                       | X                |                        |                 |                        |
| 4-5 hr (4 hr + 1 hr)               |                  | X                      |                 |                        |
| 24 hr (± 30 min)                   | X                |                        |                 |                        |
| 24 hr (±2 hr)                      |                  | X                      |                 |                        |
| 48 hr (± 1 hr)                     | X                |                        |                 |                        |
| 48 hr(±2 hr)                       |                  | X                      |                 | X                      |
| 72 hr(±4 hr)                       | X                |                        |                 |                        |
| 7 days (± 1 day) post-infusiononly |                  |                        | X               |                        |

CSF = cerebrospinal fluid.

a:Blood and CSF samples: used both for PK and dosimetry (sample-based)investigations b: Whole-Body Gamma Scan: used for dosimetry (imaging-based) investigations.

131 I-omburtamab  infused  directly  into  the  CSF  compartment  and  measured  as  radioactive  counts  is distributed  relatively  quickly  in  the  CSF  with  a  mean  Tmax  of  0.642  hours.  The  median  volume  of distribution in the CSF compartment was 40.65 mL, exhibiting a relatively high degree of variability. This variability may be the result of sampling issues, or it may reflect variations in the degree of tumour target binding sites. The radioactivity left the CSF space with a geometric mean clearance half-life of 127.74 min. Upon entering the blood, the maximum radioactivity count was orders of magnitude lower than in CSF and occurred later with a mean Tmax in blood of 24.88 hours.

The geometric mean whole-body clearance half-lives were similar for the dosimetry dose (47 hours) and treatment dose (41 hours). The geometric mean brain clearance half-life was 24 hours.

<div style=\"page-break-after: always\"></div>

Table 20. Pharmacokinetic Parameters

| Parameter                       | Dosimetry        | Treatment      |
|---------------------------------|------------------|----------------|
| Full Analysis Set (N)           | 24               |                |
| CSF Cmr (Bq/mL)                 |                  |                |
| N                               | 23               |                |
| Geometric Mean (%CV)            | 1292386.8(89.03) |                |
| Median                          | 1413002.1        |                |
| Min - Max                       | 249643-7089229   | 一              |
| CSF Imr (h)                     |                  |                |
| N                               | 23               |                |
| Mean (SD)                       | 0.642 (0.2441)   | =              |
| Median                          | 0.500            |                |
| Min - Max                       | 0.43 - 1.12      | 一              |
| Blood Cmur (Bq/mL)              |                  |                |
| N                               | 23               |                |
| Geometric Mean (%CV)            | 2755.2 (38.48)   |                |
| Median                          | 3162.7           | 一              |
| Min - Max                       | 1315.8-4639.3    |                |
| Blood Tmr(l)                    |                  |                |
| N                               | 23               |                |
| Mean (SD)                       | 24.88 (4.922)    | 一              |
| Median                          | 23.97            |                |
| Min - Max                       | 22.7 - 47.4      |                |
| CSF Volume of Distribution (mL) |                  |                |
| N                               | 23               |                |
| Geometric Mean (%CV)            | 28.90 (253.843)  | 二              |
| Median                          | 40.65            |                |
| Min - Max                       | 0.6- 234.0       |                |
| CSF Clearance Half-life (m)     |                  |                |
| N                               | 23               | 二              |
| Geometric Mean (%CV)            | 127.74 (172.618) |                |
| Median                          | 163.64           |                |
| Min - Max                       | 6.9 - 766.0      |                |
| Whole Body Half-life (h)        |                  |                |
| N                               | 23               | 22             |
| Geometric Mean (%CV)            | 47.26 (41.219)   | 41.07 (40.422) |
| Medin                           | 46.51            | 38.92          |
| Min - Max                       | 21.4 - 94.9      | 20.9 - 138.8   |
| Brain Clearance Half-life (h)   |                  |                |
| N                               | 23               |                |
| Geometric Mean (%CV)            | 23.72 (40.251)   |                |
| Median                          | 22.01            |                |
| Min - Max                       | 11.8 - 50.6      | 一              |

Source:Table 14.2.4.1

CSF=cerebrospinal fuid; CV=geometric coefficient of variation; h= hour; m=minutes; Max = maximum;Min=minimumN=mumber of subjects;SD=standard deviation

<div style=\"page-break-after: always\"></div>

Figure 4. Mean Time-Activity Profiles in CSF and Blood - Trial 101

<!-- image -->

## PK in special populations

No PK studies of  131 I-omburtamab have been performed to assess differences among populations varying in renal or hepatic function, or across populations varying in sex, ethnicity, or age (other than children less than 3 years and 1 year of age).

As  131 I-omburtamab is primarily cleared via the kidneys, an increased radiation exposure is possible in patients with impaired renal function. However, due to exclusion of subjects with severe major organ toxicity (including renal and hepatic systems) greater than Grade 2 (Trial 03-133) or greater than Grade 3 (Trial 101), safety and efficacy in subjects with renal or hepatic impairment have not been established.

For study 03-133,  131 I-omburtamab PK CSF and blood parameters are presented by weight in Table 29. Most subjects belonged to the 0 to &lt;15 kg or 15 to &lt;30 kg groups. Only three subjects were ≥30 kg.

<div style=\"page-break-after: always\"></div>

Table 21. Pharmacokinetic Parameters of Dosimetry Dose by Weight Group in Trial 03-133

<!-- image -->

|                    |                    | Weight(k)       | Weight(k)        | Weight(k)         |                     |
|--------------------|--------------------|-----------------|------------------|-------------------|---------------------|
| PK Parameter       | Statistie/Category | 0 to~15 (N=11)  | 15to<30 (N=13)   | 230 (N=3)         | All Subjects (N=27) |
| CSF Tm (hr)        | N                  | 11              | 13               | 3                 | 27                  |
| CSF Tm (hr)        | Mean               | 1.80            | 2.16             | 1.43              | 1.93                |
| CSF Tm (hr)        | SD                 | 0.527           | 0.822            | 0.666             | 0.718               |
| CSF Tm (hr)        | Median             | 1.70            | 2.10             | 1.10              | 2.00                |
| CSF Tm (hr)        | Min,Max            | 1.1.2.9         | 1.2.3.3          | 1.0.2.2           | 1.0,3.3             |
| CSF Cn(Bq/mL)      | N                  | 11              | 13               | 3                 | 27                  |
| CSF Cn(Bq/mL)      | Mean               | 856381.8        | 758756.2         | 668466.7          | 788497.4            |
| CSF Cn(Bq/mL)      | SD                 | 483420.69       | 291376.99        | 268855.69         | 372400.81           |
| CSF Cn(Bq/mL)      | Median             | 744070          | 669700           | 560180            | 696340              |
| CSF Cn(Bq/mL)      | Min, Max           | 418840,2090500  | 432900,1435230   | 470640,974580     | 418840,2090500      |
| CSF CL te(minutes) | N                  | 10              | 10               | 3                 | 23                  |
| CSF CL te(minutes) | Mean               | 182.6040        | 284.0646         | 261.9160          | 237.0623            |
| CSF CL te(minutes) | SD                 | 108.66104       | 212.99995        | 87.35317          | 162.85092           |
| CSF CL te(minutes) | Median             | 129.8460        | 239.1480         | 307.0920          | 198.7200            |
| CSF CL te(minutes) | Min, Max           | 88.476,415.800  | 67.872,744.978   | 161.23,317.430    | 67.872, 744.978     |
| CSF Va (mL)        | N                  | 10              | 10               | 3                 | 23                  |
| CSF Va (mL)        | Mean               | 58.23767        | 9165919          | 85.12357          | 63.23213            |
| CSF Va (mL)        | SD                 | 44.555616       |                  | 30.288524         | 36.607077           |
| CSF Va (mL)        | Medisn             | 46.13075        | 60.75240         | 80.00000          | 61.51520            |
| CSF Va (mL)        | Min, Max           | 9.5238.146.4286 | 15.8692,104.5000 | 57.7236, 117.6471 | 9.5238,146.4286     |
| Blood Tmx (hr)     | N                  | 11              | 13               | 3                 | 27                  |
| Blood Tmx (hr)     | Mean               | 26.25           | 21.79            | 28.87             | 24.39               |
| Blood Tmx (hr)     | SD                 | 9.260           | 8.314            | 11.645            | 9.081               |
| Blood Tmx (hr)     | Medisn             | 22.80           | 21.00            | 24.80             | 22.00               |
| Blood Tmx (hr)     | Min.Max            | 19.5,46.5       | 2.2.42.0         | 19.8,42.0         | 2.2.46.5            |
| Blood Cm (Bq/mL)   | N                  | 11              | 13               | 3                 | 27                  |
| Blood Cm (Bq/mL)   | Mean               | 8140.774        | 6888.062         | 4676.183          | 7152.662            |
| Blood Cm (Bq/mL)   | SD                 | 3868.3510       | 5121.0513        | 1627.6874         | 4383.9355           |
| Blood Cm (Bq/mL)   | Median             | 7773.700        | 5535.200         | 3742.920          | 6555.660            |
| Blood Cm (Bq/mL)   | Min,Max            | 2349.5,17293.8  | 307.47,20553.5   | 3730.0,6555.66    | 307.47,20553.5      |

CL =clesrance; Cms = maxinum concentation; CSF = cerebrospinsl fuid hr = hour Max = maximm; Min = mirimum; PK = phamacokinetie; SD = standard devistion; ta =

aThe tunit in the souree table was incorectly stated as L/hr.

halflife; Tmu = time of maximum concentration; V= volume of distibution.

Summaries of absorbed doses to the CSF, blood, and brain by weight are provided in Table 22.

Table 22. Summary of Radioactive Absorbed Dosimetry Dose in Regions of Interest by Weight Group in Trial 03-133

<!-- image -->

CSF = cerebrospinal fluid; Max = maximum; Min =minimu; SD = standard deviation

For study 03-133,  131 I-omburtamab PK CSF and blood parameters are presented by age in Table 23.

<div style=\"page-break-after: always\"></div>

Table 23. Pharmacokinetic Parameters of Dosimetry Dose by Age Group in Trial 03-133

<!-- image -->

CL = clearance; Cnn = maximum concenbration; C SF = cerebrospinal fluid; hr = hour, Max = maximum; Min = minimum; PK = pharmacokinetic; SD = standard deviation; t = half-life; Tmx = time of maximum concenhration; Vg= voluume of dishibution.

Source: Tnial 03-133 Table 14.2.7.1

The tmit in the towce table wuu incomectly italed as L/hur.

Summaries of absorbed doses to the CSF, blood, and brain by age are provided in Table 24.

Table 24. Summary of Radioactive Adsorbed Dosimetry Dose in Regions of Interest by Age Group in Trial 03-133.

<!-- image -->

Souce:Tninl03-133Tabl14.2.7.1

CSF=cerebrospinal flid;Max=maximuum;Min=minimm;SD=standard deviation

The studies contributing to the clinical  pharmacology package of  131 I-omburtamab have solely been conducted in children. Thus, PK data provided fully refer to the paediatric population.

## Exposure relevant for safety evaluation

No information available, as PK data for the intended treatment dose are lacking and the therapeutic dose range has not been adequately assessed.

## 2.2.2.2. Pharmacodynamics

No clinical data on PD are available.

<div style=\"page-break-after: always\"></div>

## Mechanism of action

131 I-omburtamab is an iodine- 131  radiolabelled murine monoclonal antibody that recognises and binds selectively  to  the  B7-H3  (CD276)  antigen.  B7-H3  is  a  member  of  the  B7  (CD28)  immunoglobulin superfamily, which regulates T-cell function, and is a tumour-associated antigen that is overexpressed on the cell membrane of a range of solid tumours, including CNS/LM neuroblastoma tumour cells. The iodine-131 emits ionizing radiation, resulting in DNA damage and tumour cell death.

## Immunogenicity

As of the cut-off date for this MAA, no immunogenicity assessments have been conducted during the clinical programme. However, Trial 101 was amended to collect samples for immunogenicity detection from three to six subjects who received two treatment doses. This will necessitate the enrolment of up to 12 subjects to obtain the required samples. Results from a to be developed assay will investigate if there is any effect of  131 I-omburtamab antidrug antibodies on PK and safety and these analyses will be provided in the final CSR for Trial 101 (captured as REC).

## Primary and Secondary pharmacology

N/A

## 2.2.3. Discussion on clinical pharmacology

## Pharmacokinetics

In both studies contributing to the clinical pharmacology package for this submission (trial 03-133 and trial  101),  clinical  pharmacology  investigations  included  radiation  dosimetry,  based  on  imaging  and samples (CSF and blood), and PK based on radioactivity counts data from CSF and blood samples instead of protein-quantification-based PK analysis.

Radioactivity measurements were conducted using a gamma counter or well counter according to Kramer et al., Journal of Clinical Oncology, 2007. Biodistribution was assessed by dosimetry using the same methods as for PK, while imaging-based dosimetry was based on whole-body gamma scans. Method validation  for  the  radioactivity  measurements  is  considered  acceptable.  While  the  development  and validation of assays to measure the PK of omburtamab monoclonal antibody are not acceptable this issue is not further pursued. In clinical trials (Trials 101 and 03-133), PK and dosimetry were only investigated in the first dosing cycle. The applicant refers to patient derived data, demonstrating that 20 patients from Trial 03-133 had CSF and blood samples collected, following both the dosimetry dose and the treatment  dose.  The  data  did  not  indicate  any  difference  in  absorbed  dose  per  unit  administered radioactivity across administered doses in the CSF, with a treatment CSF absorbed dose of 52.5 ±31.6 cGy/mCi vs. a dosimetry CSF absorbed dose of 55.5 ±75.8 cGy/mCi (data provided as median ±SD). Currently the data are accepted, and an additional PK study is not requested.

The applicant had been asked to provide more detailed information on the stability of  131 I-iodine binding to the antibody as well as on kinetics of the antibody. This issue is also considered unresolved as no stability  testing  of  131 I-omburtamab  has  been  performed  and  thus,  no  sufficient  information  on  the systemic stability  of  iodine-131  binding  to  the  antibody  in  patients  with  malfunctioning  blood-brainbarrier  can  be  provided.  The  applicant  proposes  studies  to  investigate  the  in  vitro  stability  of 131 I-omburtamab in CSF and human plasma performed as a commitment by Y-mAbs, with an estimated timeframe for reporting the data by end of Q4 2022. This proposal is acceptable for the time being, however, if stability is not demonstrated serious concerns regarding efficacy will be raised that may lead to a reconsideration of the benefit risk of the product.

<div style=\"page-break-after: always\"></div>

## Route of administration

The route of administration of 131 I-omburtamab is intracerebroventricular infusion via an intracerebroventricular access device (e.g., Ommaya  catheter/reservoir). Intracerebroventricular administration has been used for decades in the clinic to provide treatment for adult and paediatric populations suffering from a variety of conditions, including varying cancer types.

The brain is a highly sensitive and fragile neuronal organ system that needs a regular supply of fuels, gases, and nutrients to maintain homeostasis and other vital functions. The blood brain barrier (BBB) acts as a physical barrier and imposes various obstacles. It inhibits delivery of therapeutic agents to the CNS and imposes obstruction for delivery of a large number of drugs, including antibiotics, antineoplastic agents, and neuropeptides, to pass through the endothelial capillaries to brain. Many different drug delivery methods have been developed for targeted brain delivery. Some of them are neurologically invasive and found unsafe for drug delivery.

Ommaya reservoir is a highly effective implant that provides long term access to the cerebrospinal fluid and has simplified administration of antimicrobials, antifungals, antineoplastic, and analgesic medications directly into the brain. Though initially conceived for delivery of antifungal medications into the cerebrospinal fluid (CSF), this device is commonly used today for chemotherapeutic central nervous system (CNS) delivery and CSF sampling. For the placement of the Ommaya catheter, the arachnoid epithelium is pierced resulting in a lowering of the integrity of one of the normal biological barriers. The contribution of this to the overall potential for physiological abnormal exchange between blood and brain is  however  considered  insignificant.  Contraindications  for  the  use  of  this  device  are  usually  -  scalp infection, brain abscess, known allergy to silicone. These specific contraindications are not proposed by the applicant.

## Dosimetry/Biodistribution

Preclinical studies have demonstrated that omburtamab has marginal reactivity in most normal tissues. The  131 I-omurtamab is administered locally via an intraventricular catheter placed into the ventricular system of the brain.  No specific omburtamab binding was detected in cerebral cortex or in cerebellum, or in endothelial cells in a Y-mAbs conducted GLP-compliant human tissue cross-reactivity immunohistochemistry study testing approximately 40 specified human tissues from 3 different human donors.

Absorbed doses, as reported above, were higher for the 50 mCi treatment dose than for the 2 mCi dosimetry dose, but similar mean values of absorbed doses were obtained in CSF and blood if corrected for mCi dose. As anticipated due to the intracerebroventricular route of administration, CSF absorbed a much  higher  (76-fold)  radiation  dose  than  the  blood.  The  CSF  to  blood  absorbed  doses  differs substantially in studies 101 and 03-133 (76 versus 16.78 times higher in CSF to compared to blood). One possible explanation could be an overestimation of the blood absorbed doses in Trial 03-133 using the modelling approach. If the blood clearance of  131 I-omburtamab is in fact faster (e.g., due to HAMA effects) and correctly described by the finding of a relatively low blood activity at the 72-hour sampling point  in  Trial  101,  this  would  drive  some  of  the  difference.  The  CSF  absorbed  doses  could  be  also underestimated, if  131 I-omburtamab was retained longer in the CSF compartment than what a 48-hour sample in Trial 03-133 indicate, and an artefactually low CSF activity would be the result of the modelling.

Use of radioactivity measurements in CSF and blood is an interesting approach. The long-term indwelling of  the  application  and  the  continuous  use  of  the  device  could  affect  these  measurement  (local inflammatory response, local injury of the endothelium, leakage of blood, lowered BBB integrity). The ICV catheter is one of several potential risk factors which could influence the BBB integrity, but a factor which may be considered as minimal. One would expect information on the effect of locally (to the cerebral ventricular system) administered  131 I-labelled markers demonstrating an effect especially since

<div style=\"page-break-after: always\"></div>

it  has  been noted that with respect to clearance, after the treatments of omburtamab, a consistent decline in percent of the antibody present in CSF to less than 0.01% at 168 hours was observed. Imagingbased dosimetry revealed brain and liver as primary target organs with highest absorbed radiation doses, followed by urinary bladder wall and spleen. Absorbed doses in the liver were even higher than absorbed doses in the brain, which is unexpected given the intracerebroventricular route of administration and significantly lower radiation doses determined in blood as compared to CSF. Based on the submitted dossier  the  targeted  administration  provides  an  opportunity  for  therapeutic  effect  in  the  CNS  with diminished systemic impact. The unbound  131 I-omburtamab quickly leaves the CSF compartment with a clearance half-life (T½) of ~1 hour and the subsequent whole body clearance T½ of ~48 hours is expected to be dependent on the normal physiological degradation of endogenous and recombinant antibodies via mononuclear cells abundantly located in the liver and spleen. This explains the presence of radioactivity in circulation and liver. Despite this fact, no treatment emergent adverse events (TEAEs) suggestive of significant liver dysfunction have been reported.

Uptake of  131 I-iodine in the thyroid was protected by stable iodide saturation and thus, absorbed doses in the thyroid were low. Thyroid protection is also foreseen in the label. Thyroid protection was initiated one week prior to  131 I-omburtamab dosimetry doses and continued until two weeks after each  131 Iomburtamab treatment dose.

CSF volume of distribution ranged between 28.9 - 63.2 mL, with a high degree of variability. Based on the normal CSF volume of 150 mL reached at the age of 5 years,  131 I-omburtamab distributes in less than 50% of the CSF.

PK of  131 I-iodine: For the PK properties of free iodine-131 it was referred to the EMA Guideline on core Summary of Product Characteristics for sodium iodide ( 131 I). Intracerebroventricular administered  131 Iomburtamab which has not  bound  to  B7-H3  expressing  tumour  cells  will  be  detectable  in  systemic circulation relatively quickly. When it thus enters the systemic circulation, omburtamab as a mAb is mainly metabolised and eliminated through proteolytic degradation that results in formation of smaller peptides and amino acids. Any free iodide will be distributed and eliminated.

It has been observed, after oral administration, that urinary excretion is 37 to 75%, faecal excretion is about 10%, and there is almost negligible excretion in sweat. Urinary excretion is characterised by the renal clearance, which constitutes about 3% of the renal blood flow. Clearance is affected by the impaired renal function and also affected by the state of the functional status of thyroid gland. It was clarified that the renal clearance of iodide was also found to be higher in the young similar to the thyroidal clearance of iodide, particularly between the age of 3 weeks to 6 months. When normalised for body weight, the young excrete iodide in urine at a greater rate than adults which is inconsistent with maturation of the glomerular filtration. This explanation can be accepted.

## Elimination

With regard to PK of  131 -iodine, the applicant refers to the SmPC for sodium iodide ( 131 I) for therapeutic use for which PK properties have already been adequately characterised in the past. However, it remains uncertain how far binding to omburtamab would change PK characteristics of  131 I-iodine.

Referring to radioactivity measurements in CSF, radioactivity left the CSF space with a geometric mean clearance half-life of 2 - 4 hours in study 03-133 and study 101. The movement of molecules between the intrathecal space and the blood is prevented by the BBB. Elimination of the antibody portion itself (omburtamab) has not been determined but is expected to be mediated by intracellular proteolytic catabolism as known for other mAbs. Geometric mean whole-body clearance half-lives determined in study 101 were 47 hours after the dosimetry dose and 41 hours after the treatment dose.

The  determination  of  whole-body  clearance  half-life  and  brain  clearance  half-life  is  welcomed.  The applicant  provided  in  detail  main  PK  characteristics,  absorption,  distribution  and  elimination  of  131 I-

<div style=\"page-break-after: always\"></div>

omburtamab in humans but did not collect excreta samples and therefore cannot detail if the excretion of  131 I-omburtamab follows that for free iodine-131.

## Dose proportionality and time dependency

Similar values are observed for dose-normalised absorbed radiation doses, indicating doseproportionality with regard to dosimetry. Data reported in the assessment above show that absorbed doses per target organ are similar for dosimetry (2 mCi) and treatment dose (50 mCi) if corrected for MBq administered.

Due to the absence of PK data for the treatment dose (50 mCi), dose proportionality with regard to PK parameters cannot be assessed. PK parameters have solely been determined for the dosimetry dose (2 mCi).

No data for assessment of time-dependent effects and PK characteristics of  131 I-omburtamab after the first and second treatment dose are available. Considering that omburtamab is a full IgG1 antibody with anticipated half-life of approximately 3 weeks, accumulation is expected for the treatment dose given 1 week  after  the  dosimetry  dose.  In  this  regard,  information  on  target  saturation  and  binding  and distribution of  131 I-omburtamab in case of sustained target saturation due to the preceding dosimetry dose had been required. The potential for time-dependent effects and change in PK, in particular after the second  131 I-omburtamab treatment dose was discussed and judged to be minimal for both the CSF and the systemic compartments. Detailed information about the kinetics of the antibody part of the molecule  is  pending  and  this  question  needs  to  be  re-addressed  when  these  data  will  be  further generated.

## PK in the target population

## Study 03-133

PK in study 03-133 was solely analysed for the dosimetry dose, since CSF and blood sampling for PK was restricted to the 36 - 48 hours period post dosimetry dose. Data are reported above in the report.

Only 27 patients contributed to PK data for this study, and these were patients consecutively enrolled over 3 years (2016-2018). The emphasis of PK results is based on Trial 101 analyses, and PK and dosimetry data from Trial 03-133 should be regarded as supplemental which is acknowledged and will be judged as such.

## Study 101

Compared to study 03-133, PK sampling in CSF and blood in this study was conducted more frequently after the dosimetry dose (7 samples collected at baseline, 30 minutes, 1 hour, 4 hours, 24 hours, 48 hours and 72 hours post dosing). An additional sample was collected 7 days after the treatment dose (50 mCi). The dosimetry dose was only used to assess dosimetry and PK, not to individualise treatment doses, and dosimetry was discontinued as of 01 January 2020. All PK results included in this summary are from subjects enrolled prior to 01 January 2020 and who received both a dosimetry and treatment dose (one treatment cycle). In contrast, approval of  131 I-omburtamab is sought for two treatment doses of 1850 MBq without the preceding dosimetry dose.

Median Tmax in CSF and blood after the dosimetry dose was 0.5 hours and 23.97 hours, respectively. Median CSF Tmax in Trial 03-133 was 2.0 hours and thus, longer than what was observed in Trial 101 (0.5 hours); however, this could have resulted from inclusion of an earlier sampling time (30 minutes) in Trial 101. The median blood Tmax was similar across both studies (23.97 hours in Trial 101 and 22.0 hours in Trial 03-133). The observed differences in median Tmax between the studies could be caused by many factors, including extent of diseases, volume of tumour, BBB integrity, indwelling time of the device,  and  differences  in  sampling  times  etc.  Geometric  mean  for  Cmax  in  CSF  and  blood  was

<div style=\"page-break-after: always\"></div>

1,292,386.8 Bq/mL and 2755.2 Bq/mL. As expected, the maximum radioactivity count in blood was about 470-fold lower than in CSF and occurred significantly later as seen in values for Tmax.

A high degree of variability was observed for the PK parameters analysed. This is supposed to be caused by the differences in tumour binding or sampling issues. An overview of potential factors influencing the CSF Vd was provided by the applicant and the different parameters with potential to affect PK findings and sample-based dosimetry are discussed. Differences in dosimetry approach, sampling schedule and PK  analyses  performed  in  both  trials  hamper  the  assessment  of  the  presented  data  due  to  lack  of uniformity. The applicant has no data on the analytical performance in Trial 03-133 as conducted by MSK, the qualification of equipment and standardisation of processing and analysis was not done by an independent vendor, and a retrospective qualification of MSK's analysis set-up is not feasible.

Neither study 03-133 nor study 101 provided PK data for the actual treatment dose of 1850 MBq  131 Iomburtamab. Therefore, PK data described in section 5.2 of the SmPC refers to kinetics observed with the  dosimetry  dose  (2  mCi/74  MBq),  which  is  not  considered  appropriate.  PK  should  be  adequately characterised after the treatment dose, which is actually 25-fold higher than the dosimetry dose. In this regard,  it  would  be  relevant  to  define  a  therapeutic  exposure  range  accounting  for  exposure  levels needed for efficacy with - at the same time - acceptable tolerability. For adequate characterisation of PK at the  131 I-omburtamab treatment dose, a post-authorisation PK study would be required.

## Special populations

No PK studies of  131 I-omburtamab analysing differences in patients due to impaired renal or hepatic function, sex, ethnicity, or age were conducted. Subjects with impaired kidney function were not eligible for  inclusion  in  the  clinical  trial  programme  with  131 I-omburtamab.  Therefore,  the  effect  of  impaired kidney function on the exposure/PK of  131 I-omburtamab was not studied. A comparison of exposure in different subgroups of weight (0 to &lt;15 kg; 15 to &lt;30 kg; ≥30 kg) and age (0 to &lt;1 year; 1 to &lt;3 years; ≥ 3 years) was provided. Most subjects belonged to the 0 to &lt;15 kg or 15 to &lt;30 kg groups. Only three subjects were ≥30 kg. Median CSF T max and blood Tmax were similar across weight groups. Despite the applied dose reduction in children aged &lt;1 year and 1 to &lt;3 years, higher exposure as described by Cmax in CSF and blood was seen in patients with lower body weight. Given that the applied dose reduction regimen is based on literature reference from 1977. Doses according to weight were discussed with the aim to avoid myelosuppression. The data indicate that dosing according to weight does not add further value to the safety if compared to dosing according to age.

The majority of subjects (70%) providing PK or dosimetry data were over the age of 3 years. Median CSF Tmax was similar among age groups, with each age group having a median CSF Tmax of about 2.0 hours. Median blood Tmax was also similar among age groups, with each age group having a median blood Tmax between 21.0 and 22.4 hours. No clear differences were seen in exposure comparing the different age groups and no valid conclusions may be drawn given the small numbers of subjects who were 0 to &lt;1 years of age (n = 2) and 1 to &lt;3 years of age (n = 6).

Based on the data provided,  131 I-omburtamab has been administered to 170 paediatric patients in Trial 03-133 and Trial 101 without any indication of acute adverse effects on the major physiological systems (e.g.,  cardiovascular,  respiratory,  renal,  and  CNS).  The  population  being  a  paediatric  one  limits  this conclusion. Prolonged toxicity of other factors - on the brain tissue affecting the BBB could be a major contributing  factor.  There  are  no  safety  reports  suggesting  adverse  long-term  neurological  effects following treatment with  131 I-omburtmab. Neurocognitive functioning and QoL testing were performed where  feasible  before  and  after  treatment  with  131 I-omburtamab.  The  assessment  of  the  results  is ongoing;  however,  it  should  be  noted  that  only  a  few  patients  have  a  baseline  assessment  of neurocognitive  function.  Given  the  lack  of  information,  'long-term  safety  including  neurocognitive development' will be included as missing information in the Summary of safety concerns presented in the Risk Management Plan for  131 I-omburtamab. An assessment is currently ongoing to understand the

<div style=\"page-break-after: always\"></div>

feasibility of establishing a patient registry to collect additional safety data on the important risks and explore the areas of missing information presented in the Risk Management Plan for  131 I-omburtamab. The registry study has been proposed as category 3 study in the RMP.

## Pharmacodynamics

No  data  on  clinical  pharmacodynamics  are  available.  Likewise,  the  relationship  between  radioactive dose/exposure and response (efficacy/safety) has not been investigated. Furthermore, a therapeutic exposure range accounting for maximum efficacy whilst maintaining minimal risk of toxicity has not been defined. No data on  131 I-omburtamab exposure after the treatment dose of 50 mCi (1850 MBq) that may be used for analysis of these relationships are available.

No data on immunogenicity have been provided. Study 101 was, however, amended to collect samples for immunogenicity detection from three to six subjects who received two treatment doses. Lack of immunogenicity data is a serious drawback of this application. The results on ADA in the abovementioned patients are planned to be provided with the final CSR together with a bioanalytical method report and a validation report for the assay used for detection of anti-drug anti body.

## 2.2.4. Conclusions on clinical pharmacology

Overall, PK of  131 I-omburtamab is not considered to be sufficiently characterised to support approval of the intended two  131 I-omburtamab doses at 1850 MBq in paediatric neuroblastoma patients with CNS/LM metastasis. In particular, all dosimetry and PK results are based on analytical methods, which have not been validated to prove that these methods are suitable for their intended purpose. Collectively, the reliability of dosimetry and PK data is questionable.

## 2.2.5. Clinical efficacy

Table 25. Efficacy studies submitted in support of this procedure

| Study ID   | No. of study centres / locations                     | Design     | Study Posology                                       | Study Objective                           | Subjs by arm entered/ compl.                                                    | Duratio n                              | Diagnosis Incl. criteria              | Primary Endpoin t                                     |
|------------|------------------------------------------------------|------------|------------------------------------------------------|-------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------|---------------------------------------|-------------------------------------------------------|
| 03- 133    | Single center, initiated 2004, closed 2018           | Single arm | Combined dose escalation cohort and expansion cohort | Toxicity of intrathecal 131 I- omburtumab | Safety: 109 neuroblasto ma, 37 non- neuroblasto ma Efficacy: 107 neuroblasto ma | 1-2 doses, long term follow-up ongoing | Neuroblast oma with CNS/LM metastasis | OS at 3 years (not prespecifi ed at trial initiation) |
| 101        | 3 US sites, 1 European site, initiated 2018, ongoing | Single arm | 1850 MBq / dose                                      | Efficacy as determined by OS              | Efficacy: 50                                                                    | 1-2 doses                              | Neuroblast oma with CNS/LM metastasis | CNS/LM PFS at 6 months                                |

## 2.2.5.1. Dose response study(ies)

The recommended dosing for  131 I-omburtamab in the proposed label is two 1850 MBq (50 mCi) infusions. Support for this recommended dosing comes from the 94 subjects in the Part 2, expansion phase of Trial

<div style=\"page-break-after: always\"></div>

03-133 who received a treatment dose of 50 mCi. Part 1 of Trial 03-133 was a dose escalation phase. However, the maximum tolerated dose was not reached, and no dose-limiting toxicities were reported. Instead,  the 131 I-omburtamab  50  mCi  dose  was  selected  for  Part  2  of  Trial  03-133,  because myelosuppression observed at that dose level was found to be manageable.

The route of administration of 131 I-omburtamab is intracerebroventricular infusion via an intracerebroventricular access device (e.g., Ommaya catheter). Intracerebroventricular administration has been used for decades in the clinic to provide treatment for adult and paediatric populations suffering from a variety of conditions, including varying cancer types (Kramer et al, 2014; Cohen-Pfeffer et al, 2017).  Kramer  et  al.,  assessed  the  safety  and  complication  rate  associated  with  ventricular  access devices in patients receiving compartmental intraventricular radioimmunotherapy and concluded that minimal acute complications are observed and that long-term complications are rare. In addition, a literature review conducted by Cohen-Pfeffer and colleagues concluded that the intracerebroventricular route of administration appears to be a safe and well-tolerated method of long-term drug delivery in both paediatric and adult patients.

## 2.2.5.2. Main study(ies)

This submission is based on two trials. The 03-133 was a single centre 'basket' trial in the US intended to investigate dose-finding and the toxicity of intrathecal administration of iodinated omburtamab. The majority  of  patients  had  neuroblastoma  with  leptomeningeal/parenchymal  metastasis.  The  trial  was initiated in 2004 and data were recorded over more than a decade, enrolment was stopped in 2018. This trial provides most of the efficacy data with respect to OS including long-term outcomes.

The 101 study is a multi-centre single-arm trial that is still ongoing. This trial recruits only neuroblastoma patients with LM/CNS metastasis. An interim analysis was conducted on data from patients recruited up to 01 January 2020. Further data were submitted during the procedure and currently 50 patients have been recruited (instead of 32 planned).

To  provide  context  for  both  trials  and  for  the  evaluation  of  efficacy  several  external  controls  were provided.  These  controls  are  derived  from  registries  (Central  German  Childhood  Cancer  Registry, CGCCR), SIOPEN, literature review and single-centre experiences prior to the start of the trial (Memorial Sloan-Kettering Cancer Center, MSKCC).

## Title of study

Phase I Study of Intrathecal Radioimmunotherapy using  131 I-omburtamab for Central Nervous System/Leptomeningeal Neoplasms

## Methods

## · Study Participants

This trial included:

- Patients with malignancies that stained positive with omburtamab i.e., bound the monoclonal antibody, no confirmation of staining was required for patients with neuroblastoma.
- Subjects which have CNS/LM disease which is refractory to conventional therapies or for which no conventional therapy exists OR a recurrent brain tumour with a predilection for leptomeningeal dissemination (primitive neuroectodermal tumour, rhabdoid tumour).
- Patients were required to be clinically stable and not have rapidly progressing or deteriorating neurological examination.
- Bone marrow function was required to be stable.

<div style=\"page-break-after: always\"></div>

The trial was initiated and run at a single site, the Memorial Sloan-Kettering Cancer Center in NYC.

The trial excluded:

- Patients with obstructive or symptomatic communicating hydrocephalus.
- Patients with an uncontrolled life-threatening infection.
- Patients who are pregnant: Pregnant women are excluded for fear of danger to the foetus. Therefore, negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period.
- Patients who have received cranial or spinal irradiation less than 3 weeks prior to the start of this protocol.
- Patients who have received systemic chemotherapy (corticosteroids and immunotherapies not included) less than 3 weeks prior to the start of this protocol.
- Patients with severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity should all be less than Grade 2. Patients with stable neurological deficits (because of their brain tumour) are not excluded. Patients with ≤ 3 hearing loss are not excluded.

## · Treatments

131 I-omburtamab  was  administered  via  intrathecal  access  (e.g.,  Ommaya  reservoir).  Each  patients received one cycle with a single dosimetry dose at week 1 and a single treatment dose at week 2. Subjects without objective disease progression 5 weeks after the first dose and no grade 4 toxicities could  receive  a  second  dose  at  the  discretion  of  the  investigator.  The  treatment  dose  that  was administered to the majority of patients was 1850 MBq (50 mCi).

Figure 5. Treatment schedule

<!-- image -->

Doses were reduced in patients less than three years of age:

Table 26. Dose Reduction

| Age (year's)     | DoseReduction   |   131 I-omburtamabDose (mCi)a |
|------------------|-----------------|-------------------------------|
| Less than 1      | 50% reduction   |                          25   |
| 1 to less than 3 | 33%reduction    |                          33.5 |
| 3 and above      | No reduction    |                          50   |

- 25.0 mCi =925 MBq: 33.5 mCi = 1,239 MBq;: 50.0 mCi= 1,850 MBq. a

All patients received thyroid protection (oral potassium iodide, liothyronine) one week prior to  131 Iomburtamab dosimetry dose until 2 weeks after the treatment dose. In addition, oral or intravenous

<div style=\"page-break-after: always\"></div>

dexamethasone was started 24 hours prior to  131 I-omburtamab twice daily for three days. Anti-pyretic (e.g., paracetamol) and an antihistamine (e.g., diphenhydramine) were administered hours prior to intrathecal infusion and as needed after infusion.

- Objectives

This  was  an  exploratory  trial  intended  to  investigate  toxicity  of  intrathecal  administration  of 131 Iomburtamab. The plan for interim analysis for the evaluation of efficacy was developed after the majority of patients were recruited. The changed objectives as stated in amendment 25 (see list below as per synopsis submitted) was to evaluate the OS rate at 3 years and compare to external controls:

Overall Objectives:

- Primary Objective - Define the clinical toxicities of intrathecal  131 I-omburtamab
- Secondary Objectives - To evaluate efficacy in terms of survival rate at 3 years
- o To evaluate efficacy in terms of overall response rate (ORR) 6 months after the first treatment dose
- o To evaluate efficacy in terms of CNS/LM progression 6 months after the first treatment dose
- o To evaluate long term safety
- o To collect neurocognitive and long term follow up data

Interim Analysis Objectives:

- Primary objective - To assess the overall survival at 3 years after the first treatment dose of 131 I-omburtamab
- Secondary objective
- o To evaluate CNS/LM progression-free survival (CNS/LM PFS) at 12 months
- o To evaluate duration of follow-up

## · Outcomes/endpoints

The primary efficacy endpoints were introduced via amendment 25 (dated 05 June 2019).

- Overall survival rate at 3 years

Overall survival, defined as the time from first date of diagnosis of CNS relapse to the date of death. The survival time was calculated from the date of first diagnosis of CNS relapse until the date of death (event) or until the latest date confirmed alive (censored observation).

- CNS/LM PFS at 12 months

CNS/LM PFS time was calculated from the date of first dose of  131 I-omburtamab until the date of CNS/LM progression  or  death  (event)  or  until  the  latest  date  confirmed  to  be  progression-free  (censored observation).

- Duration of follow-up

Duration of follow-up for OS and for CNS/LM PFS was estimated by the reverse Kaplan-Meier method, the median follow-up time with 95% CI is presented.

Secondary efficacy endpoint

<div style=\"page-break-after: always\"></div>

Baseline CSF cytology was used as a secondary efficacy measurement. CSF cytology was assessed at screening as positive/negative. If positive, it was to be repeated within 3 weeks of the first and eventually second  131 I-omburtamab treatment infusions and during follow-up.

## · Sample size

With Amendment 25 (dated 05 June 2019) the sample size was justified as follows. Assuming an OS rate at 3 years of 40% and a sample size of 100 patients in this trial, the statistical power to show that the OS rate at 3 years is &gt;30% was estimated as 80%. The maximum 3-year OS rates to which omburtamab can be found superior, which can be excluded with 80% power for several assumed OS rates at 3 years are shown in the table below.

## Table 27. statistical power

<!-- image -->

The numbers reported were derived based on simulations, which could not be fully reproduced and understood.

## · Randomisation and Blinding (masking)

Not applicable. This is a single-arm, dose escalation and dose expansion study.

## · Statistical methods

## Analysis sets

Three analysis sets were defined. The full analysis set (FAS) was to include all patients enrolled in the trial who begin an infusion of  131 I-omburtamab; the per-protocol set (PPS) was to include all FAS patients who have no major protocol violations (patients with other protocol violations might have been uniformly excluded on the basis of data review, which was to be fully defined and documented before data lock); and the safety analysis set was to include all enrolled patients who receive at least one dose of IMP. The FAS was defined as primary efficacy analysis set and the PPS will be used for supplementary analyses.

## Statistical analyses

The survival rate at 3 years including its 95% confidence interval, was to be estimated using the KaplanMeier method. Additionally, the median OS time were to be estimated, and 95% confidence intervals were to be calculated. Additionally, a multiple Cox-regression analysis including all or a reasonable subset of the most important prognostic factors: Age at diagnosis of CNS/LM relapse (≤18 months vs &gt;18 months),  INSS  stage  at  diagnosis  (4  vs  non-4),  isolated  CNS/LM  metastasis  (yes  vs  no),  MYCN amplification status, time from NB diagnoses, prior irradiation therapy for CNS/LM relapse (yes vs no), prior debulking surgery for CNS/LM relapse (yes vs no), and prior chemotherapy for CNS/LM relapse (yes vs no), was to be used to estimate the hazard ratio of survival in the contemporary CGCCR data vs. 03-133 data.

ORR and CNS/LM progression will be calculated and presented by the same subgroups, waterfall plots for response will be presented.

## Subgroup analyses

OS was also to be analysed and presented by age above and below 18 months, MYCN amplification, and degree of salvage therapy.

## Interim Analysis

<div style=\"page-break-after: always\"></div>

An interim analysis, evaluating the survival rate at 3 years as well as a comparison of OS to external controls, was to be conducted when 6 months follow-up data was available for all neuroblastoma patients accrued to the protocol before 1st of January 2019. The interim analyses were to follow the same lines as described above.

## Missing data

For OS, patients who do not have an event were to be censored at their date of their last evaluation. It was considered unlikely that missing of safety data will occur in the targeted patient population, but in case it happened the data was not to be imputed. No other data was to be imputed.

## External control

An additional external control group was defined. External controls were to be primarily obtained from a query to the Central German Children's Cancer Registry (CGCCR). CGCCR initiated in 1980, registers approximately 2,000 children per year who are diagnosed with a malignant disease. CGCCR receives patient  data  from  all  paediatric  oncology  centres  across  Germany.  99%  of  all  paediatric  patients diagnosed with cancer in Germany were included in the national trials, with continuous update of the clinical data within the CGCCR. The CGCCR data was to be used to obtain an estimate of the 3-year survival rate in a contemporary systemically treated cohort of children. To explore the development of systemic treatment cut-offs in 2000 and 2004 were employed.

The database contains information on a total of 112 NB patients with CNS/LM relapse. Subjects were selected in multiple stages from the CGCCR data base according to the following flow chart (Figure 12).

<div style=\"page-break-after: always\"></div>

Figure 6: Flow chart of selection process for ECA

## Stage1

- Stage4neuroblastoma
- Ageatinitialdiagnosis≥18months to&lt;21yearsatinitialdiagnosis
- Diagnosisbetween01-Jan-1990 and31-Dec-2010
- FirstCNSrecurrence

Datatransfer1:N=85

## Stage2

- Stage4neuroblastoma
- Age&lt;18monthsatinitial diagnosis
- TrialsNB90/97/2004
- Diagnosedbetween01-Jan-1990 and31-Dec-2015
- CNSinvolvementwithCNS recurrence

Data transfer2:N=27

<!-- image -->

## Stage1/Stage2Update

- Stage1+Stage2criteria
- Additionof8subjects&lt;18monthsofageatinitialdiagnosis
- ? Additionofbaselinevariablesforall subjects&lt;18monthsatinitial diagnosis
- Clarificationoftimingoftreatmentsforallsubjects

## Data transfer3:N=120

<!-- image -->

Using cut-offs for CNS relapse diagnosis in 2000 or later and in 2004 or later, a total of 71 and 44 subjects remained respectively (updated later to 78 and 49 patients with cutoffs ≥2000 and ≥2004). The proportion of the youngest children ≤18 months at C NS/LM relapse diagnosis was approximately 27%. The estimated 3-year survival rates from the CGCCR data were to be used to support the estimates obtained from published literature, and the superiority of the estimate obtained from the 03-133 data.

A propensity score weighted analysis for OS comparing CGCCR data with trial 03-133 was defined posthoc. The analyses were conducted by an external CRO in a two-stage process including external control arm (ECA) construction (Stage 1) and subsequent ECA usage as a comparator in outcome analysis (Stage 2). In Stage 1, baseline composition of the ECA was aligned to that of the Trial 03-133 subjects using propensity score weighting. Despite the outcome data having been provided to the CRO during the creation of the harmonised dataset, the ECA construction was solely based on the baseline demographics and  disease  characteristics  as  specified  in  a  dedicated  ECA  SAP  (dated  28  Feb  2022).  No  outcome variables were considered in the ECA construction. No outcome analyses were conducted until the ECA

<div style=\"page-break-after: always\"></div>

construction was completed by the CRO and subsequently reviewed and approved by the applicant. Comparison of Trial 03-133 and the ECA was carried out using methods specified in the SAP (Stage 2).

The primary propensity score weighted analysis included subjects who received radiotherapy and at least one other treatment modality (i.e., chemotherapy or surgery). The primary index date was defined as the start date of the last post-CNS relapse treatment (i.e., radiotherapy, chemotherapy, or surgery). Average treatment effect on the treated (ATT) weighting by propensity score was utilised to create a comparison of Trial 03-133 and the external control in a 3:1 ratio and to balance baseline composition of prognostic factors. Prognostic factors with less than 15% missing data were included in the estimation of propensity scores, and missing values were imputed.

## Results

## · Participant flow

<!-- image -->

## · Recruitment

The trial was initiated on 5 Feb 2004 and enrolment was finished 31 October 2018. Follow-up is intended for the full life-span of the recruited patient.

## · Conduct of the study

The trial was planned as a safety trial using dose escalation. The trial ran over a very long time and

<div style=\"page-break-after: always\"></div>

multiple changes were made to the protocol, including changes to the objectives, the primary endpoint, the analysis populations and sample size.

## · Baseline data

Median age for the FAS population (N=107) at consent was 4.7 years (Min 0.85, Max 13), 72 (67%) were male, 84 (79%) where Caucasian.

46 patients received one cycle, 59 patients received 2 cycles and 2 patients received more than 2 cycles of treatment. 55 patients received two treatment doses.

The median age at diagnosis for subjects in the FAS was 2.3 years with a range of 0.02 to 12.1 years. A total of 84 subjects (78.5%) were older than 18 months. The INSS stage at diagnosis for the majority of subjects in the FAS was Stage 4 in 78 patients (72.9%). 61 (57%) had no prior relapses. For 24 patients the stage of disease was unknown.

For  the  FAS  the  site  of  disease  reported  was  'unifocal  parenchymal  site'  in  51  patients,  'multifocal parenchymal site' in 16 patients, 'leptomeningeal' in 10 patients and 'parenchymal and leptomeningeal' in  9  patients. It was reported as not known or not reported in 21 patients. MYCN amplification was reported in 55 FAS subjects (51.4%), and MYCN gain was reported in two subjects (1.9%).

In line with the inclusion criteria the majority had received prior therapy for CNS/LM disease (radiation 102 (95%), chemotherapy 107 (100%) or surgery.

## · Numbers analysed

The trial had two parts, a dose escalation part and a cohort expansion part. In part 1 patients received one dosimetry dose (2 mCi) and varying treatment doses (up to 70 mCi). In part 2 all patients received a 50 mCi dose (with age adaptation in children less than 3 years). The applicant defines the FAS including patients that received at least one cycle of treatment, this includes 107 patients and excludes those that did not receive treatment (n=2). This population either received one cycle (n=46), two cycles (n=59) or &gt;2 cycles (n=2).

## · Outcomes and estimation

## Primary endpoint: 3-year survival rate estimates from the time of CNS diagnosis in the FAS

The three-year OS rate (KM estimate) in the FAS was 0.56 (95%CI 0.46, 0.65). Death was observed in 57 cases, 40 cases were censored in the KM analysis. The following figure shows the respective KM plot.

<div style=\"page-break-after: always\"></div>

Figure 6. Kaplan-Meier plot of OS (FAS) - Product-Limit Survival Estimate

Product-LimitSurvival Estimate

<!-- image -->

## Secondary endpoint: 12 months CNS/LM progression free survival rate from first dose of 131 I-omburtamab in the FAS

The estimate for the 12 months CNS/LM progression free survival rate was 0.59 (95% CI: 0.44, 0.68). 58 subjects reached the endpoint, 30 subjects had CNS/LM progression and 28 subjects had died. 49 subjects were censored in the analysis.

The following figure shows the respective Kaplan-Meier plot of CNS/LM PFS (FAS).

Figure 7. Product-Limit Survival Estimate

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary endpoint: duration of follow-up

The median duration of follow-up was 75.0 (95% CI 49.3, 104.0) months, with a minimum duration of follow-up of 0.7 months and a maximum duration of follow-up of 176.0 months. For the 94 Trial 03133 neuroblastoma subjects at the 50 mCi dose group, the median duration of follow-up was 63.3 (95% CI 46.3, 90.1) months, with a minimum duration of follow-up of 0.7 months and a maximum duration of follow-up of 133.2 months.

## · Ancillary analyses

## Subgroup analyses

The 3-year survival probability for the whole FAS of 107 patients in study 03-133 was 0.56 and the median survival estimate 50 months. Unifocal parenchymal site was diagnosed in 51 patients, multifocal parenchymal sites in 16, leptomeningeal involvement in 10, parenchymal and leptomeningeal in 9, not known in 11 and not reported in 10. The trial was not powered for subgroup analysis of the various metastases and the number of patients in the subgroups were small and variable (ranging from 9 to 51 subjects). It was observed that about 50% of the neuroblastoma subjects of the FAS (51 of 107 patients 48%) demonstrated unifocal parenchymal site type of disease. For these subjects the 3-year probability survival estimate was 0.65 and median survival estimate 83.2 months. Ten subjects (9%) had only leptomeningeal disease. The 3-year survival estimate for this group was 0.60 and the median survival estimate 46.6 months. 8% of the 107 FAS patients demonstrated parenchymal and leptomeningeal disease. The 3-year survival probability for these patients was 0.56 and the median survival estimate was 46.6 months. Sixteen of the 107 FAS patients had a multifocal parenchymal site of disease (15%). The 3-year survival probability was 0.42, and the median survival estimate was 27.7 months. 21 patients consisted of two categories - 11 in whom the type of disease reported by site was unclear, and 10 where this value was not reported.

The majority of the FAS subjects (77 of 107) had isolated CNS/LM disease prior to treatment in Trial 03133. The 3-year survival probability was 0.66 and median survival estimate of 83.2 months. In patients with CNS relapse and systemic refractory disease (28 of 107) had a 3 year survival probability 0.32 and the  median  survival  estimate  23.4  months.  Similar  to  the  OS  results  the  12-month  CNS/LM  PFS probability  and  median  PFS  estimates  were  numerically  greater  for  Trial  03-133  FAS  subjects  with isolated CNS/LM disease prior to treatment in Trial 03-133.

## Comparison to external controls

Comparisons  of  the  survival  data  from  the  03-133  trial  with  external  data  were  provided.  Four comparisons  have  been  conducted:  comparison  to  the  CGCCR  dataset,  comparison  to  the  SIOPEN dataset, literature review, MSK controls.

## Central German Childhood Cancer Registry (CGCCR)

The CGCCR registers cases from all paediatric oncology units affiliated with the German Society for Paediatric Oncology and Haematology. It is estimated that more than 95% of all German children and adolescents under the age of 15 years with malignant diseases are reported to the CGCCR.

To account for a potential temporal effect on survival, estimates of survival were also evaluated in subsets of the population after applying CNS/LM relapse cut-off dates in the years 2000 and 2004. Trial 03-133 enrolled the first patient  in  2004,  and  the  latest  subset  grouping  ('2004  and  later')  should therefore be regarded as a contemporaneous external comparator in these subsets. The following plot is representative of several KM analyses comparing different subgroups of 03-133 and CGCCR based on date of diagnosis, age (≤18 months, &gt;18 months) and MYCN status amplified/non amplified.

<div style=\"page-break-after: always\"></div>

Figure 8. Unadjusted Kaplan-Meier plot of OS, 03-133 vs CGCCR (Neuroblastoma diagnosis 2004 or later)

<!-- image -->

## SIOPEN dataset

Patient-level data from SIOPEN could contribute to the understanding of survival in this population. In 2002 SIOPEN initiated a randomised Phase III trial (HR-NBL1/SIOPEN) in high-risk neuroblastoma (HRNBL) patients. Patients with newly diagnosed stage 4 HR-NBL were enrolled in the HR-NBLI/SIOPEN trial (NCT00030719) from February 2002 to June 2015. Of the 1,977 Stage 4 HR-NBL patients enrolled in the trial, there were 1,161 recurrent patients (855 patients with metastatic relapse), including 53 patients with CNS involvement at first recurrence confirmed by central imaging review. Of the 53 patients with confirmed CNS relapse, 31 received at least one relevant post-relapse treatment for CNS disease (e.g., chemotherapy, surgery, or radiotherapy), or any combination of these.

## Analysis according to treatment modalities (additional therapy administered for CNS/LM metastasis)

All patients in the trial 03-133 had received either radiotherapy, chemotherapy or surgery while this was only the case for 80 of the 120 patients from the CGCCR control group rendering these population not comparable. To account for different treatments and duration of prior treatments the applicant developed 'treatment modality groups': Modality group 1 includes subjects who received at least one treatment modality of radiotherapy, chemotherapy, or surgery; modality group 2 includes subjects who received radiotherapy and at least one other treatment modality (chemotherapy or surgery); modality group 3 includes subjects who received three treatment modalities (radiotherapy, chemotherapy, and surgery).

The following table shows results of OS rate at 3 years by Treatment Modality group (Assessor's table derived from table 5-11 of additional statistical report). Of note, these analyses include also patients that were diagnosed prior to 2004 while the more relevant control is the concurrent external control.

Table 28. OS rate at 3 years by Treatment Modality group

| 03-133   | CGCCR   | SIOPEN   |
|----------|---------|----------|

<div style=\"page-break-after: always\"></div>

|                  |   n | 3y-OS rate (95%CI)   |   n | 3y-OS rate (95%CI)   |   n | 3y-OS rate (95%CI)   |
|------------------|-----|----------------------|-----|----------------------|-----|----------------------|
| Modality group 1 | 107 | 0.56 (0.46, 0.65)    |  80 | 0.15 (0.08, 0.24)    |  31 | 0.13 (0.04, 0.27)    |
| Modality group 2 |  99 | 0.56 (0.45, 0.65)    |  35 | 0.26 (0.13, 0.41)    |  18 | 0.22 (0.07, 0.43)    |
| Modality group 3 |  77 | 0.58 (0.46, 0.68)    |  21 | 0.38 (0.18, 0.58)    |   8 | 0.38 (0.09, 0.67)    |

## Propensity score modelling

In response to the concern that the external control population would not be comparable to the trial population with regard to many baseline characteristics further analysis methods were employed. In order to compensate for the lack of a randomised control a propensity score model was developed. The primary analysis includes subjects who received radiotherapy and at least one other treatment modality (i.e., chemotherapy or surgery). Average treatment effect on the treated (ATT) weighting by propensity score was utilised to create a comparison of Trial 03-133 and the external control in a 3:1 ratio and to balance baseline composition of prognostic factors. Prognostic factors with less than 15% missing data were included in the estimation of propensity scores, and missing values was imputed. The OS was compared between Trial 03-133 and the ECA using the weighted log-rank test. In comparison to the subjects in the ECA with well-balanced baseline characteristics by propensity score-based weighting, the Trial 03-133 cohort was associated with a numerical improvement in OS (HR=0.62, 95% CI: 0.34, 1.13; log-rank test p-value=0.084).

The applicant presented this analysis also at an Oral Explanation in front of CHMP and the strategy for the comparison was described. It was acknowledged by the applicant that not all known prognostic factors were included in the propensity score model (complete surgical resection, presence of systemic disease, number of recurrences). It was also acknowledged that craniospinal irradiation was considerably more common in the trial patients compared to the external controls. No new data were presented.

## Trial 101

## Title:

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using  131 I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

## Methods

## · Study participants

This trial included:

- Patients with histologically confirmed neuroblastoma with CNS or LM metastasis either progressing through induction therapy or following induction therapy, i.e., relapsing.
- Stable systemic disease, stable neurologic function for three weeks prior to the first dose and sufficient function bone marrow and major organs was required.

This trial is ongoing in three academic sites in the USA and one site in Europe.

## · Treatments

<div style=\"page-break-after: always\"></div>

131 I-omburtamab  was  administered  via  intrathecal  access  (e.g.,  Ommaya  reservoir).  Each  patients received one cycle with a single dosimetry dose at week 1 and a single treatment dose at week 2. Subjects without objective disease progression 5 weeks after the first dose and no grade 4 toxicities received a second dose at the discretion of the investigator.

The  treatment  administered  was  essentially  identical  to  the  treatment  administered  in  trial  03-133 without the dose-escalation part.

## · Objectives

Primary objective of the trial is to evaluate efficacy and safety of  131 I-omburtamab:

Primary Objective:

- o Overall survival (OS) rate at 3 years.

Secondary Objectives:

- o To evaluate central nervous system/leptomeningeal (CNS/LM) progression-free survival (PFS) at 6 and 12 months.
- o To evaluate OS at 12 months.
- o To evaluate the objective response rate at 6 months
- o To evaluate dosimetry of  131 I-omburtamab
- o To evaluate the pharmacokinetics (PK) of  131 I-omburtamab
- o To evaluate safety of  131 I-omburtamab
- o To evaluate the immunogenicity of  131 I-omburtamab

For the purpose of this submission an interim analysis was introduced in version 10 of the protocol that evaluates the data for patients that were enrolled prior to 01 January 2020.

## · Outcomes/endpoints

The primary endpoint is OS rate at 3 years with starting time defined as the time of first treatment dose. Several secondary endpoints for evaluation of efficacy are proposed. These include CNS/LM PFS (time from first treatment dose to documented progression of CNS metastasis, leptomeningeal metastasis or death), OS (from the date of first  131 I-omburtamab infusion until the date of death by any cause), OS at 12 months (KM estimate) and ORR at 6 months. The objective response rate (ORR=CR+PR) at 6 months as defined by RANO criteria for CNS disease and EANO-ESMO guidelines for LM disease.

For the interim analysis amendment 10 introduced CNS/M PFS at 6 months as primary endpoint.

## · Sample size

At least 32 and a maximum of 50 patients were to be enrolled in this trial. With an estimated screen failure rate of 25% it was considered likely that 40-50 patients were to be screened to reach 32 eligible. Assuming an OS rate at 3 years of 40%, a sample size of 32 patients in this trial provides statistical power of 99% to show that the lower limit of a 95% confidence interval of the OS rate at 3 years is &gt;10%. The power for alternative assumed 3 years OS rates are shown in Table 37 below. Power was estimated by simulation using an exponential model and an assumed lost to follow-up rate of 10%.

<div style=\"page-break-after: always\"></div>

Table 29. Assumed power for 3 years OS rate

## · Randomisation

Not applicable. This is a single-arm, open-label trial.

## · Blinding (masking)

In principle this is an open-label trial. The 'Independent Review Charter' describes that a central, blinded review  of  imaging  would  be  performed  by  two  independent  reviewers  using  the  RANO-BM  and/or EANO/ESMO guideline. A third reviewer may be involved for the purpose of adjudication.

## · Statistical methods

## Analysis sets

Analyses sets were defined as for Trial 03-133. See Trial 03-133 for a description.

## Statistical analyses

The primary endpoint of the OS rate at 3 years as well as OS at 12 months, and CNS/LM PFS at 6 and 12  months  with  corresponding  95%  confidence  intervals,  was  to  be  estimated  using  Kaplan-Meier methods  using  the  FAS.  The  comparison  to  external  controls  (OS  only)  was  to  be  exploratory  and performed using  multiple  Cox  regression  taking  into  account  the  most  important  prognostic  factors identifiable in the historic data. The median OS and CNS/LM time and associated 95% confidence interval was to be calculated.

ORR according to RANO criteria and CSF cytology as well as CSF cytology alone, will be assessed, 95% confidence intervals will be calculated using the Clopper-Pearson exact methodology.

## Interim analyses

An interim analysis, evaluating the dosimetry and pharmacokinetic endpoints as well as available safety and efficacy data, was to be conducted on data from patients having received at least treatment cycle 1 prior to January 1st, 2020. Starting January 1st, 2020, no further patients were to be administered dosimetry doses. Progression in CNS/LM was to be assessed at 6 and 12 months for the full analysis. The primary efficacy endpoint for the interim analysis was to be CNS/LM PFS at 6 months.

## Missing data

For the primary time to event efficacy endpoint, patients who do not have an event was to be censored at their date of their last evaluation. It was considered unlikely that missing of safety data will occur in the targeted patient population, but in case it happens the data was not to be imputed.

## External control

External controls were defined as for Trial 03-133. See Trial 03-133 for a description.

## Results

## · Participant flow

## Study Participant flow

<div style=\"page-break-after: always\"></div>

## · Recruitment

Several updated documents with different focus were provided during the procedure. For the interim analysis patients recruited between December 2018 until 20 October 2020 are included. Overall, 50 patients were recruited at the present time.

## · Conduct of the study

With version 5 of the protocol issued on 12 April 2019 the trial objectives were changed to evaluate the objective response rate at 6 months instead of up to 3 years and evaluate CNS/LM progression instead of CNS progression-free survival. The objective to compare the overall survival with historical controls was deleted.

With version 7 issued 11 Sept 2019 an interim analysis for dosimetry, PK safety and efficacy was introduced.

Version 10 issued 01 May 2020 added two secondary efficacy objectives/endpoints (by request of U.S. FDA) 1) to evaluate CNS/LM progression-free survival (CNS/LM PFS) at 6 months and 2) to evaluate Overall Survival (OS) at 12 months at the interim analysis.

## · Baseline data

Median age for the FAS population at the interim analysis (N=32) was 4.0 years (Min 0, Max 10), 21 (66%) were male, 25 (78%) where Caucasian.

The INSS stage at diagnosis for the majority of subjects in the FAS was Stage 4 in 27 patients (84%).

<!-- image -->

<div style=\"page-break-after: always\"></div>

For the FAS the site of disease reported was 'parenchymal metastasis' in 4 patients, 'leptomeningeal metastasis' in 5 patients, 'parenchymal and leptomeningeal' in 5 patients, 'unadjudicated' 2 patients and 'no parenchymal and leptomeningeal metastasis' in 16 patients. MYCN amplification was reported in 14 FAS subjects (46%), and MYCN gain was reported in two subjects (8%).

In line with the inclusion criteria the majority had received prior therapy for CNS/LM disease (irradiation 30 (94%), craniospinal irradiation 25 (78%), chemotherapy 29 (91%). The most frequently administered chemotherapy was temozolomide and irinotecan. 26 patients had surgery.

Many  patients  received  additional  therapy  after 131 I-omburtamab  administration.  Eleven  received Naxitamab, 17 received temozolomid and/or irinotecan.

## · Numbers analysed

13  patients  received  one  treatment  dose,  19  patients  received  2  treatment  doses  and  no  patients received more than 2 treatment doses.

## · Outcomes and estimation

## Primary endpoint: CNS/LM Progression Free Survival at 6 Month

The CNS/LM PFS rate (KM estimate) at week 26 was 0.77 (95%CL 0.58, 0.88). The following figure shows the corresponding KM plot.

Figure 8. CNS/LM Progression Free Survival Rate

<!-- image -->

## Secondary endpoint: Overall survival at 12 months

The 12 months survival rate was 0.74 (95%CL 0.54;0.86). The following figure shows the corresponding KM-plot.

<div style=\"page-break-after: always\"></div>

Figure 9. Overall survival

<!-- image -->

Program:fig\\_os.sas-output:fig\\_os.rtf-executed:05JAN2022-Cutoffdate:01JUN2021

## Secondary endpoint: objective response rate at 6 months

Objective  response  was  assessed  26  weeks  after  the  first  treatment  dose  of  131 I-omburtamab  as  a combination of best overall Partial Response or Complete Response. The evaluation followed the response assessment in the Neuro-Oncology (RANO) group criteria for brain metastases or in the guideline by EANO-ESMO for LM metastases.

The ORR at Week 26 was defined as the proportion of subjects with response (Complete Response or Partial  Response)  from  the  total  population  of  subjects  with  radiographically  evaluable  disease  at baseline. The following table shows details on responses.

<div style=\"page-break-after: always\"></div>

Table 30. objective response rate

| Full Amalysis Set, N                            | 32                                          |
|-------------------------------------------------|---------------------------------------------|
| Objective Response (CR and PR), N (%) [95% CI*] | 5 (31.3) [11.0; 58.7]                       |
| Best Overall Response, N (%)                    | Best Overall Response, N (%)                |
| Complete Response                               | 3 (18.8)                                    |
| Paitial Response                                | 2 (12.5)                                    |
| Stable Disease                                  | 7 (43.8)                                    |
| Progressive disease                             | 3 (18.8)                                    |
| Not evaluable                                   | 1( 6.3)                                     |
| Total                                           | 16 (100.0)                                  |
| No Evidence of Disease (N)                      | 16                                          |
| Duration of Response incl. Follow-up (Days)     | Duration of Response incl. Follow-up (Days) |
| N                                               | 5                                           |
| Mean (SD)                                       | 332.8 (300.80)                              |
| Median                                          | 280.0                                       |
| Min -Max                                        | 37 - 715                                    |
| [Mean 95% CI]                                   | [-40.7; 706.3]                              |

Source: Table 14.2.1.3.1

During the procedure, data were provided for all 50 patients recruited, 20 of which had evaluable disease at baseline. Overall, there were 7 patients who achieved an objective response, resulting in an ORR of 35.0% (95% CI: 15.4; 59.2) of which 5 with CR (25%) and 2 with PR (10%). Seven (7) patients achieved SD (35%), 5 PD and 1 not evaluable. Most patients with CR or PR received additional therapies after the omburtamab treatment either for systemic disease or as an experimental adjuvant treatment.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 31. Summary of efficacy for trial 03-133

| Title: Phase I Study of Intrathecal Radioimmunotherapy using 131 I-omburtamab for Central Nervous System/Leptomeningeal Neoplasms   | Title: Phase I Study of Intrathecal Radioimmunotherapy using 131 I-omburtamab for Central Nervous System/Leptomeningeal Neoplasms                                                  | Title: Phase I Study of Intrathecal Radioimmunotherapy using 131 I-omburtamab for Central Nervous System/Leptomeningeal Neoplasms                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                    | Protocol number: 03-133 Clinicaltrials.gov identifier: NCT00089245                                                                                                                 | Protocol number: 03-133 Clinicaltrials.gov identifier: NCT00089245                                                                                                                 |
| Design                                                                                                                              | Two-part, single-arm, open-label, non-randomised, single-centre. Part 1 investigated escalating doses of 131 I-omburtamab with the goal of identifying the maximum tolerated dose. | Two-part, single-arm, open-label, non-randomised, single-centre. Part 1 investigated escalating doses of 131 I-omburtamab with the goal of identifying the maximum tolerated dose. |
| Design                                                                                                                              | Duration of main phase:                                                                                                                                                            | A treatment cycle was 5 weeks, including premedication and 131 I-omburtamab                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                            |                                                                                                                                            | administration (one dosimetry dose during Week 1 and one treatment dose during Week 2). A repeated cycle of treatment was initiated with a dosimetry dose at least 4 weeks after completion of the first cycle. Not applicable.   |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                      | Exploratory: Time-to-event endpoints were estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI) | Exploratory: Time-to-event endpoints were estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI) | Exploratory: Time-to-event endpoints were estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI)                                                                                        |
| Treatment groups                                | 03-133 FAS                                                                                                                                 | 03-133 FAS                                                                                                                                 | 131 I-omburtamab Up to two cycles (each including one dosimetry and one treatment dose). N= 107 (full analysis set, FAS).                                                                                                         |
|                                                 | External controls (CGCCR)                                                                                                                  | External controls (CGCCR)                                                                                                                  | Retrospective data collected from the Central German Childhood Cancer Registry (CGCCR) on patients with CNS neuroblastoma (N=120). Patients diagnosed in 2004 and later (N=49).                                                   |
| Endpoints and definitions                       | Primary                                                                                                                                    | 3 years OS                                                                                                                                 | OS at 3 years after first treatment dose of 131 I-omburtamab.                                                                                                                                                                     |
| Endpoints and definitions                       | Secondary                                                                                                                                  | 12 months CNS/LM PFS                                                                                                                       | Central Nervous System/Leptomeningeal progression-free survival (CNS/LM PFS) at 12 months.                                                                                                                                        |
| Endpoints and definitions                       | Secondary                                                                                                                                  | FU                                                                                                                                         | Duration of follow-up (FU) for OS and CNS/LM PFS from first dose of 131 I-omburtamab.                                                                                                                                             |
| Data cut-off                                    | Enrolment cut-off date: Data cut-off                                                                                                       | date:                                                                                                                                      | 31 December 2018 30 June 2019                                                                                                                                                                                                     |
| Results and Analysis                            | 12 March 2020 (survival follow-up)                                                                                                         | 12 March 2020 (survival follow-up)                                                                                                         | 12 March 2020 (survival follow-up)                                                                                                                                                                                                |
| Analysis population and time point description  | 03-133 Full Analysis Set (FAS): subjects who began an infusion of a treatment dose of 131 I-omburtamab. Timepoint:                         | applicable.                                                                                                                                | 03-133 Full Analysis Set (FAS): subjects who began an infusion of a treatment dose of 131 I-omburtamab. Timepoint:                                                                                                                |
| Descriptive statistics and estimate variability | Treatment group 03-133 FAS                                                                                                                 | Treatment group 03-133 FAS                                                                                                                 | Treatment group 03-133 FAS                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Number of subjects 107                                                                                                                     | Number of subjects 107                                                                                                                     | Number of subjects 107                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | 95% CI 0.46 ; 0.65                                                                                                                         | 95% CI 0.46 ; 0.65                                                                                                                         | 95% CI 0.46 ; 0.65                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Median survival 50.0                                                                                                                       | Median survival 50.0                                                                                                                       | Median survival 50.0                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | CI 27.4 ; NE                                                                                                                               | CI 27.4 ; NE                                                                                                                               | CI 27.4 ; NE                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% NE: Not estimable                                                                                                                      | 95% NE: Not estimable                                                                                                                      | 95% NE: Not estimable                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability |                                                                                                                                            |                                                                                                                                            |                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                 | 12 months CNS/LM PFS (Rate)                                                                                                                                                                                                                         | 0.59                                                                                                                                                                                                                                                | 0.59                                                                                                                                                                                                                                                |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | 95% CI                                                                                                                                                                                                                                              | 0.44, 0.68                                                                                                                                                                                                                                          | 0.44, 0.68                                                                                                                                                                                                                                          |
|                                                 | Median CNS/LM PFS (months)                                                                                                                                                                                                                          | 21.8                                                                                                                                                                                                                                                | 21.8                                                                                                                                                                                                                                                |
|                                                 | 95% CI                                                                                                                                                                                                                                              | 11.3 ; 46.2                                                                                                                                                                                                                                         | 11.3 ; 46.2                                                                                                                                                                                                                                         |
|                                                 | Median FU time (months)                                                                                                                                                                                                                             | 75.0                                                                                                                                                                                                                                                | 75.0                                                                                                                                                                                                                                                |
|                                                 | 95% CI                                                                                                                                                                                                                                              | 49.3 ; 104.0                                                                                                                                                                                                                                        | 49.3 ; 104.0                                                                                                                                                                                                                                        |
|                                                 | Range (months)                                                                                                                                                                                                                                      | 0.7-176.0                                                                                                                                                                                                                                           | 0.7-176.0                                                                                                                                                                                                                                           |
| Analysis description                            | Exploratory analysis Pre-specified exploratory analyses of OS comparing 131 I-omburtamab subjects with the external CGCCR control group using Cox regression models with adjustment for prognostic factors. Hazard ratio and 95% CI were estimated. | Exploratory analysis Pre-specified exploratory analyses of OS comparing 131 I-omburtamab subjects with the external CGCCR control group using Cox regression models with adjustment for prognostic factors. Hazard ratio and 95% CI were estimated. | Exploratory analysis Pre-specified exploratory analyses of OS comparing 131 I-omburtamab subjects with the external CGCCR control group using Cox regression models with adjustment for prognostic factors. Hazard ratio and 95% CI were estimated. |
| Analysis population and time point description  | - 03-133 FAS: subjects who began an infusion of a treatment dose of 131 I- omburtamab. - External controls (CGCCR): All patients diagnosed with CNS neuroblastoma in 2004 and later.                                                                | - 03-133 FAS: subjects who began an infusion of a treatment dose of 131 I- omburtamab. - External controls (CGCCR): All patients diagnosed with CNS neuroblastoma in 2004 and later.                                                                | - 03-133 FAS: subjects who began an infusion of a treatment dose of 131 I- omburtamab. - External controls (CGCCR): All patients diagnosed with CNS neuroblastoma in 2004 and later.                                                                |
|                                                 | Timepoint: Not applicable.                                                                                                                                                                                                                          | Timepoint: Not applicable.                                                                                                                                                                                                                          | Timepoint: Not applicable.                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                     | 03-133 FAS                                                                                                                                                                                                                                          | External controls (CGCCR)                                                                                                                                                                                                                           |
|                                                 | Number of subjects                                                                                                                                                                                                                                  | 107                                                                                                                                                                                                                                                 | 49                                                                                                                                                                                                                                                  |
|                                                 | 3 years OS (Rate)                                                                                                                                                                                                                                   | 0.56                                                                                                                                                                                                                                                | 0.17                                                                                                                                                                                                                                                |
|                                                 | 95% CI                                                                                                                                                                                                                                              | 0.46 ; 0.65                                                                                                                                                                                                                                         | 0.08 ; 0,28                                                                                                                                                                                                                                         |
|                                                 | Median survival (months)                                                                                                                                                                                                                            | 50.0                                                                                                                                                                                                                                                | 9.1                                                                                                                                                                                                                                                 |
|                                                 | 95% CI                                                                                                                                                                                                                                              | 27.4 ; NE NE: Not estimable                                                                                                                                                                                                                         | 3.6 ; 15.7                                                                                                                                                                                                                                          |
|                                                 | 03-133 FAS versus External controls (CGCCR)                                                                                                                                                                                                         | 03-133 FAS versus External controls (CGCCR)                                                                                                                                                                                                         | 03-133 FAS versus External controls (CGCCR)                                                                                                                                                                                                         |
|                                                 | Hazard ratio 95% CI                                                                                                                                                                                                                                 | 0.352 (p<0.0001) 0.228                                                                                                                                                                                                                              | 0.542                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Not applicable                                                                                                                                                                                                                                      | Not applicable                                                                                                                                                                                                                                      | Not applicable                                                                                                                                                                                                                                      |

Table 32. Summary of efficacy for trial 101

| Title: A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131 I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases - Interim Analysis   | Title: A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131 I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases - Interim Analysis   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                             | Protocol number: 101 Clinicaltrials.gov identifier: NCT03275402 EudraCT number: 2017-001828-22                                                                                                                               |
| Design                                                                                                                                                                                                                       | Single-arm, open-label, non-randomised, multi-centre.                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                                                       | Subjects received up to two cycles of 131 I-omburtamab, each including one dosimetry dose [2 mCi =74 MBq] and one treatment dose [50 mCi = 1850   | Subjects received up to two cycles of 131 I-omburtamab, each including one dosimetry dose [2 mCi =74 MBq] and one treatment dose [50 mCi = 1850   | Subjects received up to two cycles of 131 I-omburtamab, each including one dosimetry dose [2 mCi =74 MBq] and one treatment dose [50 mCi = 1850                                                                                                                                    |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                       | Duration of main phase:                                                                                                                           | Duration of main phase:                                                                                                                           | A treatment cycle was 5 weeks, including premedication and 131 I-omburtamab administration (one dosimetry dose during week 1 and one treatment dose during week 2), and a 3-week observation period (following the treatment dose). The subjects could receive up to two cycles.   |
|                                                                       | Duration of Run-in phase: Duration of                                                                                                             | Extension phase:                                                                                                                                  | Not applicable. Subjects will be followed for assessment of Overall Survival (OS) at 3 years.                                                                                                                                                                                      |
| Hypothesis                                                            | Exploratory: Time-to-event endpoints will be estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI).    | Exploratory: Time-to-event endpoints will be estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI).    | Exploratory: Time-to-event endpoints will be estimated by Kaplan-Meier methods and presented with corresponding 95% confidence intervals (CI).                                                                                                                                     |
| Treatment groups                                                      | Full Trial Population                                                                                                                             | Up and                                                                                                                                            | 131 I-omburtamab. to two cycles (each including one dosimetry one treatment dose).                                                                                                                                                                                                 |
| Endpoints and definitions                                             | Primary interim endpoint                                                                                                                          | 6 months CNS/LM PFS                                                                                                                               | Central Nervous System/Leptomeningeal progression-free survival (CNS/LM PFS) at 6 months based on the time from first dose of 131 I-omburtamab to CNS/LM progression or death from any cause.                                                                                      |
| Endpoints and definitions                                             | Secondary                                                                                                                                         | 12 months OS                                                                                                                                      | OS at 12 months after first dose of 131 I-omburtamab.                                                                                                                                                                                                                              |
| Endpoints and definitions                                             | Secondary                                                                                                                                         | 6 months ORR                                                                                                                                      | 6 months overall response rate (ORR) (combination of partial response and complete response) as defined by RANO group criteria for brain metastasis, or LM metastases as defined by EANO-ESMO criteria. ORR will be assessed at 6 months after the first dose of 131 I-omburtamab. |
| Data cut-off                                                          | Enrolment cut-off date:                                                                                                                           | Enrolment cut-off date:                                                                                                                           | 20 October 2020                                                                                                                                                                                                                                                                    |
| Results and Analysis                                                  | Results and Analysis                                                                                                                              | Results and Analysis                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                                               |
| Analysis description                                                  | Primary Analysis                                                                                                                                  | Primary Analysis                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                                   |
| Analysis population and time point description Descriptive statistics | All 32 subjects enrolled who began Time point: Not applicable Treatment group                                                                     | All 32 subjects enrolled who began Time point: Not applicable Treatment group                                                                     | Full Trial Population                                                                                                                                                                                                                                                              |
| Analysis population and time point description Descriptive statistics | Number of subjects                                                                                                                                | Number of subjects                                                                                                                                | 32                                                                                                                                                                                                                                                                                 |
| Analysis population and time point description Descriptive statistics | 6 months CNS/LM PFS (Rate) 95% CL                                                                                                                 | 6 months CNS/LM PFS (Rate) 95% CL                                                                                                                 | 0.77 0.58; 0.88                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                      | Median Follow-Up Time (weeks) 95% CI                    | 91 69 ; 101                   |
|----------------------|---------------------------------------------------------|-------------------------------|
|                      | 12 months OS (Rate)                                     | 0.74                          |
|                      | 95% CL                                                  | 0.54; 0.86                    |
|                      | Median Follow-Up Time (weeks)                           | 101                           |
|                      | 6 months ORR (Rate)                                     | 0.31 0.11;                    |
|                      | 95% CI                                                  | 0.59                          |
|                      | Median (SD) duration of response incl. Follow-up (days) | 280 (33.23)                   |
|                      | Min-Max                                                 | 37-715                        |
| Notes                | None                                                    | None                          |
| Analysis description | Other analyses Not applicable                           | Other analyses Not applicable |

## 2.2.5.3. Clinical studies in special populations

Not applicable

## 2.2.5.4. Supportive study(ies)

Not applicable

## 2.2.6. Discussion on clinical efficacy

General and methodological considerations on the clinical development plan

The demonstration of efficacy is based on data from two trials, 03-133 and 101.

Study 03-133 was a single centre, uncontrolled, exploratory 'basket' trial in the US intended for dosefinding  and  to  investigate  the  toxicity  of  intrathecal  administration  of  iodinated  omburtamab.  The majority of patients had neuroblastoma with leptomeningeal/parenchymal metastases that had been pre-treated for their systemic disease as well as for their CNS disease. This trial generated the majority of the clinical data under discussion. It was initiated in 2004 and data were recorded over more than a decade. Enrolment was stopped in 2018. The analyses regarding the evaluation of efficacy in study 03133 and its promotion to a trial for marketing authorisation purposes was introduced with amendment 25 in 2019 and is regarded as post hoc given the long history of the trial and its open-label nature. From the protocols and interim CSR of trial 03-133 it is apparent that no specific, falsifiable hypotheses were formulated.  Descriptive  analyses  of  OS  and  PFS  were  planned  and  comparisons  to  several  external controls were planned post-hoc. The trial 03-133 is proposed as the main trial supporting the MAA. This cannot be accepted for the above reasons.

The 101 study is an ongoing multi-centre single-arm trial recruiting only neuroblastoma patients with LM/CNS metastasis. An interim analysis was conducted on data from patients recruited up to 01 January 2020, an update was provided during the procedure including data up to 01 June 2021 and an expansion to 32 patients. In a further update, data from 20 patients with measurable disease at baseline were

<div style=\"page-break-after: always\"></div>

submitted. Within this application the trial is regarded as supportive by the applicant. In comparison to study 03-133, study 101 is much closer to the current treatment landscape, appears to have a much better-defined plan for the evaluation of efficacy data, and response data was systematically collected which is considered potentially important for establishing efficacy in a single arm trial. Therefore, for the purpose of efficacy assessment, study 101 is in principle better suited to provide relevant data on the effect of the medicinal product. Overall, 50 patients have now been recruited in the study, but the data is  currently limited especially regarding follow-up time. The study was only planned with descriptive analyses, again no success criteria (statistical hypotheses) were pre-planned.

Both clinical trials lack an internal control and therefore the evaluation of efficacy in this complex disease with several treatment options poses challenges. To provide context for both trials and for the evaluation of  efficacy  several  external  controls  were  investigated.  These  controls  were  derived  from  a  registry (Central  German  Childhood  Cancer  Registry,  CGCCR),  SIOPEN,  literature  review  and  single-centre experiences (at MSKCC prior to the start of the trial 03-133).

The chosen endpoints (landmark analyses of time related endpoints, e.g., 3-year OS rate, 12-month CNS/LM PFS) are not appropriate to establish efficacy in single arm trials as the characteristic of the patient population and their importance for prognosis has a major influence on outcome. On the other hand, survival rate at 3 years when a plateau has been established could provide relevant information on long term efficacy in case efficacy has been established by other means.

Considering the difficulties in interpreting time-related endpoints in single-arm trials (unless extreme results are observed) evaluating response rates is of particular interest. Although it is stated that tumour response was not an objective of study 03-133, in other parts of the protocol ORR was mentioned as an efficacy endpoint. It was clarified during the procedure that responses were not systematically assessed in Study 03-133. Study 101 investigates ORR as a secondary endpoint with an appropriate methodology.

## Study conduct

Study 03-133 was initially designed as a Phase 1 trial to evaluate the MTD in a 3 + 3 design. Later, the study  design  was  modified  and  the  patient  population  to  be  enrolled  during  dose  escalation  was increased. Only late in the trial the sample size was justified and a comprehensive description of efficacy analyses for neuroblastoma patients was added (Amendment 25). The statistical considerations hence can be considered rather ad hoc than pre-specified given the open label nature of the study and the duration of recruitment to the dose expansion cohorts which was initiated more than two and a half years earlier. Only one SAP was drafted one year after the protocol amendment 25. In this SAP further details regarding the historic controls were provided in addition to the very limited information from the protocol. Overall, the planning of the analyses cannot be considered agnostic of the outcome of study 03-133 and are not considered sufficient for a confirmatory trial.

The reasons for the termination of dose escalation part of study 03-133 were clarified in the responses and were related to myelotoxicity which was not included in the list of expected dose-limiting toxicities for the definition of an MTD.

It is unknown how many patients were screened for inclusion in study 03-133, even at the main trial site MSKCC. During the procedure, it was clarified that the majority of patients were referred from other centres in the USA but also internationally. The screening procedure in these external centres was not defined, it is unknown how many patients were screened. The recruited study population was therefore very  likely  highly  selected,  but  the  selection  criteria  are  not  explicit  and  cannot  be  established  in hindsight. Any attempt to find a relevant external control cohort is therefore challenging. The proposed FAS population resembles a per protocol set. Two patients were not included in the FAS population.

For study 101 it is unclear how the multiple interim analyses are justifiable in this small trial even if the data are only considered supportive.

<div style=\"page-break-after: always\"></div>

## Population

In study 03-133 the majority of patients had parenchymal metastasis. As expected, the majority had stage 4 disease and MYCN amplification. For 24 patients the stage of underlying neuroblastoma was unknown. Even though the response of the tumour to the experimental therapy was investigated with MRI the results are not reported in a systematic fashion based on pre-specified criteria which constitutes a major shortcoming. It is evident from the line listings that in some patients there was no evidence of disease after surgery/radiotherapy at the baseline MRI prior to  131 I-omburtamab therapy. Other patients had documented treatment response at baseline, i.e., prior treatment had already resulted in a response and the contribution of the additional therapy with  131 I-omburtamab is unknown. It is not clear how many patients had objective evidence of CNS/LM disease at baseline. Even though cure is unlikely in this population at least two prognostically different subgroups are contained that could also be investigated separately: patients with (measurable) disease at baseline could show response to treatment while in patients without disease at baseline, prevention of relapse would be the treatment goal.

Different doses were applied with 8 subjects receiving doses &lt;50 mCi and 5 subjects receiving higher doses (&gt;50 mCi). The majority of the population received a dose of 1850 MBq/50 mCi (n = 94). This complicates the interpretation of results. Furthermore, patients received either a single administration or two administrations of the study drug. The requested analysis indicated that patients who received two doses appear to have a somewhat better prognosis. The choice for the number of cycles might be influenced by a number of factors including prognostic ones.

Study  101  also  included  a  heterogeneous  population.  Most  but  not  all  subjects  had  received chemotherapy, radiotherapy and surgery for the CNS/LM disease. Of note 16/32 patients (30 out of 50 in the updated data cut-off 31 March 2022) had no evidence of disease at baseline. More than half of the patients received additional therapies including anti-GD2 antibody and chemotherapy after they had received  131 I-omburtamab.

## External Control

It is a particular challenge to establish with reasonable certainty that the external control population is comparable to the trial population. As a general principle, external controls in single-arm trials are only considered supportive to further explore the derived efficacy, in case efficacy was established solely based on the single-arm trial itself. This is not considered to be the case in this application.

The analysis of the CGCCR population in comparison to the population from study 03-133 give some strong indication of differences. This is related to prognosis as evidenced by the different shape of the OS  KM-  curves  in  the  initial  phase  after  diagnosis  of  relapse  when  no  therapeutic  effect  of 131 Iomburtamab therapy is to be expected. In addition, it is related to the treatments that were administered for CNS relapse. As a general observation the German neuroblastoma population received less therapies compared  to  the  trial  population.  Comparing  the  populations  which  had  received  chemotherapy, radiotherapy and surgery, and that could be considered more homogenous than the full populations, diminished  the  assumed  treatment  effect  by  improving  the  survival  of  the  external  control.  These observations, in addition to the general issue of selection bias as discussed above, make it likely that populations with different prognostic factors were included in the study and the external control. During the procedure, the applicant provided new propensity score (PS) weighted analyses for the comparison of study 03-133 and the CGCCR data. These various post hoc analyses intend to improve the balance between the cohorts and have become the main argument for concluding on efficacy for this application.

Propensity score methods and similar methods can only adjust for measured confounders. Unmeasured confounder and further differences in data quality cannot be incorporated. Hence, such approaches might reduce the bias but cannot completely remove it and make results comparable to the standard from a

<div style=\"page-break-after: always\"></div>

randomised controlled trial. Thus, standard criteria to conclude on a statistically significant result are not applicable and a higher uncertainty is expected and should be taken into account.

The propensity score weighted analyses was based on time-to-event endpoints (OS as primary EP) as was the study 03-133 and the initial comparison to the external control. The considerations on the endpoint in single arm trials with external controls hence remain valid (see below). It is acknowledged that the implemented method intended to account for some of the issues (e.g., immortal time bias) by better aligned definitions of the index date and the choice of more homogenous patient populations (based on treatment modalities, see below). However, the fundamental issue remains that patients have to survive until inclusion in the trial whereas all patients are included in the external control.

The primary PS weighted analysis is based on a post hoc selected population with at least two (out of three) post CNS relapse treatment modalities. The size of the group in comparison to all eligible subjects in the cohorts varies and furthermore the number of subjects in the group which were treated with more than two (i.e., all three) treatment modalities vary substantially. This might induce significant bias. While the propensity score method further tried to take this into account, it remains unclear how successful this was. Furthermore, all decisions for the propensity score method were made post hoc when trial and external control data were already available. Some choices were even made in a data driven fashion; confounders used in the propensity score model were e.g., chosen based on a maximum number of missing values (and perceived clinical relevance).

Uncertainties with respect to the choice of analysis sets and the choice and definition of confounders remain. The sample sizes in treatment modality groups (MG) presented in the new ECA analysis differ from  numbers  previously  reported  in  the  CSR,  sometimes  to  a  large  extent.  The  reasons  for  these deviations were not discussed by the applicant and are not understood. Furthermore, the algorithm to select subjects from CGCCR is not comprehensible. In Stage 1 of the selection process only older subjects ( ≥ 18 months of age ) were selected but with cutoff for diagnosis on 31 December 2010. More recently treated  subjects  were  selected  in  Stage  2  but  only  subjects  younger  than  18  months  of  age  were extracted. Newer data, which is more relevant as comparator, were restricted to an exceptionally young population not reflected in Trial 03-133 where the median age was 4.7 years (Range 0.85 - 13). Which subjects ended up in the finally selected 80 subjects is not clear from the flowchart. This all underlines the uncertainties with respect to the database.

Overall, the presented analyses do not overcome the issues raised. The amount of remaining bias is unknown  and  not  quantifiable.  Given  the  relatively  small  difference  between  cohorts  it  cannot  be excluded that this is a result of prognostic variables, differences in the data quality or other sources of bias.

## Endpoints, Efficacy results

The choice of 3-year OS rate, 12-month CNS/LM PFS rate and follow-up time in itself is not suitable to establish efficacy in a single arm setting because the prognosis of the selected population cannot be separated from a possible effect of therapy. The obtained result for 3-year OS rate and CNS/LM PFS are not interpretable on their own. It has also to be noted that there were no prior definitions for a relevant survival rate to establish an efficacious treatment. No specific hypotheses were formulated a priori, and no proposals were brought forward for an effect to be considered relevant on a population level. Because of these issues the seemingly important observed 3-year OS rate cannot be regarded as a robust sign of efficacy. It is also entirely possible that the observed survival rates are achievable with the multimodal treatment (surgery, combination of radiation therapies, chemotherapy in various combinations) that patients received in a preselected population in a highly specialised treatment centre.

Based on further statistical analyses the applicant considers that an effect is shown overall, and across treatment modality groups and subgroups. Furthermore, a propensity score based inverse probability

<div style=\"page-break-after: always\"></div>

weighting  analysis  for  the  treatment  modality  group  2  is  interpreted  as  showing  superiority  while prognostic factors and post-CNS relapse treatments are balanced. It is understood that modality group 2 was chosen based on the pragmatic reasons to obtain relatively homogenous population with sufficient sample size. However, neither the pre-treatment is considered sufficiently homogenous nor the sample size optimal. Furthermore, these choices were all made post hoc. These analyses are hence regarded as exploratory  and  hypothesis-generating  and  not  sufficient  to  establish  efficacy  (see  also  discussion above).

The same considerations apply to study 101, here the issue is even more prevalent as the result CNS/LM PFS rate at 6 months or OS rate at 12 months are rather short term and generated in a very small population.  In  an  updated  report  five  CR  were  observed  in  20  patients  with  measurable  disease  at baseline. Based on the characteristics of the cases (e.g., only adjudication resulted in CR in at least two cases),  the  overall  small  numbers  and the  fact  that  additional  therapies  were  administered to  most patients, in some even prior to establishment/confirmation of CR these findings are not considered a robust demonstration of efficacy.

## 2.2.7. Conclusions on the clinical efficacy

The design of the trials, the choice of endpoints, the conduct of the trials, the recruited population and the obtained results do not allow to establish that there is a treatment effect that is attributable to  131 Iomburtamab therapy. Further analyses of the existing dataset and updates on the ongoing trial have been provided but were not able to alleviate the totality of concerns.

## 2.2.8. Clinical safety

The safety and tolerability data for  131 I-omburtamab in support of this application were collected from two clinical trials, i.e., Trial 03-133 and 101.

Trial 03-133 : Ongoing single-site trial conducted at Memorial Sloan Kettering Cancer Center (MSK); the applicant presents interim report data of a safety analysis based on 109 paediatric neuroblastoma subjects. Enrolment for Trial 03-133 was closed in December 2018 for patients with neuroblastoma. Trial 03-133 was open for enrolment of patients with CNS/LM malignancies known to be omburtamabreactive  [i.e.,  express  B7-H3  (CD276)].  The  majority  of  patients  were  neuroblastoma  patients,  but patients with several different brain tumour types were also enrolled. The CSR is based on the paediatric (neuroblastoma and non-neuroblastoma) subjects enrolled in Trial 03-133 by 31 December 2018. The safety data cut-off was 30 June 2019 with follow-up survival data collected through 12 March 2020. Supportive serious adverse event (SAE) data for 37 paediatric non-neuroblastoma subjects were also provided. This report focuses on results of neuroblastoma patients.

Trial 101: Ongoing, international, multisite clinical trial sponsored by Y-mAbs with enrolment cut-off for the interim analysis 01 January 2020 and safety data cut-off of 01 June 2020 compiled in an interim CSR. The trial continued enrolment after 01 January 2020. Primary clinical safety analyses were based on 24 neuroblastoma subjects. An updated interim CSR including 32 patients with cut-off 01 June 2021 was provided with the responses to the D120 LOQ. These data are added in the respective sections.

The pooled  data (both  trials)  were  included  in  the  initial  submission  and  are  still  included  in  this overview for a better comparability of the results.

## Table 33. Clinical Trials  Providing  Subject-Level  Data  Used  for  the  Safety  Analysis  of  131 IOmburtamab

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Trial      | Typeof Data Provided in Supportofthe Application   | Trial Design                                                                             | Treatmenta                                                                                                                                                                                                                                                       | Subjects Providing Safety Data                                                               | Population                                                                                                 | Trial Status/Type of Report in Application   |
|------------|----------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| Tral03-133 | PK Safety Efficacy                                 | Open-label, single arm, single-cenre trial.dose escalation (Part 1）and expansion(Part 2) | Part l: ic.v.-omburtamab:Week1at 2mCi （74MBq dosimetry dose) ie.v.13I-omburtamab:Week2at10-80 mCi(370-2960 MBq:treatment dose) Part 2: i.c.v.3omburtamab:Week1and6 at 2mCi(74MBq, dosimetry dose)b ie.v.I-omburtamab:Week2and7at 50 mCi(1850 MBq:treatment dose) | Safery:146 -109paediatric neuroblastoma subjects - 37 paediatric non- neuroblastoma subjects | Subjects witha histologically confurmed diagnosis of reactive malignancy anomburtamab- with CNS/LM disease | Ongoing/Interim CSRd                         |
| Tnal101    | PK Safety Efficacy                                 | Open-label,single am, multicentre trial                                                  | ic.v.omburtamab:Week1and 6at 2 mCi(74 MBq: dosimetry dose) ic.v.13I-omburtamab:Week2and7at 50 mCi(1850 MBq: treatment dose)                                                                                                                                      | Safety:24                                                                                    | Paediatric NB subjects metastasis with CNS/LM                                                              | Ongoing/Interim CSR                          |

aInTrial 03-133(Part 1andPart 2）andTrial 101.subjects were administered twocyclesofic.v.I-omburtamab（if tolerated andnoprogressive disease between thecycles)

CNS=central nervous system: CSR=clinical study report,ic.v.=intracerebroventricular,LM=leptomeningeal;MSK=Memorial SloanKetteringCancer Center, NB=neuroblastoma:PK=phamacokinetics;Y-mAbs=Y-mAbsTherapeutics,Inc.

bT-omburtamab was administered forthe dosimetry dose forsome subjects.I-omburtamab was administered for all treatment doses.

dEnrolment ofNB subjects closedDecember 2018.The data cut-off forneuroblastoma subjects was 30June 2019 forEU MAA.As per the protocol.follow-up for all subjects is ongoing.Although the CSRfo 03.133indicatesthat it is aninterimreport,this CSRis actually the finalreport withrespect to data beingincluded in theMAA.The CSRfo Trial 03-133includes a full assessment of safety andeffcacy data collected for paediatric patients withneuroblastoma enrolled by 31 December 2018;safety data are presented as ofa cut-off of30June 2019 with follow-up survival data collected through12March2020（CSR 03-133Section7.0）.Phanmacokinetic(PK)and dosimetry dataare also presented for the paediatric neuroblastoma patients dosed in the trialinyears 2016-2018,inclusive.This report also inchudes serious adverse events (SAEs)from paediatric nonneuroblastoma subjects.

cThe higbest treatment doselevel administered to any subject inTrial 03-133was S0mCi(2960MBq),thehighest treatment dose level administered to a neuroblastoma subject was 70mCi(2590 MBq)

eTreatment doses were reduced by 50%for subjects less than1 year of age,and by 33%for subjects between 1 and3years of age fSafety data cut-off was 01 June 2020 for this SCS

## 2.2.8.1. Patient exposure

## Subject Disposition and exposure to trial medication

## Trial 03-133

As of 31 December 2018, there were 109 neuroblastoma subjects and 37 paediatric non-neuroblastoma subjects enrolled in Trial 03-133. Of the 109 neuroblastoma subjects, two subjects had an International Neuroblastoma  Pathology  Classification  (INPC)  classification  of  ganglioneuroblastoma  and  a  subhistology of ganglioneuroblastoma at diagnosis of systemic disease. However, both subjects had a subhistology of neuroblastoma at the time of CNS/LM relapse.

<div style=\"page-break-after: always\"></div>

Table 34. Summary of Radiolabelled Omburtamab Administration for Subjects in the Safety Analysis Set

<!-- image -->

|                                     | Statistic/ Category   | 50mCi (N=10)   | 50mCi (N=94)   | 50mCi (N=5)             | All Subjects (N=109)   |
|-------------------------------------|-----------------------|----------------|----------------|-------------------------|------------------------|
| Totalactual dosage (mCi)            | Mean SD Median        | 10 43.685      | 94 75.032      | 5 71.324 18.5296 61.750 | 109 71.986             |
| Totalactual dosage (mCi)            |                       | 28.4526        | 30.3896        |                         | 30.9466                |
| Totalactual dosage (mCi)            |                       | 44.235         | 69.935         |                         | 55.500                 |
| Totalactual dosage (mCi)            | Q1.03                 | 25.610,67.430  | 52.890,103.040 | 60.620,71.930           | 52.450.102.190         |
| Totalactual dosage (mCi)            | Min.Max               | 1.87.84.79     | 28.35.218.33   | 59.10,103.22            | 1.87.21833             |
| No.of dosimety doses [n (%6)]       |                       | 3(30.0)        | 41(43.6)       | 4(80.0)                 | 48(44.0)               |
| No.of dosimety doses [n (%6)]       |                       | 6(60.0)        | 51(543)        | 1(20.0)                 | 58(53.2)               |
| No.of dosimety doses [n (%6)]       |                       | 1(10.0)        | 1(1.1)         | 0                       | 2(1.8)                 |
| No.of dosimety doses [n (%6)]       | 4                     | 0              | 1(1.1)         | 0                       | 1(0.9)                 |
| No.of treatment doses [n (%）]       |                       | 1(10.0)        | 45(47.9)       | 4(80.0)                 | 50(45.9)               |
| No.of treatment doses [n (%）]       | 2                     | 7(70.0)        | 47 (50.0)      | 1(20.0)                 | 55 (50.5)              |
| No.of treatment doses [n (%）]       |                       |                | 1(1.1)         | 0                       | 1(0.9)                 |
| No.of treatment doses [n (%）]       | 4                     |                | (1.1)          | 0                       | 1(0.9)                 |
| Total actual treatment dosage (mCi) | N                     | 8              | 94             | 5                       | 107                    |
| Total actual treatment dosage (mCi) | Mean                  | 50.058         | 71.835         | 69.094                  | 70.079                 |
| Total actual treatment dosage (mCi) | SD                    | 20.7407        | 29.4340        | 17.4617                 | 28.8627                |
| Total actual treatment dosage (mCi) | Median                | 51.250         | 66.040         | 60.090                  | 51.980                 |
| Total actual treatment dosage (mCi) | Q1.Q3                 | 34.825.63.950  | 50.700.98.910  | 59.030.70.000           | 50.410.98.410          |
| Total actual treatment dosage (mCi) | Mm.Max                | 19.30.81.11    | 2630.210.78    | 57.30,99.05             | 19.30.210.78           |

Sowrce:Table 14.1.8.1

Note:For subjcts under 3 years ofage, dose groups were assiged based on the treatent dose before age adjustment (ie. 33% or 50% dose rednction) SDstandard deviation:Mn=minimumMaxmaximm

All 109 enrolled neuroblastoma subjects are included in the SAF. Most subjects were in the 50 mCi group (94 subjects [86.2%]). 28 SAF subjects were documented as having discontinued treatment due to an intervening  circumstance.  For  the  SAF,  progressive  disease  (12  subjects  [11.0%])  and  Other  (11 subjects  [10.1%]) accounted for the highest number of reasons for discontinuing treatment. 4 SAF subjects (3.7%) discontinued treatment due to excessive toxicity. The Other reasons were low platelets with or without low neutrophils (6 subjects [5.5%]), medical events that required treatment cessation (3 subjects [2.8%]), or investigator discretion for other treatments (2 subjects [1.8%]).

The majority of non-neuroblastoma analysis set (NNAS) subjects received a 50 mCi treatment dose (23 subjects [62.2%]. Of the 37 NNAS subjects, 13 were categorised in the clinical database as having completed treatment as of the data cut-off date. Progressive disease (11 subjects [29.7%]) was the most frequently documented reason for discontinuing treatment. One subject (2.7%) ended treatment due to excessive toxicity, and one subject (2.7%) ended treatment due to a reason in the category of 'Other'.

## Trial 101

A total of 36 subjects were screened and enrolled in this ongoing trial from end-November 2018 to the enrolment cut-off date for this interim analysis, 20-Oct-2020. Three subjects failed screening and one subject was withdrawn by the physician before receiving any treatment. A total of 32 subjects were included in the full analysis set.

Of the eight deaths reported in the trial, one AE leading to death was reported (intracranial haemorrhage, received one treatment cycle). The remaining seven deaths were due to disease progression (4 Subjects received  one  treatment  cycle.  3  Subjects  received  two  treatment  cycles).  A  total  of  13  subjects discontinued treatment: ten due to AEs, two due to disease progression and one as a result of parents deciding to seek other treatment.

The subject disposition is summarised in Table 35.

<div style=\"page-break-after: always\"></div>

Table 35. Subject Disposition

| Disposition                           | N (%)     |
|---------------------------------------|-----------|
| Sereened subjects                     | 36        |
| Screening fhilures                    | 3         |
| Withdrawnbefore treatment             | 1         |
| Eligible subjects included            | 32 (100)  |
| Full analysis set                     | 32 (100)  |
| Safety analysis set                   | 32 (100)  |
| End oftrial status                    |           |
| Ended participation                   | 9 (28.1)  |
| Ongoing                               | 23 (71.9) |
| Reason for end of trial participation |           |
| Death                                 | 8 (88.9)  |
| Withdrawal byparent/guardian          | 1 (11.1)  |
| Discontinued trealment                | 13 (40.6) |
| Reason for discontinued treatment     |           |
| Adverse event                         | 10 (76.9) |
| Other                                 | 1 (7.7)   |
| Progressive disease                   | 2 (15.4)  |

Source: Table 14.1.1.1 and Appendix 16.2.1.2

N: Number of subjects; %: Percenthage of subjects.

Other: refers to parents decided to pursue other possibilities for the subject and parents decided to seek other treatment, no fomal withdrawal of consent.

Exposure by total number of  131 I-omburtamab infusions and number of cycles is presented for Trial 101 in Table 36. A total of 26 subjects were administered the full treatment dose of 50 mCi, whereas the remaining six subjects were administered a reduced treatment dose as they were below 3 years of age. A total of 92 infusions were administered up until the data cut-off date for this interim analysis.

Table 36. Exposure to  131 I-Omburtamab by Total Number of IMP Infusions and Number of Cycles (Safety Analysis Set)

|                                | 13l-omburtamab N(%)   |
|--------------------------------|-----------------------|
| Dosimetry infusions            |                       |
| 1                              | 11 (34.4)             |
| 2                              | 15 (46.9)             |
| Treatment infusions            |                       |
| 1                              | 13 (40.6)             |
| 2                              | 19 (59.4)             |
| Number of Cycles\"              |                       |
| 一                              | 12 (37.5)             |
| 2                              | 20 (62.5)             |
| Total dosimetry exposure (mCi) |                       |
| N                              | 26                    |
| Mean (SD)                      | 3.27 (1.054)          |
| Median                         | 3.85                  |
| Min -Max                       | 1.8=4.4               |
| Total exposure (mCi)           |                       |
| N                              | 32                    |
| Mean (SD)                      | 74.00 (25.220)        |
| Median                         | 69.45                 |
| Min-Max                        | 31.7-107.5            |

Source: Table 14.1.4.1,Appendix 16.2.5.1

IMP=investigational medicinal product.N=number of subjects:%=percentage of treated subjects: SD= standard deviation.

The number of cycles is calculated by initiated cycle

<div style=\"page-break-after: always\"></div>

## Demographics and Other Characteristics of Study Population

## Demographics

## Trial 03-133

More subjects (72/109; 66.1%) were male. The median age of subjects was 4.74 years with a range of 1 to 15 years. The median weight of subjects was 15.10 kg, ranging from 6.9 to 71 kg. The majority of the subjects were White (86/109; 78.9%). The remaining subjects were Black/African American (9/109; 8.3%), Asian/Far East Indian Subcontinent (3/109; 2.8%), Unknown (6/109; 5.5%). The majority of the subjects were not Hispanic or Latino (79/109; 72.5%).

As with the Trial 03-133 SAF, the majority of subjects in the NNAS were White males and the majority were not Hispanic or Latino. Subjects in the NNAS were older and weighed more than those in the SAF with a median age of 8.42 years (mean age of 8.33 years) and a median weight of 24.45 kg, ranging from 11.1 to 78.2 kg. Most of the paediatric non-neuroblastoma subjects received  131 I-omburtamab for CNS cancer (31/37; 83.8%), with the remaining subjects receiving  131 I-omburtamab for sarcoma (3/37; 8.1%), retinoblastoma (2/37; 5.4%), and melanoma (1/37; 2.7%).

## Trial 101

Of the 32 treated subjects, 21 were male (65.6%), and 11 were female (34.4%). At baseline, the mean and median age of subjects were 4.5 and 4.0 years, respectively. The majority of subjects included in the trial were 'White' (78.1%) followed by 'Asian' (15.6%). Subjects were recruited from four U.S. sites (MSK [New York, NY], Nationwide Children's Hospital [Columbus, OH], Riley Hospital for Children [Indianapolis, IN] and MD Anderson Cancer Center [Houston, TX]) that treated 26 subjects and one site in Spain (Hospital Sant Joan de Déu, Barcelona) that treated 6 subjects.

## Baseline Subject and Disease Characteristics

## Trial 03-133

The median age at neuroblastoma diagnosis for subjects in Trial 03-133 was 2.387 years with a range of  0.02  to  13.53  years.  A  total  of  86  of  109  (78.9%)  subjects  were  older  than  18  months.  The International Neuroblastoma Staging System (INSS) stage at diagnosis for the majority of subjects was Stage  4  (79/109;  72.5%).  The  site  of  disease  reported  most  often  was  unifocal  parenchymal  site (52/109;  47.7%).  MYCN  amplification  was  reported  for  55  of  109  (50.5%)  subjects,  and  v-myc myelocytomatosis viral related oncogene (MYCN) gain was reported in two of 109 (1.8%) subjects. The tumour subtype for about half of the subjects was neuroblastoma poorly differentiated (56/109; 51.4%). For subjects in the NNAS, MYCN amplification was reported in one subject in the &lt;50 mCi treatment group. INSS stage at diagnosis was not reported for any subject. Similar to the SAF in Trial 03-133, most subjects (94.6%) in the NNAS had prior radiation therapy. Thirty-four (91.9%) subjects had prior surgery and 34 (91.9%) subjects had prior chemotherapy.

## Trial 101

The median age at neuroblastoma diagnosis for subjects in Trial 101 was 2.77 years with a range of 0 to 9 years. Most subjects (27/32; 84.4%) were INSS Stage 4 at diagnosis. MYCN amplification was reported for 14/32 (43.8%) and MYCN gain was reported in two of 32 (6.3%) subjects. Neither gain nor amplification  was  reported  for  the  remaining  15  subjects.  International  Neuroblastoma  Pathology Classification was reported for 25 subjects. A common tumour subtype for subjects was neuroblastoma poorly differentiated (13/32; 40.6%). The median time from neuroblastoma diagnosis to first relapse was 544 days, ranging from 65 to 1534 days. The median time from CNS/LM relapse until treatment with  131 I-omburtamab was 146 days, ranging from 70 to 513 days.

<div style=\"page-break-after: always\"></div>

## Prior and Concomitant Treatments

## All Prior Treatments for Neuroblastoma Trial 03-133

Exposure to all prior treatments with surgery, autologous stem cell transplantation (ASCT), and radiation for neuroblastoma for Trial 03-133 subjects are presented in Table 37.

Table 37. Summary of Other Prior Treatments for Study Disease in the Safety Analysis Set of Trial 03-133

| OtherPrior Treatments   | Statistie/ Category   | <50mCi (N=10) [a(%)]   | 50mCi (t6=N) [n(%%)]   | >50mCi (N=5) [n(%)]   | All Subjects (601=N) [n(96)]   |
|-------------------------|-----------------------|------------------------|------------------------|-----------------------|--------------------------------|
| Any Prior Surgery?      |                       | 10 (100.0)             | 94 (100.0)             | 5(100.0)              | 109 (100.0)                    |
| Type of Surgery         | Curative              | 2 (20.0)               | 3 (3.2)                | 0                     | 5(4.6)                         |
| Type of Surgery         | Palliative            | 0                      | 3 (3.2)                | 0                     | 3 (2.8)                        |
| Type of Surgery         | Not Reported          | 9(90.0)                | 94 (100.0)             | 5 (100.0)             | 108 (99.1)                     |
| Any Prior ASCT?         | s                     | 8(80.0)                | 68 (72.3)              | 4(80.0)               | 80 (73.4)                      |
| TypeofASCT              | Single                | 1(10.0)                | 18 (19.1)              | 0                     | 19 (17.4)                      |
|                         | Tandem                | 1(10.0)                | 4(4.3)                 | 0                     | 5(4.6)                         |
|                         | Not Reported          | 6(60.0)                | 53 (56.4)              | 4(80.0)               | 63 (57.8)                      |
| AnyPriorRadiation?      |                       | 10 (100.0)             | 89 (94.7)              | 5(100.0)              | 104 (95.4)                     |

Source:CSR03-133 Table 14.1.6.1

ASCT=autologous stem cell transplantation

Note:50mCi=1850MBq

While all Trial 03-133 subjects (N=109) underwent surgery as a prior treatment of neuroblastoma, 80 of 109 subjects (73.4%) had ASCT and 104 of 109 (95.4%) were exposed to radiation. Of the surgery types reported, 5 of 109 (4.6%) subjects underwent curative surgery and 19 of 109 (17.4%) had single ASCT. All subjects (109/109; 100.0%) had received antineoplastic and/or immunomodulating agents.

## Trial 101

All subjects had received multiple types of treatment for NB prior to the treatment with  131 Iomburtamab. All subjects received prior chemotherapy (combination treatment: 32 subjects; single agent treatment: 10 subjects). Chemotherapy was for most subjects administered in 1-2 cycles, but a few subjects received up to 13 cycles of treatment.

A total of 22 subjects received immunotherapy. Most subjects (15 subjects) received autologous stem cell transplant (ASCT). The majority of subjects (31 subjects) received radiation therapy. A total of 30 subjects had 57 previous surgeries performed, with the majority being curative surgery (38 surgeries in 22 subjects).

## Prior  Treatments  for  Neuroblastoma:  Period  between  CNS/LM  Relapse  and  before  131 Iomburtamab Administration

## Trial 03-133

The  subset  of  the  prior  treatments  (i.e.,  radiation  therapy,  surgery,  and  autologous  stem  cell transplantation [ASCT]) for neuroblastoma reported for the period between CNS/LM relapse and before 131 I-omburtamab administration for SAF subjects is summarised in Table 46.

Most subjects received radiation therapy (99/109; 90.8%), a majority of subjects had surgery (84/109; 77.1%), and a minority of subjects had ASCT (23/109; 21.1%) during this period. The vast majority of

<div style=\"page-break-after: always\"></div>

subjects received chemotherapy during this period, 103 (94.5%) subjects received antineoplastic and/or immunomodulating agents.

Table 38. Summary of Other Prior Treatments for Neuroblastoma Between CNS/LM Relapse and  131 I-omburtamab Administration for Safety Analysis Set of Trial 03-133

|                           |              | <50mCi (N=10) [n(%)]      | 50mCi (N=94) [%]   | >50mCi (N=5) [n(]   | All Subjects (N=109) [（%]   |
|---------------------------|--------------|---------------------------|--------------------|---------------------|-----------------------------|
| Any PriorSurgery?         | s            | 5(50.0)                   | 76 (80.9)          | 3 (60.0)            | 84 (77.1)                   |
| Type of Surgery           | Curative     | 2 (20.0)                  | 2(2.1)             | 0                   | 4(3.7)                      |
| Type of Surgery           | Palliative   | 0                         | 2(2.1)             | 0                   | 2(1.8)                      |
| Type of Surgery           | Not Reported | 3 (30.0)                  | 74 (78.7)          | 3 (60.0)            | 80 (73.4)                   |
| Any Prior AsCT?           | s            | 3 (30.0)                  | 18 (19.1)          | 2 (40.0)            | 23 (21.1)                   |
| Type ofASCT               | Single       | 1(10.0)                   | 11(11.7)           | 0                   | 12 (11.0)                   |
| Type ofASCT               | Tandem       | 0                         | 1(1.1)             | 0                   | 1(0.9)                      |
| Type ofASCT               | Not Reported | 2 (20.0)                  | 6(6.4)             | 2 (40.0)            | 10(9.2)                     |
| Any PriorRadiation?       | Yes          | 9(90.0)                   | 85 (90.4)          | 5(100.0)            | 99 (90.8)                   |
| Total Radiation Dose (Gy) |              | 9                         | 84                 | 5                   | 98                          |
|                           | Mean         | 16.200                    | 19.891             | 22.280              | 19.674                      |
|                           | SD           | 8.4427                    | 38.2372            | 23.8108             | 35.8026                     |
|                           | Median       | 21.600                    | 18.000             | 21.600              | 18.000                      |
|                           | Q1.Q3        | 10.800.21.6001.800.21.600 |                    | 2.000.26.000        | 1.800.21.600                |
|                           | Min.Max      | 1.80.21.60                | 1.20,300.00        | 1.80.60.00          | 1.20.300.00                 |

Source:CSR03-133Table14.1.6.3

ASCT=autologous stem cell transplantation:Max=maximum:Min=minimum:n=number ofsubjects:SD=standard deviation

Note:50mCi=1850MBq.

Note: Multiole responses are Dossible.

## Trial 101

All subjects had received multiple types of treatment for neuroblastoma prior to the treatment with 131 I-omburtamab. Most subjects received chemotherapy, radiation therapy, and surgery in the period between CNS/LM relapse and before entering the screening period (i.e., before  131 I-omburtamab administration).

Chemotherapy was administered to 29 subjects (90.6%) (Table 39). A total of 30 subjects (93.8%) received radiation therapy during this period, and of these, 25 subjects received craniospinal irradiation (CSI). Surgery was performed in 26 subjects (81.3%).

<div style=\"page-break-after: always\"></div>

Table  39.  Prior  Treatments  (Chemotherapy,  irradiation  and  surgery)  for  Target  Indication Between CNS/LM Relapse and  131 I-Omburtamab Administration.

|                                                                           | I3I-omburtamab N (%)                                                      |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Full analysis set (N)                                                     | 32                                                                        |
| Prior chemotherapy between CNS/LM relapse and I-omburtamab administration | Prior chemotherapy between CNS/LM relapse and I-omburtamab administration |
| No                                                                        | 3 (9.4)                                                                   |
| Yes                                                                       | 29 (90.6)                                                                 |
| Prior irradiation between CNS/LM relapse and 1I-omburtamab administration | Prior irradiation between CNS/LM relapse and 1I-omburtamab administration |
| No                                                                        | 2 (6.3)                                                                   |
| Yes                                                                       | 30 (93.8)                                                                 |
| CSI between CNS/LM relapse and 'I-omburtamab administration               | CSI between CNS/LM relapse and 'I-omburtamab administration               |
| No                                                                        | 7 (21.9)                                                                  |
| Yes                                                                       | 25 (78.1)                                                                 |
| Prior surgery between CNS/LM relapse and I'I-omburtamab administration    | Prior surgery between CNS/LM relapse and I'I-omburtamab administration    |
| No                                                                        | 6 (18.8)                                                                  |
| Yes                                                                       | 26 (81.3)                                                                 |

Source: Table 14.1.2.2 and Table 16.2.4.6

N =Number of subjects: % =Percentage of subjects; CSI = craniospinal imadiation

## 2.2.8.2. Adverse events

## Trial 03-133

TEAEs were reported in 102/109 (93.6%) subjects and 97/109 subjects (89.0%) reported at least one related TEAE, as judged by the investigator (Table 48). 89/109 subjects (81.7%) reported at least one related  TEAE  of  Grade  3  or  greater.  SAEs  were  reported  in  53/109  (48.6%)  subjects,  with  35/109 (32.1%) subjects reporting at least one related SAE. TEAEs leading to drug discontinuation were reported for 11/109 subjects (10.1%). No TEAEs resulted in death.

Table 40. Overview of Treatment-emergent Adverse Events in the Safety Analysis Set of Trial 03-133

| Parameter                                                                     | 50 mCi (N=10) [n(%)]   | 50 mCi (N=94) [m(%)]   | >50mCi (N-5) [(%)川]   | All Subjects (N=109) [(%)]   |
|-------------------------------------------------------------------------------|------------------------|------------------------|-----------------------|------------------------------|
| Subjects with at least one TEAE                                               | 10 (100.0)             | 87 (92.6)              | 5 (100.0)             | 102 (93.6)                   |
| Subjects with at least one related TEAE                                       | 9(90.0)                | 83 (88.3)              | 5 (100.0)             | 97 (89.0)                    |
| Subjects with at least one TEAE of Grade 3 or Greater                         | 9 (90.0)               | 78 (83.0)              | 5 (100.0)             | 92 (84.4)                    |
| Subjects with at least one related TEAE of Grade 3 or Greater                 | 8 (80.0)               | 76 (80.9)              | 5 (100.0)             | 89 (81.7)                    |
| Subjects with at least one TEAE leading to discontinuation of shudy treatment | 2 (20.0)               | 7 (7.4)                | 2 (40.0)              | 11 (10.1)                    |
| Subjects with TEAEs lending to death                                          | 0 (0.0)                | 0 (0.0)                | 0(0.0)                | 0 (0.0)                      |
| Subjects with at least one SAE                                                | 6 (60.0)               | 46 (48.9)              | 1 (20.0)              | 53 (48.6)                    |
| Subjects with at least one related SAE                                        | 2 (20.0)               | 32 (34.0)              | 1 (20.0)              | 35 (32.1)                    |

Source: CSR 03-133 Table 14.3.1.1.Table 14.3.1.32.Table 14.3.1.33

SAE=serious adverse events: TEAE=treatment-emergent adverse events

Note: Safety Analysis Set consists of all neuroblastoma subjects who began an infiusion of any dose of Dl-omburtamab.

Note: 50 mCi=1850 MBq

Note: For subjects under 3 years and 1 year of age, dose groups were assigned based on the treatment dose before age adjustment (i.e., 33% or 50% dose reduction).

<div style=\"page-break-after: always\"></div>

## Trial 101

All subjects reported at least one TEAE, with most events (253/269; 94%) being non-serious and the majority were CTCAE Grade 1 or 2 (204/269; 76%; see Table 41). 156/269 TEAEs (58%) were assessed as related, probably, or possibly related to treatment by the investigator.

16 SAEs were reported in 10/24 (41.7%) subjects; 15/16 SAEs were determined by the investigator to be at least possibly related. Eleven TEAEs leading to drug discontinuation were reported for 8/24 (33.3%) subjects. One TEAE resulted in death. The majority of reported TEAEs had the outcome recovered/resolved (237/269; 88%). There were 28 unresolved cases as of the data cut-off date for this interim report. Unresolved cases of Grade 3 and above included platelet count decreased/thrombocytopenia, WBC count decreased/leukopenia, and lymphocyte count decreased/lymphopenia.

Table 41. Overview of Treatment-emergent Adverse Events in the Safety Analysis Set of Trial 101

| Overall TEAEs                                    | 13I-omburtamab N(%) E   |
|--------------------------------------------------|-------------------------|
| Safety Analysis Set (N)                          | 24                      |
| TEAEs                                            | 24 (100.0) 269          |
| Serious TEAEs                                    | 10 (41.7) 16            |
| Nonserious TEAEs                                 | 23 (95.8) 253           |
| Fatal TEAEs                                      | 1(4.2)1                 |
| Related TEAEs                                    | 24 (100.0) 156          |
| TEAEs Leading to Discontinuation ofII-omburtamab | 8 (33.3) 11             |
| Toxicity Grade of TEAEs                          |                         |
| Gade 1                                           | 22 (91.7) 134           |
| Gade 2                                           | 19 (79.2) 70            |
| Grade 3                                          | 20 (83.3)48             |
| Grade 4                                          | 11 (45.8) 16            |
| Grade 5                                          | 1 (4.2) 1               |
| Outcome of TEAEs                                 |                         |
| Not recovered/not resolved                       | 12 (50.0)28             |
| Fatal                                            | 1 (4.2)1                |
| Recovered/resolved                               | 23 (95.8) 237           |
| Not reported                                     | 1 (4.2) 1               |
| Recovered/resolved with sequelae                 | 2 (8.3)2                |

Source: CSR 101 Table 14.3.1.1 and Appendix 16.2.7.1.

N=Number of subjects experiencing the event at least once: E=Total number of reports of the event.

TEAE=Treatment-emergent AE. A treatment-emergent adverse event is defined as an AE with onset at or after administration ofinfusion of lI-omburtamab. Related AEs: Events with drug relationship Related, Possibly related or Probably related. SAEs are reported until 3 weeks after last IMP administration. For SAEs occuming later than 3 weeks after last IMP treatment only events related to the trial drug are reported, hence some fatal events are not reported as SAEs.

The interim analysis with cut-off date of 01-Jun-2020 provided similar results, see Table 42.

<div style=\"page-break-after: always\"></div>

Table 42. Overall Treatment-Emergent Adverse Events

| Overall TEAEs                            | I-omburtamab N(%) E   |
|------------------------------------------|-----------------------|
| Safety Analysis Set (N)                  | 32                    |
| AEs in post-treatment follow-up period   | 14 (43.8) 92          |
| TEAEs\"                                   | 31 (96.9)239          |
| Serious TEAEs                            | 13 (40.6) 19          |
| Nonserious TEAEs                         | 29 (90.6) 220         |
| Fatal TEAEs                              | 1 (3.1) 1             |
| Related TEAEs                            | 30 (93.8) 179         |
| TEAEs Leading to Discontinuation of Drug | 6 (18.8) 7            |
| TEAEs Leading toDiscontinuation of Study | 1 (3.1) 1             |
| Toxicity Grade of TEAEs                  |                       |
| Grade 1                                  | 26 (81.3) 132         |
| Grade 2                                  | 21 (65.6)41           |
| Grade 3                                  | 23 (71.9) 51          |
| Grade 4                                  | 11 (34.4) 14          |
| Grade 5                                  | 1 (3.1) 1             |
| Relationship of TEAEs                    |                       |
| Related                                  | 3 (9.4) 7             |
| Probably related                         | 20 (62.5) 74          |
| Possibly related                         | 25 (78.1) 98          |
| Not related (unlikely)                   | 10 (31.3)15           |
| Not related                              | 17 (53.1) 45          |
| Outcome of TEAEs                         |                       |
| Recovered/resolved                       | 30 (93.8)210          |
| Recovered/resolved with sequelae         | 4(12.5) 5             |
| Not recovered/resolved                   | 12 (37.5) 23          |
| Fatal                                    | 1 (3.1) 1             |

Source: Table 14.3.1.1 and Appendix 16.2.7.1

N: Number of subjects experiencing the event at least once; E: Total number of reports of the event; TEAE: Treatment emergent adverse event. A treatment emergent adverse event is defined as an AE with onset at or after administration of infusion of I-omburtamab. Related AEs: Events with drug investigational medicinal product (IMP) administration.For SAEs occurring later than 3 weeks after last IMP treatment only events related to the trial drug are reported, hence some deaths are not reported as SAEs. AEs in post-treatment follow up period cquals non-scrious adverse cvents that occur more than 21+2 days afterlast treatment

does not include non-serious AEs in post-treatment follow-up period

## All Treatment-Emergent Adverse Events

A summary of TEAEs by preferred term (PT) reported for at least 5% of subjects in Trial 03-133 is presented in Table 43.

<div style=\"page-break-after: always\"></div>

Table 43. Summary Treatment-Emergent Adverse Events Reported for at Least 5% of Subject in the Safety Analysis Set of Trial 03-133

| Svstem Organ Class Preferred Term                    | <50 mCi (N-10) [n(%)]. events   | 50 mCi (N-94) [n(%)].Hevents   | >50mCi (N-5) [n(%)].#events   | All Subjects (60I-ND [n(%)].Hevents   |
|------------------------------------------------------|---------------------------------|--------------------------------|-------------------------------|---------------------------------------|
| Number ofTEAEs                                       | 213                             | 1496                           | 53                            | 1762                                  |
| Subjects with at least one TEAE                      | 10 (100). 213                   | 87(92.0).1496                  | 5 (100).53                    | 102(93.0).1762                        |
| Blood and lymphatic system disorders                 | 8(80.0).57                      | 60(63.8).387                   | 4 (80.0).10                   | 72 (66.1).454                         |
| Lymphopenia                                          | 7 (70.0), 56                    | 59 (62.8). 385                 | 4(80.0).10                    | 70 ( 64.2), 451                       |
| Cardiac disorders                                    | 1(10.0).1                       | 7(7.4. 7                       | 0                             | 8(7.3).8                              |
| Sinus tachycardia                                    | 1(10.0). 1                      | 7( 7.4). 7                     | 0                             | 8( 73).8                              |
| Gastrointestinal disorders                           | 8(80.0).22                      | 47 (50.0).117                  | 5 (100).7                     | 60 (55.0). 146                        |
| Vomiting                                             | 5(50.0).8                       | 31(33.0). 53                   | 2 (40.0).3                    | 38 (34.9).64                          |
| Diarhoea                                             | 1 ( 10.0). 1                    | 17 (18.1). 28                  | 0                             | 18(16.5).29                           |
| Abdominal pain                                       | 1(10.0.2                        | 10(10.0). 11                   | 1 (20.0). 1                   | 12 (11.0). 14                         |
| Nausea                                               | 3(30.0).4                       | 8(8.5).8                       | 1 (20.0). 1                   | 12 (11.0), 13                         |
| Abdominal pain upper                                 | 2(20.0).2                       | 5( 5.3). 5                     | 0                             | 7 ( 6.4).7                            |
| General disorders and administration site conditions | 4 (40.0).8                      | 22 ( 23.4), 40                 | 2 (40.0). 4                   | 28 (25.7),52                          |
| Pyrexia                                              | 2(20.0).4                       | 13 ( 13.8). 13                 | 0                             | 15 (13.8). 17                         |
| Fatigue                                              |                                 | 5( 5.3).7                      | 1 (20.0). 1                   | 6(5.5.8                               |
| Injury,poisoning and procedural complieations        | 2 (20.0).3                      | 23 (24.5).32                   | 3 (60.0).3                    | 28 (25.7).38                          |
| Contusion                                            | 2(20.0).3                       | 18 (19.1).24                   | 3 (60.0).3                    | 23 (21.1). 30                         |
| Investigations                                       | 8(80.0).90                      | 65 (69.1). 669                 | 5(100).13                     | 78 (71.0). 772                        |
| Platelet count decreased                             | 7(70.0),48                      | 49 (52.1). 243                 | 3 (60.0). 5                   | 59 (54.1).296                         |
| White blood cell count decreased                     | 5 (50.0).23                     | 44 (46.8). 196                 | 2(40.0).4                     | 51(46.8).223                          |
| Neutrophil count decreased                           | 4 (40.0). 11                    | 41 (43.6). 143                 | 2 (40.0).3                    | 47 (43.1). 157                        |
| Haemoglobin decreased                                | 2(20.0).2                       | 30 (31.9).78                   | 1(20.0).1                     | 33 (30.3).81                          |
| Alanine aminotransferase increased                   | 3(30.0). 5                      | 4 ( 4.3). 6                    | 0                             | 7 ( 6.4). 11                          |
| Metabolismandnuhitiondisorders                       | 2 (20.0).2                      | 24(25.5).28                    | 1 ( 20.0). 1                  | 27 (24.8).31                          |
| Decreased appetite                                   | 2(20.0).2                       | 13 (13.8). 13                  | 1(20.0).1                     | 16 (14.7).16                          |
| Mfusculoskeletal and connectivetissue disorders      | 4 (40.0).5                      | 13 (13.8), 19                  | 0                             | 17 (15.0). 24                         |
| Pain in exlremity                                    | 2(20.0).2                       | 8( 8.5).9                      |                               | 10 ( 9.2). 11                         |
| Nervous svstem disorders                             | 7(70.0).8                       | 28 (29.8).49                   | 1 (20.0).3                    | 36 (33.0).60                          |
| Headache                                             | 6(60.0).6                       | 20 (21.3).29                   | 1(20.0).3                     | 27(24.8).38                           |
| Psvchiahie disorders                                 | 1 (10.0).1                      | 13 (13.8). 20                  | 1 ( 20.0). 1                  | 15 (13.8),22                          |
| Imtability                                           | 0                               | 7(7.4). 9                      | 1 (20.0). 1                   | 8(73).10                              |
| Respiratory, thoracie and mediastinal disorders      | 4(40.0).8                       | 35 (37.2). 57                  | 2 (40.0).4                    | 41 (37.0), 69                         |
| Cough                                                | 3 (30.0).4                      | 25 (26.6),26                   | 1 (20.0). 1                   | 29 (26.6),31                          |
| Rhinorrhoea                                          | 1 (10.0. 1                      | 15 (16.0). 16                  | 2 (40.0.2                     | 18 (16.5). 19                         |
| Skin and subcutaneous tissue disorders               | 3 (30.0).5                      | 17 (18.1),27                   | 2 (40.0), 4                   | 22 (20.2).36                          |
| Petechiae                                            | 1(10.0).2                       | 5(5.3).5                       | 1(20.0).1                     | 7( 6.4).8                             |

Sowrce: CSR 03-133 Table 14.3.1.2

TEAEs-treabment-emergent adverse events.

Note: 50 mCi-1850 MIBq.

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in system organ class (SOC) and prefered tem (PT) rows are numbers of subjects who reported at least one AE in that SOC or PT. Subjects reported more than one AE in a given SOC or PT were counted only once for that particular SOC or PT.

Note: For subjects wnder 3 years and 1 year of age, dose groups were assigmed based on the teatment dose before age adjustment (ie, 33% or 50% dose reduetion

More TEAEs were reported for the Investigations SOC than any other SOC. Within the Investigations SOC,  772/1762  (43.8%)  events  were  reported  for  78/109  (71.6%)  subjects.  Within  the  Blood  and lymphatic system disorders SOC, 454/1762 (25.8%) events were reported for 72/109 (66.1%) subjects. Commonly reported TEAEs by preferred term (PT) were lymphopenia (451 events for 70 of 109 (64.2%) subjects), platelet count decreased (296 events for 59/109 (54.1% subjects), and WBC count decreased (223  events  for  51/109  (46.8%)  subjects).  WBC  count  decrease  and  platelet  count  decrease  are

<div style=\"page-break-after: always\"></div>

consistent with myelosuppression. Myelosuppression was anticipated to be a significant risk resulting from exposure to radiation and  131 I-omburtamab (Kramer et al, 2010).

## Trial 101

A summary of TEAEs by PT reported for at least 5% of subjects (three or more subjects) in Trial 101 is presented in Table 44:

Table 44. Treatment-Emergent Adverse Events Reported by at Least 5% of Subjects

| System Organ Class Preferred Term                    | Wl-omburtamab N(%)E   |
|------------------------------------------------------|-----------------------|
| Safety Analysis Set (N)                              | 32                    |
| Any adverseevent≥S%onprefenred temlevel              | 31 (96.9) 191         |
| Investigations                                       |                       |
| Platelet count decreased                             | 17 (53.1)20           |
| Whiteblood cell count decreased                      | 13(40.0)18            |
| Lymphocyte count decreased                           | 12 (37.5)13           |
| Neutrophil count decreased                           | 10 (31.3)24           |
| GastrointestinalDisorders                            |                       |
| Nausea                                               | 11 (34.4)12           |
| Vomiting                                             | 8 (25.0)11            |
| Abdominalpain                                        | 2 (6.3)2              |
| Respiratory.Thoracie and Mfediastinal Disorders      |                       |
| Cough                                                | 6(18.8)6              |
| Nasal congestion                                     | 4 (12.5)4             |
| Epistaxis                                            | 2 (6.3)4              |
| NervousSystemDisorders                               |                       |
| Headache                                             | 8 (25.0)12            |
| Haemorrhage intracranial                             | 3 (9.4)3              |
| Neuralgia                                            | 2 (6.3) 5             |
| BloodandLymphaticSystemDisorders                     |                       |
| Anaemia                                              | 10 (31.3)13           |
| MetabolismandNuhitionDisorders                       |                       |
| Decreased appetite                                   | 5 (15.0)5             |
| Hyperglycaemia                                       | 2 (6.3) 2             |
| Hypokalaemia                                         | 2 (6.3)2              |
| General disorders and administration site conditions |                       |
| Fatigue                                              | 3 (9.4)3              |
| Pain                                                 | 3(9.4)3               |
| Pyrexia                                              | 2(6.3)3               |
| Skin and subcutaneous tissue disorders               |                       |
| Rash                                                 | 2(6.3)3               |
| Dermatitis acneifomm                                 | 2(6.3)2               |
| Dry skin                                             | 2(6.3)2               |
| Rashmaculo-papular                                   | 2(6.3)2               |
| Injury. poisoning and procedural complications       |                       |
| Contusion                                            | 3 (9.4)3              |
| Meningitis chemical                                  | 2(6.3)2               |
| Vasculardisorders                                    |                       |
| Haematoma                                            | 3 (9.4)4              |
| Endoerine disorders                                  |                       |
| Hypothyroidism                                       | 2(6.3)3               |
| Infections and infestations                          |                       |
| Nasopharyngitis                                      | 2 (6.3) 3             |
| Musculoskeletal and connective tissue disorders      |                       |
| Painm exlremity                                      | 2(6.3)2               |

Source: Table 14.3.1.15 and Appendix 16.2.7.1.

Overall, 31/32 patients experienced any adverse event (96.9%). The most frequently reported SOC was Investigations, and the most common TEAEs by preferred term were platelet count decreased (17/32, 53.1%), white blood cell count decreased (13/32, 40.6%), and lymphocyte count decreased (12/32, 37.5%). One case of infection (sepsis) was reported as Grade 4, serious and not related to study drug (resolved). A total of 3/32 (9.4%) subjects experienced 3 events of intracranial

<div style=\"page-break-after: always\"></div>

hemorrhage. The events were serious and of Grade 3, 4 and 5, respectively (possibly related to the study drug by the sponsor). One of the events was fatal.

## Pooled Trial 03-133 and Trial 101

The most common TEAE were compatible with myelosuppression and anticipated given exposure to radiation  and  131 I-omburtamab.  Radiation  exposure  and  treatment  with  cytotoxic  drugs  before  trial initiation may confound the assessments of events such as myelosuppression as they may also promote the development of prolonged cytopenia following myelosuppression.

## Treatment-Emergent Adverse Events by Intensity - Grade 3 and 4 TEAEs

## Trial 03-133

92/109  (84.4%)  subjects  reported  a  total  of  1220  TEAEs.  that  were  CTCAE  Grade  3  or  higher (1220/1762; 69.2% of all TEAEs; Table 45).

Table 45. Summary of Treatment Emergent Adverse Events by Highest CTCAE Grade from Subjects in the Safety Analysis Set

|                                          | CTCAE Grade   | <50mCi (N-10)   | 50mCi (F6-N)   | >50mCi (N-5)   | AllSubjects (N-109)   |
|------------------------------------------|---------------|-----------------|----------------|----------------|-----------------------|
| Numberof subjectsby highestgrade of TEAE | Grade l       | 1 (10.0)        | 7 (7.4)        | 0              | 8 (7.3)               |
| Numberof subjectsby highestgrade of TEAE | Grade2        | 0               | 2(2.1)         | 0              | 2 (1.8)               |
| Numberof subjectsby highestgrade of TEAE | Grade3        | 4(40.0)         | 43 (45.7)      | 4(80.0)        | 51 (46.8)             |
| Numberof subjectsby highestgrade of TEAE | Grade4        | 5(50.0)         | 35 (37.2)      | 1(20.0)        | 41(37.6)              |

Source:Table 14.3.1.4

Note:For subjects under 3 years of age, dose groups were assigned based on the treatment dose before age adjustment(ie..33%6or 5096dose reduction).

TEAE=treatment-emergent adverseevents.

The majority of Grade 3 or higher TEAEs belonged to the SOC Investigations (731/1220 TEAEs; 60.0%). The Grade 3 or higher TEAEs reported for 5% of all subjects were lymphopenia (70/109, 64.2%), platelet count  decreased  (59/109,  54.1%),  WBC  decreased  (51/109,  46.8%),  neutrophil  count  decreased (47/109,  43.1%),  haemoglobin  decreased  (33/109,  30.3%),  ALT  increased  (7/109,  6.4%),  and hypokalaemia (7/109, 6.4%).

Grade 4 TEAEs reported by at least two subjects included platelet count decreased (32/109, 29.4% subjects), neutrophil count decreased (18/109, 16.5%), WBC decreased (11/109, 10.1%), lymphopenia (8/109, 7.3%), haemoglobin decreased (6/109, 5.5%), myelodysplastic syndrome (3/109, 2.8%), and acute myeloid leukaemia (2/109, 1.8%). No subject had a Grade 5 (fatal) TEAE.

## Trial 101

24/32 (75%) subjects reported a total of 66 TEAEs that were CTCAE Grade 3 to Grade 5 (see Table 46).

<div style=\"page-break-after: always\"></div>

Table 46. Treatment-Emergent Adverse Events Grade 3 or Higher by System Organ Class and Preferred Terms (Safety Analysis Set)

| System Organ Class Preferred Term             | Grade 3 N(%)E   | Grade 4 N(%) E   | Grade 5 N(%)E   | Total N(%) E   |
|-----------------------------------------------|-----------------|------------------|-----------------|----------------|
| Safety Analysis Set. N=32                     |                 |                  |                 |                |
| Any adverse event of Gnde 3 and above         | 23 (71.9) 51    | 11 (34.4) 14     | 1 (3.1) 1       | 24 (75.0) 66   |
| Investigations                                | 23 (71.9)46     | 9 (28.1) 12      |                 | 24 (75.0) 58   |
| Platelet count decreased                      | 7(21.9) 7       | 7 (21.9) 7       |                 | 13 (40.6) 14   |
| Whitebloodcell coumt decreased                | 10 (31.3) 12    | 1 (3.1) 1        |                 | 10 (31.3) 13   |
| Lymphocyte count decreased                    | 10 (31.3)10     | 1 (3.1) 1        |                 | 10 (31.3) 11   |
| Neutrophil count decreased                    | 9 (28.1) 16     | 2 (6.3)3         |                 | 9(28.1)19      |
| Alanine aminotransferase increased            | 1 (3.1) 1       |                  |                 | 1 (3.1) 1      |
| Blood and LymphatieSystem Disorders           | 3 (9.4)3        |                  |                 | 3 (9.4) 3      |
| Anaemia                                       | 2(6.3)2         |                  |                 | 2(6.3)2        |
| Febrileneutropenia                            | 1(3.1)1         |                  |                 | 1 (3.1) 1      |
| Nervous SystemDisorders                       | 1 (3.1) 1       | 1 (3.1) 1        | 1 (3.1) 1       | 3 (9.4)3       |
| Hemomhage intracranial                        | 1 (3.1) 1       | 1 (3.1) 1        | 1 (3.1) 1       | 3 (9.4) 3      |
| Infeedons and infestadons                     |                 | 1 (3.1) 1        |                 | 1 (3.1) 1      |
| Sepsis                                        |                 | 1 (3.1)1         |                 | 1 (3.1) 1      |
| Injury,Poisoning and Procedural Complieations | 1 (3.1) 1       |                  |                 | 1 (3.1) 1      |
| Meningitis chemical                           | 1 (3.1)1        |                  |                 | 1 (3.1) 1      |

Source:Table 14.3.1.8 and Listing 14.3.2.3

N: Number of subjects: %: Percentage of subjects:E: Number ofevents.A treatment emergent adverse event is defined as an AE with onset at or after administration of infiusion of U'I-omburtamab The summary does not include non-serious AEs that occu more than 21+2 days after last treatment

The majority of these events belonging to the SOCs 'Investigations' and 'Blood and lymphatic system disorders', were consistent with myelosuppression. Three subjects experienced intracranial haemorrhage: Grade 3 and 4 in two subjects and fatal (Grade 5) in one subject. This case was already reported in the initial submission, thus no further fatal cases occurred.

## Pooled Trial 03-133 and Trial 101

Within pooled safety populations of Trial 03-133 and Trial 101, Grade 3 or greater TEAEs of low white blood cell counts were common. A total of 59.4% of subjects reported lymphocyte count decreased, 54.9% of subjects reported platelet count decreased, 46.6% of subjects reported white blood cell count decreased, and 42.1% of subjects reported neutrophil count decreased that were Grade 3 or greater.

## Related Treatment-Emergent Adverse Events by Intensity

## Trial 03-133

89/109 (81.7%) subjects reported at least one related Grade 3 or higher treatment-related TEAE. 67.7% reported treatment-related TEAEs of Grade 3 or higher. Related TEAEs of Grade 3 or higher reported for &gt;5% of all subjects were lymphopenia (69/109, 63.3%), platelet count decreased (59/109, 54.1%), WBC  decreased  (51/109,  (46.8%),  neutrophil  count  decreased  (47/109,  43.1%),  haemoglobin decreased (32/109, 29.4%), and hypokalaemia (7/109, 6.4%). Two subjects reported a related Grade 3 event of chemical meningitis. Both subjects belonged to the 50 mCi group.

Related TEAEs of Grade 4 or higher reported for at least two subjects included platelet count decreased (31/109,  28.4%),  neutrophil  count  decreased  (17/109,  15.6%),  WBC  decreased  (11/109,  10.1%),

<div style=\"page-break-after: always\"></div>

lymphopenia (7/109, 6.4%), haemoglobin decreased (5/109, 4.6%), and myelodysplastic syndrome (2/109, 1.8%).

## Trial 101

A summary of all TEAEs judged by the investigator as being related to  131 I-omburtamab is provided in Table 47.

There were 179 TEAEs in 30/32 (93.8%) subjects considered related to  131 I-omburtamab by the investigator. Similar to all TEAEs, the majority of the related events were preferred terms consistent with myelosuppression: Most frequent related TEAEs were platelet count decreased (17/32, 53.1%) subjects, white blood cell count decreased (12/32, 37.5%), lymphocyte count decreased (12/32, 37.5%), neutrophil count decreased (10/32, 31.3%) and anaemia (8/32, 25%) subjects. Additional frequently reported related TEAEs were nausea (10/32, 31.3%), headache (8/32, 25.0%) and vomiting (4/32, 12.5%).

Table 47. Related ( 131 I-omburtamab) Treatment-Emergent Adverse Events

| SystemOrganClass PreferredTerm                  | 3'I-omburtamab N (%) E   |
|-------------------------------------------------|--------------------------|
| Safety Analysis Set (N)                         | 32                       |
| Anyrelated adverseevent                         | 30(93.8)179              |
| Investigations                                  | 25 (78.1)77              |
| Platelet count decreased                        | 17 (53.1) 20             |
| Whitebloodcellcountdecreased                    | 12 (37.5)16              |
| Lymphocytecountdecreased                        | 12 (37.5)13              |
| Neutrophil countdecreased                       | 10 (31.3)24              |
| Alanineaminotransferaseincreased                | 1 (3.1) 1                |
| Aspartate aminotransferaseincreased             | 1 (3.1)1                 |
| Bloodthyroidstimulatinghomoneincreased          | 1(3.1)1                  |
| Red bloodcell count decreaed                    | 1(3.1) 1                 |
| NervousSystemDisorders                          | 11 (34.4)22              |
| Headache                                        | 8 (25.0) 12              |
| Neuralgia                                       | 2(6.3) 5                 |
| Dizziness                                       | 1 (3.1) 1                |
| Dysaesthesia                                    | 1(3.1)1                  |
| Haemonhage intracranial                         | 1 (3.1) 1                |
| Hypoaesthesia                                   | 1 (3.1) 1                |
| Peripheral sensoryneuropathy                    | 1 (3.1) 1                |
| GastrointestinalDisorders                       | 13 (40.0)19              |
| Nausea                                          | 10 (31.3) 11             |
| Vomiting                                        | 4 (12.5) 5               |
| Abdominalpain                                   | 1 (3.1)1                 |
| Dianhoea                                        | 1 (3.1) 1                |
| Dyspepsia                                       | 1 (3.1)1                 |
| Bloodand LymphaticSystemDisorders               | 9 (28.1) 12              |
| Anaemia                                         | 8 (25.0)11               |
| Febrileneutropena                               | 1(3.1)1                  |
| MetabolismandNutritionDisorders                 | 6(18.8)11                |
| Decreased appetite                              | 3 (9.4)3                 |
| Hyperglycaemia                                  | 2(6.3)2                  |
| Hypokalaemia                                    | 2 (6.3)2                 |
| Hyperphagia                                     | 1(3.1)3                  |
| Dehydation                                      | 1 (3.1) 1                |
| GeneralDisordersandAdministrationSiteConditions | 6 (18.8) 10              |
| Fatigue                                         | 3 (9.4)3                 |
| Pyrexia                                         | 2 (6.3)3                 |
| Xerosis                                         | 1 (3.1)2                 |

<div style=\"page-break-after: always\"></div>

| System Organ Class PreferredTerm               | BI-omburtamab N (%) E   |
|------------------------------------------------|-------------------------|
| Malaise                                        | 1 (3.1) 1               |
| Pain                                           | 1 (3.1) 1               |
| SkinandSubcutaneousTissueDisorder's            | 3 (9.4) 7               |
| Rash                                           | 2 (6.3)3                |
| Rash maculo-papular                            | 2 (6.3)2                |
| Eczema                                         | 1 (3.1) 1               |
| Rash erythematous                              | 1 (3.1) 1               |
| VascularDisorders                              | 4 (12.5) 6              |
| Haematoma                                      | 2 (6.3)3                |
| Flushing                                       | 1 (3.1) 1               |
| Hot flush                                      | 1 (3.1) 1               |
| Peripheral coldness                            | 1 (3.1) 1               |
| Injury, Poisoning and Procedural Complications | 5 (15.0)5               |
| Contusion                                      | 3 (9.4) 3               |
| Meningitischemical                             | 2 (6.3)2                |
| MusculoskeletalandConnectiveTissueDisorder's   | 3 (9.4) 3               |
| Arthralgia                                     | 1 (3.1) 1               |
| Myalgia                                        | 1 (3.1) 1               |
| Pain in extremity                              | 1 (3.1) 1               |
| EndocrineDisorder's                            | 2 (6.3) 3               |
| Hypothyroidism                                 | 2 (6.3) 3               |
| Respiratory,Thoracic and Mediastinaldisorders  | 1 (3.1) 3               |
| Epistaxis                                      | 1 (3.1) 3               |
| Cardiac Disorders                              | 1 (3.1) 1               |
| Ventricular arrhythmia                         | 1 (3.1) 1               |

Source: Table 14.3.1.12 and Appendix 16.2.7.2

N: Number of subjects; %: Percentage of subjects; E: Number of events. A treatment emergent adverse event is defined as an AE with onset at or after administration of infusion of I3'I-omburtamab. Related AEs:EventswithdrugrelationshipRelated,PossiblyrelatedorProbablyrelatedasassessedby the investigator.Thesummarydoesnotincludenon-seriousadverseeventsthatoccurredmorethan 21+2 days after last treatment

1)There were three events of intracranial hemorrhage in total (Appendix 16.2.7.1). One was considered related by the investigator. All three were considered possibly related by the sponsor (Section 14.3.3)

## Infusion-related Treatment-Emergent Adverse Events Trial 03-133

A total of 174 of 1353 (12.9%) related TEAEs had an onset on the same day as a  131 I-omburtamab infusion. Infusion-related TEAEs were reported for 61/109 (56.0%) subjects. Infusion-related TEAEs not associated with abnormal laboratory parameters reported for two or more subjects were vomiting (13 subjects), pyrexia (6 subjects), nausea (3 subjects), and chemical meningitis (2 subjects). The time from infusion of  131 I-omburtamab to the onset of infusion-related TEAEs is not available for Trial 03-133. Serious  infusion-related  TEAEs  not  associated  with  abnormal  laboratory  parameters  were  chemical meningitis (two subjects) and nausea, vomiting, pyrexia, headache (one subject each).

## Trial 101

A total of 27/156 (17.3%) subjects related TEAEs had an onset on the same day as a  131 I-omburtamab infusion (Table 56). Infusion-related TEAEs were reported for 12/24 (50.0%) subjects.  The mean (SD) time from infusion of  131 I-omburtamab to onset of infusion-related TEAEs was 25.6 (75.8) minutes, ranging from 0-300 minutes. The mean (SD) duration of the events were 4.4 (7.6) days, ranging from 0-33 days. Events of headache, pyrexia, vomiting and other events typically associated with infusion of antibodies had a duration of maximum two days.

Infusion-related TEAEs not associated with abnormal laboratory parameters reported for two or more subjects were headache (5 subjects), nausea (2 subjects), and chemical meningitis (2 subjects). One subject reported a serious infusion-related TEAE (Table 48). This was a single event of Grade 3 chemical meningitis (one of the two mentioned above). The SAE was reported for the investigator as probably related, and  131 I-omburtamab was discontinued.

<div style=\"page-break-after: always\"></div>

Until  the  second  data  cut-off  (June  2021),  infusion-related  TEAEs  were  reported  for  13/32  (40.6%) subjects,  there  were  no  infusion-related  TEAEs  above  Grade  3.  Most  of  the  infusion-related  events (19/29)  were  Grade  1,  of  which  'headache'  (five  events  in  five  subjects),  'nausea'  (2  events  in  2 subjects), and 'neuralgia' (3 events in 1 subject) were among the most frequently reported events by preferred term. 4 Grade 3 infusion-related TEAEs were reported for 3 subjects, i.e. chemical meningitis (SAE), platelet count decreased, neutrophil and WBC count decreased; all recovered.

Table 48. Summary of Infusion-Related TEAEs by System Organ Class and Preferred Terms in the Safety Analysis Set of Trial 03-133 and Trial 101

| Ssten Qpn Caw Pefned Term                             | Shudy 03-133 (N-109) (ocol. gmnts   | Shudy 101 AI (N-20)   |
|-------------------------------------------------------|-------------------------------------|-----------------------|
| Number efInfusios-related TEAE:                       | 174                                 | 27                    |
| Nuubar efsubjet with atlext ooe infrsicn-ralated TEAE | 61 (56.0)                           | 12 (50.0)             |
| Bloed aad lymphssesyem diwrhni                        | 37 (01.9).60                        | 1(42),1               |
| Lyuphopeia                                            | 37 (033.9).60                       |                       |
| Aria                                                  |                                     | 1(4.2),.1             |
| oraigatioal                                           | 23 (21.1).50                        | 2(9.)                 |
| Platrkt eout derase                                   | 14(2.0.20                           | 1(42).1               |
| White Mood eall coust decreased                       | 11 (10.1),15                        | 1(42).1               |
| Neuhopll ewmt derwsed                                 | 800.8                               | 1(4.2),.1             |
| Haeuwglobin dereased                                  | 4(.5).7                             |                       |
| Gatheintrtinal dsordan                                | 17 (15.6),.21                       | 3(125),3              |
| Vonling                                               | 13 (11.9),.15                       | 1(42).1               |
| Na                                                    | 30.0.4                              | 2(0.2                 |
| Abdouinal pain                                        | 100.9).1                            | 0                     |
| AMdominnl prin upptt                                  | 10.9.1                              | 0                     |
| Nrrvoue sysien disorden                               | 14 (12.5).18                        | 6(25.0).9             |
| Headche                                               | 19 (119).14                         | 5(20.5).5             |
| Penipben sensory nruroputly                           | 2(1.5.2                             |                       |

<div style=\"page-break-after: always\"></div>

| System Organ Class/ Prefenred Term                   | Study 03-133 All (N=109) [n(%)], #events   | Study 101 All (N=24) [n(%)], #events   |
|------------------------------------------------------|--------------------------------------------|----------------------------------------|
| Nervous system disorders (continued)                 |                                            |                                        |
| Cerebrospinal fuid leakage                           | 1 (0.9), 2                                 | 0                                      |
| Dizziness                                            | 0                                          | 1 (4.2), 1                             |
| Newalgia                                             | 0                                          | 1 (4.2), 3                             |
| General disorders and administhation site conditions | 8 (7.3), 10                                | 3 (12.5), 4                            |
| Pyrexia                                              | 6 (5.5), 6                                 | 1 (4.2), 1                             |
| Catheter site pain                                   | 2 (1.8), 2                                 | 0                                      |
| Chills                                               | 0                                          | 1 (4.2), 1                             |
| Feeling cold                                         | 0                                          | 1 (4.2),1                              |
| Hypothermia                                          | 1 (0.9). 1                                 | 0                                      |
| Injection site pain                                  | 1 (0.9), 1                                 | 0                                      |
| Malaise                                              | 0                                          | 1 (4.2), 1                             |
| Injuy, poisoning and procedual complications         | 3 (2.8), 3                                 | 2 (8.3),2                              |
| Meningitis chemical                                  | 2 (1.8), 2                                 | 2 (8.3), 2                             |
| Injection site haemonhage                            | 1 (0.9), 1                                 | 0                                      |
| Skin and subcutaneous tissue disorders               | 3 (2.8), 3                                 | 2 (8.3), 4                             |
| Exfoliative rash                                     | 1 (0.9), 1                                 | 0                                      |
| Pain of skin                                         | 1 (0.9), 1                                 | 0                                      |
| Rash                                                 | 0                                          | 1(4.2),2                               |

Study 03-133

All

[n(%)], #events

(N=109)

0

0

1 (0.9),1

4 (3.7), 5

1 (0.9), 1

1 (0.9), 1

1 (0.9), 1

1 (0.9),2

2 (1.8). 2

1 (0.9), 1

1 (0.9), 1

0

1 (0.9), 1

1 (0.9), 1

1 (0.9), 1

1 (0.9), 1

System Organ Class/

Prefered Tem

Skin and subcutaneous tissue disorders (continued)

Rash erythematous

Rash maculo-papular

Urticaria

Psychiatic disorders

Agitation

Anxiety

Depression

Imitability

Respiratory, thoracic and mediastinal disorders

Oropharyngeal pain

Rhinitis allergic

Cardiac disorders

Venticular anhythmia

Metabolism and nutition disorders

Hypokalaemia

Musculoskeletal and connective tissue disorders

Pain in extremity

%=Percentage of subjects; N=Number of subjects.

Source: Appendix 13.5

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in system organ class (SOC) and prefered term (PI) rows are numbers of subjects reported at least one AE in that SOC or PT. Subjects wl reported more than one AE in a given SOC or PT were counted only once for that particular SOC or PT.

Study 101

All

[n(%)], #events

(N=24)

1 (4.2), 1

1 (4.2), 1

0

0

0

0

0

0

0

0

0

1 (4.2), 1

1 (4.2), 1

0

0

0

<div style=\"page-break-after: always\"></div>

Table 49. Summary of Infusion-Related Adverse Events by System Organ Class and Preferred Terms in the Safety Analysis Set of Trial 03-133 and Trial 101

| System Organ Class/ Prefened Term                    | Stody03-133 AII (N=109) [nCo)]. feveuts   | 101Apns All (N-24) [acol. leremts   |
|------------------------------------------------------|-------------------------------------------|-------------------------------------|
| Number of Infusion-related SAEs                      | 7                                         |                                     |
| Numberoftubject withat leastone insatioe-related SAE | 4(.7)                                     | （）1                                 |
| Iajury.poisoning andprocedualcomplications           | 2(1.8).2                                  | 142.1                               |
| Meningitis chemieal                                  | 2 (1.8).2                                 | 1(4.2)1                             |
| Gastrointestinal disoeders                           | 2 (1.8). 2                                | 0                                   |
| Nasea                                                | 1 (0.9).1                                 |                                     |
| Vomiting                                             | 1 (0.9),1                                 |                                     |
| General disorders amd admimistration site comditioms | 1 (0.9).1                                 | 0                                   |
| rari                                                 | 1 (0.9),1                                 | 0                                   |
| Invesgations                                         | 1(0.9).1                                  |                                     |
| Platelet count decreased                             | 1(0.9).1                                  | 0                                   |
| Nervous system disorders                             | 1(0.9).1                                  | 0                                   |
| Headache                                             | 1(09.1                                    |                                     |

Peage f es, NNuber  sbecs.

Sowce:Appendin 13.24

s  eodar o sa    dp o   a o  ( saa PT.Subectsho reportedmore than one AEinagiven SOCor PT were countedonly onoe fortatpaticular SOC or PT.

## Treatment-Emergent Adverse Events by Treatment Cycle

An analysis of TEAEs by treatment cycle was not performed for Trial 101 due to the small number of subjects in the trial.

## Trial 03-133

Overall, the proportion of subjects with TEAEs is similar for subjects receiving one or 2+ treatment cycles (93.8% versus 93.4%). For related TEAEs a numerically higher proportion of subjects receiving 2+ cycles (31.1%) reported related TEAEs compared to subjects receiving only one cycle (18.8%). No differences were seen for related serious TEAEs. Most TEAEs occur for a comparable proportion of subjects, whether they had one or 2+ treatment cycles. Noticeable differences for related TEAEs include numerically higher proportions of subjects receiving 2+ cycles for WBC count decreased and for neutrophil count decreased, whereas  there  was  no  notable  difference  for  platelet  count  decreased  or  for  lymphopenia.  Another observed numerical difference is a higher proportion of subjects receiving 2+ cycles reporting vomiting.

## 2.2.8.3. Serious adverse event/deaths/other significant events

## Trial 03-133

1 Subject received the last treatment cycle of  131 I-omburtamab in July 2009 (total dose 104.75 mCi) and was  subsequently  treated  with  3F8  and  GM-CSF,  Immunotherapy  (not  further  specified)  and temozolomide. The subject was diagnosed with acute myeloid leukaemia and died about 2 and half year after treatment with  131 I-omburtamab. The case was assessed as possibly related to  131 I-omburtamab.

## Trial 101

4 deaths occurred during the study. 3 deaths were due to disease progression. One TEAE leading to death  was  reported  (intracranial  haemorrhage).  A  full  narrative  description  of  this  fatal  event  was provided.

<div style=\"page-break-after: always\"></div>

## Other Serious Adverse Events

## Trial 03-133

Almost half of the subjects (53/109; 48.6%) had at least one SAE (see Table 58). Most SAEs were in the SOC Investigations. Platelet count decreased, neutrophil count decreased, and WBC count decreased all occurred  in  more  than  5%  of  the  subjects  and  were  attributable  to  myelosuppression.  Other  SAEs occurring  in  more  than  2  subjects  were  haemoglobin  decreased,  alanine  aminotransferase  (ALT) increased, myelodysplastic syndrome, meningitis chemical, and vomiting.

The 65 treatment-related SAEs were reported for 35/109 (32.1%) subjects. Frequently reported (for &gt;5% of subjects) treatment-related SAEs were platelet count decreased (21/109, 19.3%) followed by neutrophil count decreased (12/109, 11.0%) and WBC count decreased (8/109, 7.3%).

In addition to the SAEs, 19 SAEs with onset greater than 30 days after last dose were reported for 12 subjects. The majority of SAEs with onset greater than 30 days after last dose (12/109, 63.2%) were within the SOC Investigations, including platelet count decreased (4.6%), neutrophil count decreased (2.8%), haemoglobin and WBC decreased (each 0.9%). The 7 remaining SAEs with onset greater than 30  days  after  last  dose  were  myelodysplastic  syndrome  (2.8%),  acute  myeloid  leukaemia  (1.8%), hypoglycaemia and seizure (each 0.9%).

<div style=\"page-break-after: always\"></div>

Table 50. Summary of Serious Adverse Events Reported for Subjects in the Safety Analysis Set

| System Organ Clas Preferred Teim                                  | ≤50mCI (N=10) [n(o].events   | 50 mCi (N=94) [a（).mevents   | >50mC1 (N=25) [（）.events   | All Subjects (N=109) [no]],revrnts   |
|-------------------------------------------------------------------|------------------------------|------------------------------|----------------------------|--------------------------------------|
| Number of SAEs                                                    | 11                           | 82                           | I                          | 94                                   |
| Subjects with at least one SAE                                    | 6(60.0）.11                   | 46 (48.9).82                 | 1(20.0）.1                  | 53(48.6).94                          |
| Blood and Isnphatiessstem divorders                               | 2(20.0.2                     | 2(2.1.2                      |                            | 4(3.74                               |
| Lymphopenia                                                       | 1(10.0）.1                    | 1(1.1L1                      | 0                          | 2(1.82                               |
| Fehrileneuropenia                                                 | 0                            |                              | 0                          | 1(0.9.1                              |
| Immwne fhrombocytopenie ptrpuna                                   | 1(10.0）.1                    | 0                            | 0                          | 10.91                                |
| Gastrointestinal disorders                                        | 0                            | 4 ( 4.3) 4                   |                            | 4(3.7.4                              |
| Vorniting                                                         | 0                            | 3(3213                       | 0                          | 311813                               |
| Nallsea                                                           |                              | 101.1L1                      | 0                          | 1[0.91                               |
| General disorders and administration site conditions              | 1(10.0)）.1                   | 1（1.11                       |                            | 2(182                                |
| Pyresia                                                           | 1(10.0.1                     | 1(1.1L1                      |                            | 2(1.82                               |
| Immune systeim disorders                                          |                              | 1(1.11                       | 0                          | 1(0.9.1                              |
| Hypersensitivity                                                  | 0                            | 1(11L1                       |                            | 1[0.9.1                              |
| Iafectious and infestations                                       |                              | 6(6.46                       | 0                          | 6(5.5).6                             |
| Device related infection                                          | 0                            | 2(2.0.2                      | 0                          | 2(18.2                               |
| Gastic Infection                                                  |                              | 1(1.1L1                      | 0                          | 1[0.91                               |
| Infectious colitis                                                |                              |                              | 0                          | 1[0.9.1                              |
| Infectious colitis                                                |                              | 1(1.1LI                      | 0                          | 1[0.91                               |
| Pneumenia                                                         | 0                            | LCLILI                       | 0                          | 1(0.9.1                              |
| Sepsis                                                            | 0                            |                              |                            | 10.9.1                               |
| Injury-polsoningandproceduralcomplicatlons                        | 0                            | 4(4.34                       |                            | 4(3.7.4                              |
| Meningitis chemical                                               | 0                            | 303.23                       | 0                          | 3[28.3                               |
| Uppe limb fiacure                                                 | 0                            | 1(1.1L1                      | 0                          | 1[0.91                               |
| Investigations                                                    | 4(40.0）.6                    | 29 (30.9）.52                 | 1(20.0）1                   | 4(31.2).59                           |
| Platelet cont decreaced                                           | 1(10.0.1                     | 21(22.3.24                   | 1(20.0.1                   | 23(21.0.26                           |
| Neutrophil count decreased                                        | 0                            | 13(13.8.13                   | 0                          | 13(11.9）.13                          |
| White blood cell comt decrensed                                   | 0                            | 8(8.5.8                      |                            | 817318                               |
| Haemoglobin decreased                                             | 0                            | 5(5.3L5                      | 0                          | 5f4.6L5                              |
| Alanine aminotransferase increased                                | 3(30.0）.4                    | 1(LL1                        | 0                          | 4[3.7].3                             |
| Apartate aminotransfrase inceased                                 | 1(10.0）.1                    | 11111                        | 0                          | 2(1.8）.2                             |
| Metabolism andnutrition disorders                                 | 0                            | 1(11L1                       |                            | 1(0.91                               |
| Hypoglyeaemia                                                     | 0                            |                              | 0                          | 1[0.9.1                              |
| Nroplasms benign, malignant and unspecifed (incl eysts and pobps) | 1(10.0).1                    | 4 (4.3). 4                   |                            | $ (4.6).5                            |
| Myelodyplassic symdrome                                           | 1(10.01                      | 2(2.0.2                      |                            | 3(2.8L3                              |
| Acute myeloid lenkaemia                                           | 0                            | 202.02                       |                            | 201312                               |
| Nervous system disorders                                          | 1(10.0）.1                    | 6(6.4).7                     |                            | 7 (6.4.8                             |
| Headache                                                          |                              | 2021.1                       |                            | 2018L2                               |
| Nervons system disorder                                           |                              | 2(2.1.2                      |                            | 2(1.8L3                              |
| Seirue                                                            |                              | 2(2.13.2                     |                            | 2(1.812                              |
| Cerebrospinal fusd leakage                                        | 1(10.0.1                     |                              |                            | 1(0.9).1                             |
| Depreed level of ceniciousneis                                    |                              | 1(1.1.1                      |                            | 1(0.9.1                              |

Seuree: Table 14.3.1.17

Note: Adverse eveats (AEs） ane coded using MedDRA 20.1.Frequencies in system oram class (SOC) asd preferred enm (PT) rows are mumbers of subjects who experienced at least oe AE in tha SOC or PT. Sabjects experienced more than one AE in a given SOC or PT were counted omly once for that particular SOC or PT

p p op op  p p p  sp f SAl = senioas adverse event.

| Neoplasmsbenign,malignantandunspecified (incl cysts and polyps)   | 1 (10.0),1   | 4 ( 4.3), 4   |   0 | 5(4.6),5    |
|-------------------------------------------------------------------|--------------|---------------|-----|-------------|
| Myelodysplastic syndrome                                          | 1 (10.0).1   | 2 ( 2.1). 2   |   0 | 3 ( 2.8). 3 |
| Acute myeloid leukaemia                                           | 0            | 2 ( 2.1). 2   |   0 | 2 (1.8). 2  |
| Nervous system disorders                                          | 1 (10.0),1   | 6 ( 6.4), 7   |   0 | 7 ( 6.4), 8 |
| Headache                                                          | 0            | 2 ( 2.1).2    |   0 | 2 ( 1.8). 2 |
| Nervous system disorder                                           | 0            | 2 ( 2.1).2    |   0 | 2 (1.8). 2  |
| Seizure                                                           | 0            | 2 ( 2.1). 2   |   0 | 2 ( 1.8). 2 |
| Cerebrospinalfluidleakage                                         | 1 (10.0).1   | 0             |   0 | 1 ( 0.9). 1 |
| Depressed level of consciousness                                  | 0            | 1 ( 1.1). 1   |   0 | 1 ( 0.9). 1 |

Source:Table 14.3.1.17.

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in system organ class (SOC) and preferred term (PT) rows are numbers of subjects who experienced at least one AE in that SOC orPT.Subjects experienced more than one AE in a given SOC orPT were counted only oncefor that particular SOC or PT.

Note: For subjects under 3 years of age, dose groups were assigned based on the treatment dose before age adjustment (i.e., 33% or 50% dose reduction).

SAE=serious adverse event.

## Trial 101

11/32 (34.4%) subjects experienced treatment-related SAEs (Table 51). The fatal SAE described above (Grade 5 intracranial  hemorrhage) was reported as not related by the investigator but assessed as possibly related by the sponsor.

The majority of the related SAEs were consistent with myelosuppression as most frequently reported preferred terms were 'platelet count decreased' and 'lymphocyte count decreased'. Aside from SAEs of myelosuppression, one subject had a related SAE of 'chemical meningitis' (resolved), one subject had a

<div style=\"page-break-after: always\"></div>

related SAE of 'intracranial haemorrhage' (recovered with sequelae) and one subject had a related SAE of 'alanine aminotransferase increased' (resolved).

Table 51 Related ( 131 I-Omburtamab) Serious Treatment -Emergent Adverse Event by Grade, System Organ Class and Preferred Term.

<!-- image -->

| System Organ Class Preferred Term        | Grade 3 N(%6)E   | Grade 4 N(%)E   | Total N(%)E   |
|------------------------------------------|------------------|-----------------|---------------|
| Safety Analysis Set, N=32                |                  |                 |               |
| Any related serious adverse event        | 7 (21.9) 7       | 8(25.0)9        | 11 (34.4) 16  |
| Investigations                           | 4 (12.5)4        | 7(21.9) 8       | 8(25.0)12     |
| Platelet count decreased                 |                  | 6(18.8)6        | 6 (18.8)6     |
| Lymphocyte count decreased               | 3(9.4)3          | 1(3.1)1         | 4 (12.5)4     |
| Alanine aminotransferase increased       | 1 (3.1)1         |                 | 1(3.1)1       |
| Neutrophil count decreased               |                  | 1 (3.1)1        | 1(3.1)1       |
| Blood and Lynphatic System disorders     | 2(6.3)2          |                 | 2(6.3)2       |
| Annemia                                  | 1 (3.1) 1        |                 | 1 (3.1)1      |
| Febrile neutropenia                      | 1 (3.1) 1        |                 | 1(3.1) 1      |
| Injuy.PoisoningandProcedual Complieation | 1(3.1)1          |                 | 1(3.1)1       |
| Meningitis chemical                      | 1 (3.1)1         |                 | 1 (3.1) 1     |
| Nervous SystemDisorder's                 |                  | 1 (3.1) 1       | 1(3.1) 1      |
| Hemonhage intracranial                   |                  | 1(3.1) 1        | 1(3.1)1       |

Source: Table 14.3.1.5 and Listing 14.3.2.2

N: Number of subjects; %: Percentage of subjects. E: Number of events. A treatment emergent adverse event is defined as an AE with onset at or after administration of infusion of II-omburtamab. Related investigator. Senious AEs have been extracted from the case report fomm (CRF) if answer to senious is Yes.

1): There were three serious events of intracranial hemonhage. One was considered related by the investigator. All were considered possibly related by the sponsor.

Table 52 provides a summary of SAE by SOC for both trials (03-133 and 101, first data cut-off).

<div style=\"page-break-after: always\"></div>

Table 52. Summary of SAEs by System Organ Class and Preferred Terms in the Safety Analysis Set of Trial 03-133 and Trial 101

|                                                                     | Shudy 03-133                | Study 101                  |
|---------------------------------------------------------------------|-----------------------------|----------------------------|
| System Organ Class/ Prefened Term                                   | All (N=109) [n(9o], levents | All (N=24) [n(o)], fevents |
| Number of Sonous TEAEs                                              | 94                          | 91                         |
| Number of subjects with at least one Serious TEAE                   | 53 (48.6)                   | 10 (41.7)                  |
| Inveshigahions                                                      | 34 (31.2). 59               | 6 (25.0).9                 |
| Plstelet coumt decresved                                            | 23 (21.1), 26               | 5 (20.8),5                 |
|                                                                     | 13 (11.9), 13               | 1 (4.2), 1                 |
| Neuhrophil count decreaved                                          | 8(7.3).8                    | 0                          |
| White blood cell count decreased                                    | 4 (3.7). 5                  | 1 (4.2). 1                 |
| Alanine aminohansferase increased Haemoglobin decrearad             | 5 (4.6).5                   | 0                          |
|                                                                     |                             | 0                          |
| Aspatste aminotansfease inereased                                   | 2 (1.8), 2                  |                            |
| Lymphocyte count decreased                                          | 0                           | 2 (8.3),2                  |
| Nervous system disorders Haemonhage inhacranial                     | 7(6.4), 8                   | 2 (8.3). 2 2 (8.3).2       |
|                                                                     | 0                           | 0                          |
| Hesdache Nervous system disorder                                    | 2 (1.8), 2 2 (1.8). 2       | 0                          |
| Seizure                                                             | 2 (1.8).2                   | 0                          |
| Cerebrospinal fhuid leakage                                         | 160)1                       | 0                          |
|                                                                     | 1(0.9), 1                   | 0                          |
| Depressed level of coneciousness                                    | 4(3.7). 4                   | 4 (16.7).4                 |
| Blood and lymphatie svstem disorders Lymphopenia                    | 2(1.8).2                    | 2(8.3).2                   |
| Anaemia                                                             | 0                           | 1 (4.2), 1                 |
| Febrile neutopenia                                                  | 1 (0.9), 1                  | 0                          |
|                                                                     |                             | 0                          |
| Inmune thrombocytopenic pupura                                      | 1 (0.9), 1 0                | 1 (4.2). 1                 |
| Thromboevtopenia                                                    |                             |                            |
| Infections and infestations Device related infection                | 6 (5.5). 6 2 (1.8), 2       | 0 0                        |
| Gashie infection                                                    | 1 (0.9). 1                  | 0                          |
| Infectious colitis                                                  | 1 (0.9). 1                  | 0                          |
| Pneumonia                                                           |                             |                            |
|                                                                     | 160) 1                      | 0                          |
| Sopsis                                                              | 1(0.9), 1 4 (3.7),. 4       | 0 1 (4.2), 1               |
| Injuy, poisoning and procedual complieations                        |                             | 1 (4.2), 1                 |
| Meningitis chemieal                                                 | 3 (2.8)., 3                 |                            |
| Upper limb fiachure                                                 | 1 (0.9). 1 5 (4.6). 5       | 0 0                        |
| Neoplasms benign, maligmant and unspecified (incl cysis and polyps) |                             |                            |
| Myelodyeplastie syndrome                                            | 3(2.8).3                    | 0                          |
| Acute myeloid leukaemia                                             | 2 (1.8), 2                  | 0                          |
| Gastointestinal disorders                                           | 4 (3.7), 4                  | 0                          |
| Vomiting                                                            | 3 (2.8), 3                  | 0                          |
| Nausea                                                              | 1 (0.9), 1                  | 0                          |
| Generl disorders and sdminishation site conditoms                   | 2(1.8).2                    | 0                          |
| Pyrexia                                                             | 2 (1.8). 2 1(0.9). 1        | 0 0                        |
| Immmune system disorders                                            |                             | 0                          |
| Hypersensitivity Metabolism snd nuhition disorders                  | 1 (0.9). 1 1 (0.9). 1       | 0                          |
| Hypoglyeaemia                                                       | 1 (0.9). 1                  | 0                          |

Sowce: Appendix 13.25

Note: Adverve events (AEs) are coded using MedDRA v20.1. Frequencies in system organ elass (SOC) and prefenred term (PT) rows are number ofeubject reported at leaet one AE in that SOC or PT. Subjects who reported more than one AE in a given SOC or PT were coumted only onee for that partieular SOC or PT.

## Serious Adverse Events for Non-neuroblastoma Subjects in Trial 03-133

For all subjects in the NNAS, 15 of 37 subjects (40.5%) reported at least one SAE. Frequently reported (reported for ≥5% of subjects) SAEs in the NNAS were vomiting, platelet count decreased, and headache (3 subjects each).

<div style=\"page-break-after: always\"></div>

## Adverse events of special interest

## Trial 03-133

There were no AESIs predefined in Trial 03-133.

## Trial 101

For Trial 101, AESIs were predefined as presented in Table 53.

Table 53. Definition of Adverse Events of Special Interest

| Predefined AESI                                                     | Collected and reported as AESIs according toprotocolversions   |
|---------------------------------------------------------------------|----------------------------------------------------------------|
| Neurotoxicities of Grade 3 and above                                | FromProtocol version 1                                         |
| Severe infections related to placement of cerebroventricular device | From Protocol version 1                                        |
| Chemical meningitis                                                 | From Protocol version 7                                        |
| Liver toxicities Grade 3 and above                                  | Applicable from Protocol versions 1 through 4                  |
| Worsening ofperfonmance test                                        | Applicable firom Protocol versions 1 through 4                 |
| Myelosuppression Grade 4 during treatment                           | Applicable from Protocol versions 1 through 4                  |

TEAEs of special interest are summarised in Table 54.

A total of 13 AESIs were reported for 11/32 (34.4%) subjects. The majority of AESIs were related to myelosuppression.

Three events of intracranial hemorrhage were reported in three subjects:

- One event was the fatal Grade 5 event, as described above.
- One event was Grade 3, serious, assessed as not related to study drug by the investigator and possibly related to study drug by sponsor. The event was reported as resolved.

· One event was Grade 4, serious, assessed as possibly related to study drug by the investigator and sponsor and reported as resolved with sequelae.

In all  three  cases,  disease  progression  was  observed and considered to be a potential cause of the events,  but  concomitant  low  platelet  counts  (CTCAE  grade  3-4)  cannot  be  excluded  as  a  potential contributing factor.

Two events of chemical meningitis occurred in two subjects. Both events were infusion-related, assessed as probably related to study drug by the investigator, and reported as resolved without sequelae. One event was Grade 3, serious, and led to discontinuation of further dosing with  131 I-omburtamab in one subject. The other event was Grade 2, non-serious.

<div style=\"page-break-after: always\"></div>

Table 54. Treatment-Emergent Adverse Events of Special Interest by Grade, System Organ and Preferred Term.

| Svsten Organ Class Preferred Term             | Grade l NOE   | Grade2 NCE   | Grade3 NE   | Grade 4 N()E   | Grade5 NCSE   | Total NCOE   |
|-----------------------------------------------|---------------|--------------|-------------|----------------|---------------|--------------|
| Saferv Analvus Set N=32                       |               |              |             |                |               |              |
| Any advere eves ofpecialntereu                |               |              | 39.43       | 701918         |               |              |
| levestigations                                |               |              |             | 6(18.8)7       |               | 701911       |
| Plaselet count decreased                      |               |              |             | 5(15.6)5       |               | 59505        |
| Lvmphocyte count decreased                    |               |              | 10.1        | 10.11          |               | 2(63）2       |
| Neutropnl coant decreased                     |               |              |             | IDT            |               | 10.111       |
| Iajury.poisoning and procedural complicatioss |               |              | TTI         |                |               | 2(6.3)2      |
| Meninpatischemacal                            |               |              | 13.111      |                |               | 26312        |
| NervoasSutenDiscaders                         |               |              |             | 13.1           |               | 3(9.4)3      |
| Haemonhape intacraial                         |               |              |             | ID1            |               | 39.413       |

Souce:Table143.1.10ndLiing143.2.5

N:Nuenber ofsubyects,i:Perceutage ofwubgects.E:Nuuaberofevents

A trestment emergent adverse event n defioed as an AEwith onset at or afier adminivtraton ofinfusion ofi-omburtamab

AE of special isterest selected from the case report form (CRF) w/bere AE ef special interest is ticked. The suenmary does not include noni-senioos adverse events hs occurred more dan 21+2 days afer last teeatmret

## Analysis of Adverse Events by Organ System or Syndrome

In order to better understand the safety profile of  131 I-omburtamab, investigations  of  AEs  by  organ systems  or  syndrome  were  undertaken.  Searches  for  AEs  in  Trial  03-133  and  Trial  101  relating  to myelosuppression, hepatic toxicity, thyroid suppression, anaphylactic reactions, and haemorrhage were performed using MedDRA standardised MedDRA queries (SMQs). Secondary malignancies, neurotoxicity, and infections were investigated by summarizing AEs in the associated SOCs or selected relevant TEAE PTs. These data were not updated in the interim CSR with cut-off June 2021.

## Myelosuppression

Myelosuppression  and  prolonged  cytopenia  is  a  side  effect  of  exposure  to  ionizing  radiation  due  to radiation-related adverse effects on bone marrow. A summary of TEAEs related to myelosuppression in Trial 03-133 and Trial 101 is provided in Table 63.

A  total  of  89/109  (81.7%)  and  21/24  (87.5%)  of  subjects  had  at  least  one  TEAE  related  to haematopoietic cytopenias in Trial 03-133 and Trial 101, respectively. Frequently reported (at least 30.0% of subjects in either trial) haematopoietic cytopenia events were lymphopenia, platelet count decreased, WBC count decreased, neutrophil count decreased, and anaemia. Specific haematopoietic cytopenia events were considered SAEs as follows: platelet count decreased, neutrophil count decreased, WBC count decreased, haemoglobin decreased, lymphopenia, myelodysplastic syndrome, lymphocyte count decreased, and anaemia, febrile neutropenia, thrombocytopenia.

In order to assess the possible association between myelosuppression and infection, all subjects who had  Grade  3  or  above  haematopoietic  cytopenia  events  of  neutrophil  count  decreased,  WBC  count decreased,  lymphopenia,  myelodysplastic  syndrome,  lymphocyte  count  decreased,  and/or  febrile neutropenia were investigated for infections. The findings are presented below.

<div style=\"page-break-after: always\"></div>

Table  55.  Summary  of  TEAEs  related  to  Myelosuppression  as  Identified  by  MEDRA  SMQ Haematopoietic Cytopenias by Preferred Term in Trial 03-133 and Trial 101

| SMQ/ Prefened Tenm               | Shudy 03-133 Al1 (N=109) [n(%)]. Hevents   | Shudy 101 AI1 (N=24) [n(%)], Hevents   |
|----------------------------------|--------------------------------------------|----------------------------------------|
| Haematopoietie cytopenins (SMQ)  | 89 (81.7). 1212                            | 21 ($7.5). 79                          |
| Lymphopenia                      | 70 (64.2), 451                             | 5 (20.9).5                             |
| Platelet count decreased         | 59 (54.1), 296                             | 14 (58.3), 17                          |
| White blood cell coumt decreased | 51 (46.8), 223                             | 9 (37.5), 10                           |
| Neutrophil count decreased       | 47 (43.1), 157                             | 7 (29.2), 10                           |
| Haemoglobin decreased            | 33 (30.3). 81                              | 0                                      |
| Anaemia                          | 0                                          | 8 (33.3). 12                           |
| Lymphocyte count decreased       | 0                                          | 5 (20.8).6                             |
| Leukopenia                       | 0                                          | 3 (12.5).8                             |
| Myelodysplastic symdrome         | 3(2.8.3                                    | 0                                      |
| Neutropenia                      | 0                                          | 2 (8.3). 10                            |
| Febrle neutropenia               | 1 (0.9). 1                                 | 0                                      |
| Thromboeytopenia                 | 0                                          | 1(4.2). 1                              |

%-Percenhige of subjects; N-Number of subjects.

Souree: Appendix 13.3

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in standardised MedDRA queries (SMQ) and prefered term (PT) rows are numbers of subjects reported atleast one AE in that SMQ or PT. Subjects who reported more than one AE in a given SMQ or PT were counted only once for that particular SMQ or PT.

Note: Both broad and narrow temms Were included

## Hepatic Toxicity

Organ dosimetry data show the CSF, brain, and the liver as the regions with the highest absorbed radiation dose. Subjects with severe hepatic impairment have thus been excluded from clinical trials. A summary of TEAEs related to hepatic disorders in Trial 03-133 and Trial 101 is provided in Table 64.

A total of 8/109 (7.3%) and 1/24 (4.2%) of subjects had at least one TEAE related to hepatic toxicity in Trial 03-133 and Trial 101, respectively. Specific hepatic toxicity events were considered SAEs as follows: ALT increased (five subjects) and AST increased (two subjects).

Table 56. SMQ Drug related Hepatic Disorders in Trial 03-133 and trial 101

|                                      | Study 03-133                | Study 101                  |
|--------------------------------------|-----------------------------|----------------------------|
| SMQ/ Preferred Tem                   | Al1 (N-109) [m(%)], #events | All (N-24) [n(%)], #events |
| Drug related hepatic disorders (SMQ) |                             |                            |
|                                      | 8 (7.3), 15                 | 1 (4.2), 1                 |
| Alanine aminotransferaseincreased    | 7 (6.4). 11                 | 1 (4.2). 1                 |
| Aspartate aminotransferase increased | 3 (2.8).3                   | 0                          |
| Prothrombin timeprolonged            | 1(0.9). 1                   | 0                          |

Source: Appendix 13.3

%-Percentage of subjects; NNumber of subjects.

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in standardised MedDRA queries (SMQ) and prefered term (PT) rows are mumbers of subjecis reported at least one AE in that SMQ or PT. Subjects who reported more than one AE in a given SMQ or PT were counted only once for that particular SMQ or PT.

Note:Both broad and narrow terms Were included

<div style=\"page-break-after: always\"></div>

## Secondary Malignancies

Secondary malignancies, especially haematological malignancies are a potential risk with the use of  131 Iomburtamab due to late myelotoxicity, especially in patients who have received significant amounts of chemotherapy and radiation therapy prior to treatment with  131 I-omburtamab.

In  Trial  03-133,  6/109  (5.5%)  subjects  had  one  TEAE  belonging  to  the  SOC  Neoplasms  benign, malignant, and unspecified. In Trial 101, no subjects had a TEAE belonging to the Neoplasms benign, malignant, and unspecified SOC. Myelodysplastic syndrome was reported for three subjects, two subject had acute myeloid leukaemia, and one subject had skin papilloma. With the exception of skin papilloma (wart), all TEAEs belonging to the SOC Neoplasms benign, malignant, and unspecified were considered serious.

In addition to the 6 subjects described above, malignancies were reported for 5 subjects (all in Trial 03133)  more  than  30  days  after  last  infusion  of 131 I-omburtamab  (3  subjects  with  myelodysplastic syndrome and 2 subjects with acute myeloid leukaemia).

## Neurotoxicity

Intracerebral exposure to therapeutic irradiation carries the risk of symptomatic neurological injury. The radiation emitted from a radiolabelled antibody bound to a tumour cell may also damage neighbouring cells  since  beta-emission  penetration  range  in  tissue  can  extend  over  several  cell  diameters. Neurotoxicity can also arise from local irritation of the meninges (e.g., chemical meningitis), and the origin of symptoms can hence be difficult to distinguish. TEAEs possibly associated with neurotoxicity include  the  following  PTs:  chemical  meningitis,  peripheral  sensory  neuropathy,  and  seizure.  TEAEs possibly associated with neurotoxicity are listed in Table 65.

A total of 7/109 (6.4%) and 3/24 (12.5%) of subjects had at least one TEAE possibly associated with neurotoxicity in Trial 03-133 and Trial 101, respectively. Of these, 5 subjects had chemical meningitis, 4 subjects had peripheral sensory neuropathy and 2 subjects had seizures. Specific neurotoxicity events were considered SAEs as follows: seizure (2 subjects) and chemical meningitis (4 subjects).

In Trial 101, performance testing was conducted and analysed using the Lansky Play-Performance Scale for children less than 16 years and the Karnovsky Scale for children at least 16 years to evaluate gross neurologic  function  and  measure  subjects'  overall  function.  For  Trial  101,  the  mean  Lansky  PlayPerformance Score at baseline  was  93.3.  At  Week  26,  mean  change  from  baseline  in  Lansky  PlayPerformance Score was 0.0, range was -20 to 20. Note: All children in Trial 101 were less than 16 years. Therefore, only the Lansky Play-Performance Score was used in Trial 101. In total, five subjects had a worsening of their screening performance score at follow-up. The remaining subjects had improvement or no change in score during the trial. In general, subjects were high functioning at baseline and had little or no deterioration in follow-up performance scores.

<div style=\"page-break-after: always\"></div>

Table 57. Summary of TEAEs Possibly Associated with Neurotoxicity in Trial 03-133 and Trial 101

<!-- image -->

| Subject No.   | Dose group   | Preferred Term                |   Grade | Serious   |
|---------------|--------------|-------------------------------|---------|-----------|
| XXXXXXXXXX    | 50 mCi       | Peripheral sensory neuropathy |       2 | No        |
| XXXXXXXXXX    | 50 mCi       | Peripheral sensory neuropathy |       1 | No        |
| XXXXXXXXXX    | <50 mCi      | Peripheral sensory neuropathy |       2 | No        |
| XXXXXXXXXX    | 50 mCi       | Seizure                       |       2 | Yes       |
| XXXXXXXXXX    | 50 mCi       | Seizure                       |       3 | Yes       |
| XXXXXXXXXX    | 50 mCi       | Meningitis chemical           |       2 | Yes       |
| XXXXXXXXXX    | 50 mCi       | Meningitis chemical           |       3 | Yes       |
| XXXXXXXXXX    | 50 mCi       | Meningitis chemical           |       3 | Yes       |
| XXXXXXXXXXX   | 50 mCi       | Peripheral sensory neuropathy |       1 | No        |
| XXXXXXXXXXX   | 50 mCi       | Meningitis chemical           |       3 | Yes       |
| XXXXXXXXXXX   | 50 mCi       | Meningitis chemical           |       2 | No        |

Source: Appendix 13.11 and Appendix 13.12.

Note: 50 mCi=1850 MBq.

## Thyroid Suppression

Thyroid suppression is a potential risk with  131 I-omburtamab due to the effects of radioactive iodine on the thyroid. The risk is mitigated by treating all subjects with thyroid-blocking agents from one week before treatment until 14 days after the last therapeutic dose.

No subjects in Trial 03-133 and 2/24 (8.3%) of subjects in Trial 101 had at least one TEAE related to thyroid suppression. A TEAE of blood thyroid stimulating hormone increased (Grade 1, possibly related to IMP, onset 20 days after latest infusion, not recovered at data cut-off) and hypothyroidism (Grade 2, probably related to treatment, onset 21 days after latest infusion, not recovered at data cut-off) was reported for one subject each.

While there were few measurements (at baseline or during treatment), there were no obvious trends in changes from baseline across visits for T4, free T4 or for TSH.

## Anaphylactic Reactions

No AEs met the criteria for anaphylactic reactions.

## Infections

A total of 20/109 (18.3%) and 5/24 (20.8%) of subjects had at least one TEAE belonging to the Infections and  Infestations  SOC  in  Trial  03-133  and  Trial  101,  respectively.  Specific  infection  events  were considered SAEs as follows in six subjects: device related infection and gastric infection, infectious colitis, pneumonia, and sepsis. Each of the serious infections was considered unrelated to study treatment by the investigator.

Of the 6 subjects with a serious infection, 3 had a Grade 3 or above decrease in WBCs (i.e., decrease WBC count, lymphopenia, or decreased neutrophil count). One subject (serious devise-related infection) had Grade 3 lymphopenia. Another subject (serious gastric infection) had Grade 3 lymphopenia. A further subject (serious pneumonia) had Grade 3 lymphopenia and Grade 3 neutrophil count decrease.

The risk of serious infections due to low white blood cell counts was quantified by pooling all subjects with a TEAE in the Infections and Infestations SOC from Trial 03-133 and Trial 101. Within this pool, a total of 18.8% of subjects had at least one TEAE and 3.8% had a TEAE of Grade 3 or higher belonging to the Infections and Infestations SOC.

<div style=\"page-break-after: always\"></div>

## Haemorrhage

There is a risk of haemorrhage due to low platelet count. A summary of TEAEs related to haemorrhage in Trial 03-133 and Trial 101 is provided in Table 66.

A total of 32/109 (29.4%) and 8/24 (33.3%) of subjects had at least one TEAE related to haemorrhage in  Trial  03-133  and  Trial  101,  respectively.  Specific  haemorrhage  events  were  considered  SAEs.  2 subjects had serious intracranial haemorrhage. Both subjects had platelet count decrease of Grade 3 or above and the primary reason for haemorrhage was considered to be disease progression. A third subject had serious thrombocytopenic purpura.

The risk of haemorrhage was quantified by pooling all subjects with a TEAE in the SMQ of haemorrhage from Trial 03-133 and Trial 101. Within this pool, a total of 30.1% of subjects had at least one TEAE, and 2.3% had a TEAE CTCAE Grade ≥3 related to haemorrhage.

Table  58.  Summary  of  TEAEs  Related  to  Haemorrhage  as  Identified  by  MedDRA  SMQ Haemorrhage Terms in Trial 03-133 and Trial 101

|                                                | Shudy03-133                  | Shudy 101                  |
|------------------------------------------------|------------------------------|----------------------------|
| SMQI Preferred Tem                             | AlI (N=109) [n(%o)], fevents | AlI (N=24) [n(%)], #events |
| Haemorrhage tems (excl laboratory terms) (SMQ) | 32 (29.4).49                 | 8 (33.3), 11               |
| Contusion                                      | 23 (21.1). 30                | 2(8.3). 2                  |
| Petechiae                                      | 7 (6.4).8                    | 0                          |
| Epistaxis                                      | 4 (3.7). 4                   | 1 (4.2). 3                 |
| Haematoma                                      | 0                            | 3 (12.5).4                 |
| Haemomhage intracranial                        | 0                            | 2 (8.3). 2                 |
| Angina bullosa haemorrhagica                   | 1 (0.9). 1                   | 0                          |
| Catheter site haemomhage                       | 1 (0.9). 1                   | 0                          |
| Central nervous system haemomhage              | 1 (0.9). 1                   | 0                          |
| Eechymosis                                     | 1 (0.9). 1                   | 0                          |
| Haematochezia                                  | 1 (0.9). 1                   | 0                          |
| Immune thrombocytopenic pupur                  | 1 (0.9). 1                   | 0                          |
| Injection site haemonhage                      | 1 (0.9). 1                   | 0                          |

%=Percentage of subjects; N=Number of subjects.

Source: Appendix 13.3

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in standardised MedDRA queries (SMQ) and preferred temm (PT) rows are numbers of subjects reported at least one AE in that SMQ or PT. Subjects who reported more than one AE in a given SMQ or PT were counted only once for that particular SMQ or PT. Note: Both broad and narrow tems Were included.

## 2.2.8.4. Laboratory findings

## Trial 03-133

## Lymphocytes

Mean values for lymphocytes were close to the lower reference range value for all dose groups and cycles. Changes from baseline in lymphocyte values were variable; however, decreases in lymphocytes were observed for all dose groups around Day 8 during Cycle 1 or 2. In such cases, mean lymphocyte values dropped below the lower reference range value between Day 11 to Day 14. Following this drop, lymphocyte values remained close to the lower reference range value.

## Neutrophils

In general, mean values for neutrophils were close to the lower reference range value for all dose groups and cycles. Changes from baseline in neutrophil values were highly variable. Mean neutrophil values dropped below the lower reference range value at least once for all dose groups and cycles, with the exception of the 50 mCi dose group for Cycle 3 and 4.

<div style=\"page-break-after: always\"></div>

## Platelets

Mean values for platelet were consistently below the lower reference range value for all dose groups and cycles. Changes from baseline in platelet values were highly variable. Platelet values dropped below the lower reference range value for the &lt;50 mCi and 50 mCi dose groups on Day 11 during Cycle 1. Following this drop, platelet values for both dose groups generally remained below the normal reference range for the remainder of the cycle.

## Trial 101

Across both trials (Trial 03-133 and Trial 101) trends in haematology lab values over time as well as reported TEAEs related to laboratory parameters (i.e., decreases in blood cell counts and occurrences of blood and lymphatic disorders such as lymphopenia and thrombocytopenia) indicate myelosuppression. Trends in laboratory values generally align with TEAEs in both trials. A decrease in platelet count led to the discontinuation of study treatment for eight subjects in Trial 03-133.

## Liver Function Tests

## Liver Function Test Values over Time

In Trial 03-133 mean values for laboratory parameters indicative of liver function (ALT and AST) were typically  close  to,  or  above  the  upper  reference  range  value  for  all  dose  groups  and  there  were  no pronounced trends in changes from baseline in ALT and AST values across visits.

In Trial 101, one subject had a Grade 3 abnormally high value for ALT on a single assessment. No subjects had Grade 3 abnormally high values for AST.

## Individual Clinically Meaningful Liver Function Test Abnormalities

In Trial 03-133, five subjects reported treatment-related Grade 3 or higher ALT increased (3 subjects) and  AST  increased  (two  subjects).  ALT  increased  was  reported  as  a  nonserious  lab  toxicity  in  five subjects, and AST in one subject. In Trial 101, one subject reported a treatment-related Grade 3 event of ALT increased.

## Summary of Liver Function Tests

Although  there  were  increases  in  ALT  and  AST  lab  values  in  subjects  across  both  trials,  no  TEAEs associated  with  liver  dysfunction  were  reported.  Thus,  there  is  no  indication  of  liver  dysfunction  in subjects.

## Kidney Function Tests

## Kidney Function Test Values over Time

In Trial 03-133 mean lab values for creatinine were typically close to or below the lower reference range value for all dose groups and cycles. There were no apparent trends in changes from baseline in creatinine across visits.

In Trial 101, abnormal creatinine values were all Grade 1.

## Individual Clinically Meaningful Kidney Function Test Abnormalities

No TEAEs associated with kidney dysfunction were reported in either trial.

## Summary of Kidney Function Tests

There is no indication of kidney dysfunction in subjects.

<div style=\"page-break-after: always\"></div>

## Other Blood Chemistry

For Trial 03-133, other blood chemistry parameters typically fluctuated within normal range. In addition, there were no apparent trends in changes from baseline across visits for these parameters. While there were few assessments (at baseline or during treatment), there were no obvious trends in changes from baseline across visits for free T4 or for TSH.

For Trial 101, increases in T4, free T4, and thyrotropin above the normal reference range in individual subjects was observed. Given the small number of assessments, there was a high degree of variability of mean thyroid hormones without obvious trends.

There was no change from baseline in urine protein levels from baseline to Cycle 1 Day 37.

## Vital Signs and physical findings

Vital signs measured during Trial 03-133 and Trial 101 included heart rate, temperature, and blood pressure.

A number of findings were reported as TEAEs: The 6 cases of hypertension were all unrelated and patients have recovered. 11 cases of pyrexia were diagnosed, 8 thereof were possibly or probably related to the study drug and resolved. 9 unrelated cases with Grade 1-2 hypotension have resolved, too. All 15 events of tachycardia were assessed unrelated.

## Physical Examination

Abnormal findings at physical examination were monitored during the course of Trial 03-133 and Trial 101. For Trial 101 specifically, physical examination included assessment of general appearance, mental status, and various organ systems (skin, head, eyes, ears, nose, mouth, throat, neck, thyroid, lymph nodes,  respiratory,  cardiovascular,  gastrointestinal,  extremities,  musculoskeletal,  and  neurologic systems). Clinically significant changes in physical examination were to be reported as AEs. One case of weight decreased was reported.

In trial 03-133 there were subjects who had abnormal physical examination findings associated with various organ systems, but they were predominately minor in nature (e.g., dry cough, constipation, stuffy nose, etc.).

## Radiographic Examination

## Trial 03-133

In Trial 03-133, neurotoxicity was assessed clinically and radiographically. Assessment and grading of cortical atrophy, cerebral ventricular size, white matter changes or other abnormalities were performed by a neuroradiologist. Altered CSF flow was interpreted by the study nuclear medicine physicians. Results were abnormal for only one subject in which a mid-delay in CSF flow with no evidence of significant obstruction was observed.

## Trial 101

In Trial 101, neurotoxicity assessments occurred as scheduled according to the National Cancer Institute clinical neurotoxicity criteria. All neurological abnormalities were recorded (at pre-treatment baseline and during the trial). Grade 3 or 4 neurotoxicity was assessed by trial physicians as being unrelated, possibly related, probably related, or related to trial drug. Predefined AESIs included neurotoxicities Grade 3 and above. None of the AESIs were related to neurotoxicities.

<div style=\"page-break-after: always\"></div>

## 2.2.8.5. Safety in special populations

## Intrinsic Factors

## Incidence of Adverse Events by Age Group

For Trial 03-133, a numerically higher proportion of subjects aged 3 to 5 years had events related to myelosuppression (lymphopenia, reduced platelet count, reduced WBC count, and reduced neutrophil count) compared to the children &lt;3 years. There were no other clinically meaningful differences in incidences of TEAEs between the age groups in Trial 03-133 and Trial 101.

## Incidence of Adverse Events by Body Weight

Similar to what is seen for incidence of AEs by age, for Trial 03-133, a numerically higher proportion of subjects in the 15-25 kg group had reduced WBC and neutrophil counts compared to the children &lt;15 kg. There were no other clinically meaningful differences in incidences of TEAEs between the age groups in Trial 03-133 and Trial 101.

## Incidence of Adverse Events by Gender

There were no clinically meaningful differences between incidence of TEAEs by gender in Trial 03-133 and Trial 101.

## Incidence of Adverse Events by Race

There were no clinically meaningful differences between incidence of TEAEs by race in Trial 03-133 and Trial 101.

Because of the limited number of subjects in subgroups based on age, body weight, gender, and race, it is difficult to draw any firm conclusions on safety in subgroups.

Given that neuroblastoma is a paediatric malignancy, the lack of data related to elderly subjects, pregnant women and lactation is a limited concern.

## Extrinsic Factors

During the clinical development there has been a shift of drug product intermediate (DPI). For Trial 03133 107 of 109 subjects in 03-133 were treated with  131 I-omburtamab produced from a MSK DPI batch for at least part of their treatment during the trial. 6 subjects (4 paediatric neuroblastoma subjects and 2  paediatric  non-neuroblastoma subjects) received  131 I-omburtamab from Y-mAbs-produced DPI. All subjects in Trial 101 received treatment with  131 I-omburtamab from Y-mAbs-produced DPI. Given the similarity in types of AEs reported, frequency, severity and seriousness between Trial 03-133 and Trial 101, the change in DPI does not seem to have had any impact on the safety profile of  131 I-omburtamab.

## Drug Interactions

No drug-drug interaction studies have been conducted with  131 I-omburtamab. It is recommended that live vaccines are not given concurrently with  131 I-omburtamab.

## Use in Pregnancy and Lactation

131 I-omburtamab  is  contraindicated  during  pregnancy.  Based  on  its  mechanism  of  action, 131 Iomburtamab  may  cause  foetal  harm  when  administered  to  a  pregnant  woman,  and  monoclonal antibodies are known to be transported across the placental barrier. There are no data from the use of 131 I-omburtamab in pregnant women. No animal reproductive toxicology studies of  131 I-omburtamab have been conducted.

<div style=\"page-break-after: always\"></div>

Breast-feeding should be discontinued during treatment with  131 I-omburtamab and for 1.5 months after end of treatment. It is unknown whether  131 I-omburtamab is excreted in breast milk. A risk to the newborns/infants cannot be excluded.

## Overdose

131 I-omburtamab must be used by authorised personnel in a hospital setting. The risk of overdose is therefore theoretical.

In  the  event  of  administration  of  a  radiation  overdose,  the  absorbed  dose  to  the  patient  should  be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition and by forced diuresis and frequent bladder voiding. Additionally, blockade of the thyroid gland is recommended (e.g., with potassium perchlorate) in order to reduce the radiation exposure of the thyroid gland.

## Drug Abuse

131 I-omburtamab abuse was not formally studied in clinical or nonclinical investigations.

131 I-omburtamab is administered by qualified healthcare professionals and is not for in-home use.

There  have  been  no  reports  of  drug  abuse  for  131 I-omburtamab.  The  risk  abuse  potential  for  131 Iomburtamab is considered low.

## Withdrawal and Rebound

Y-mAbs did not formally evaluate the effect of  131 I-omburtamab on withdrawal and rebound effects.

## Effects on Ability to Drive or Operate Machinery or Impairment of Mental Ability

It is considered unlikely that  131 I-omburtamab will affect a patient's ability to drive or to use machines; however, the patient's general condition and the possible side effects to treatment must be taken into account to assess this ability before driving or using machines.

## 2.2.8.6. Immunological events

As of the cut-off date for this MAA, no immunogenicity assessments have been conducted during the clinical programme.

Trial 101 was amended to collect samples for immunogenicity detection, and evaluation of immunogenicity is a secondary objective of the trial. Results from a to be developed assay will enable an investigation if there is any effect of  131 I-omburtamab antidrug antibodies on PK and safety and these analyses will be provided in the final CSR for Trial 101.

## 2.2.8.7. Adverse drug reactions

Information on Adverse Drug Reactions were provided with the responses. The methodology is described as causality assessment for each PT including an evaluation of potential biological plausible mechanism, potential temporal relationship, and established class effects. The assessment was performed by the sponsors safety and medical experts and were based on all reported AEs for  131 Iomburtamab (all doses) regardless of investigator assessment of investigational medicinal product (IMP) relationship. ADR calculation of frequencies is based on all TEAEs, which is acceptable as regards the heavily-pretreated patient population.

<div style=\"page-break-after: always\"></div>

## 2.2.8.8. Safety related to drug-drug interactions and other interactions

No drug-drug interaction studies have been conducted with  131 I-omburtamab. It is recommended that live vaccines are not given concurrently with  131 I-omburtamab.

## 2.2.8.9. Discontinuation due to adverse events

## Adverse Events Leading to Discontinuation

## Trial 03-133

Treatment-emergent adverse events that led to discontinuation of  131 I-omburtamab are summarised in Table 59. 11/109 (10.1%) subjects reported at least one TEAE leading to discontinuation of  131 Iomburtamab.

Table 59. Summary of Treatment Emergent Adverse Events Leading to Discontinuation of Study Treatment

Source: CSR 03-133 Table 14.3.1.32

| System Organ Class Prefered Temm                                    | c50mCi (N=10) [n(%)]. #events   | 50 mCi (N=94) [n(%)], Hevents   | >50mCi (N=5) [n(%)], #events _ [n(%o)]. #events   | All Subjects (N=109)   |
|---------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------------------------|------------------------|
| Number of TEAFs leading to discontinuation                          | 3                               | 7                               |                                                   | 12                     |
| Subjects with at least one TEAE leading to discontinuation          | 2 (20.0). 3                     | 7 (7.4).7                       | 2 (40.0). 2                                       | 11 (10.1). 12          |
| Blood and lymphatic system disorders Immune thrombocytopenicpurpura | 1 (10.0). 1 1 (10.0), 1         | 0 0                             | 0 0                                               | 1 (0.9). 1 1(0.9). 1   |
| Injury, poisoning and procedural complications                      | 0                               | 3 (3.2).3                       | 0                                                 | 3 (2.8), 3             |
| Meningitis chenical                                                 | 0                               | 3 (3.2). 3                      | 0                                                 | 3 (2.8). 3             |
| Investigations                                                      | 2 (20.0).2                      | 4 (4.3).4                       | 2 (40.0).2                                        | 8 (73).8               |
| Platelet coumt decreased                                            | 2 (20.0).2                      | 4(4.3).4                        | 2 (40.0).2                                        | 8(73).8                |

%-Percentage of subjects; N-Number of subjects.

Note: Adverse events (AEs) are coded using MedDRA v20.1. Frequencies in system organ class (SOC) and preferred term (PT) rows are numbers of subjects who experienced at least one AE in that SOC or PT. Subjects who experienced more than one AE in a given SOC or PT were counted only once for that particular SOC or PT.

## Trial 101

Treatment-emergent adverse events that led to the discontinuation of  131 I-omburtamab are summarised in Table 60.

<div style=\"page-break-after: always\"></div>

Table 61. Treatment-Emergent Adverse Events Leading to Discontinuation of  131 IOmburtamab Treatment by System Organ Class and preferred Term.

| System Organ Class Preferred Term                    | 13lI-omburtamab N (%) E   |
|------------------------------------------------------|---------------------------|
| Safety Analysis Set                                  | 32                        |
| Anyadverseeventleadingtodiscontinuationfromtreatment | 6 (18.8) 7                |
| Investigations                                       | 5 (15.6) 6                |
| Platelet count decreased                             | 5 (15.6) 5                |
| Lymphocyte count decreased                           | 1 (3.1) 1                 |
| Injury,Poisoningand Procedural Complications         | 1 (3.1)1                  |
| Meningilis chemical                                  | 1 (3.1)1                  |

Source: Table 14.3.1.11 and Listing 14.3.2.6.

N:Number of subjects:%:Percentage of subjects.E:Number ofevents.A treatment emergent adversc event is defined as an AE with onset at or after administration of infusion of II-omburtamab. The summary does not include non-serious adverse events that occurred more than 21+2 days after last treatment.

According to Table 61, 6/32 (18.8%) discontinued  131 I-omburtamab due to 7 TEAEs. Six of these seven TEAEs  were  consistent  with  myelosuppression  with  the  most  frequent  TEAE  being  'platelet  count decreased'.  In  addition  to  the  myelosuppression  events,  an  event  of  chemical  meningitis  led  to discontinuation of study drug of one enrolled subject.

28 SAF subjects were documented as having discontinued treatment due to an intervening circumstance. For the SAF, progressive disease (12 subjects [11.0%]) and Other (11 subjects [10.1%]) accounted for the  highest  number  of  reasons  for  discontinuing  treatment.  4  SAF  subjects  (3.7%)  discontinued treatment due to excessive toxicity. The Other reasons were low platelets with or without low neutrophils (6  subjects  [5.5%]),  medical  events  that  required  treatment  cessation  (3  subjects  [2.8%]),  or investigator discretion for other treatments (2 subjects [1.8%]).

The majority of non-neuroblastoma analysis set (NNAS) subjects received a 50 mCi treatment dose (23 subjects [62.2%]. Of the 37 NNAS subjects, 13 were categorised in the clinical database as having completed treatment as of the data cut-off date. Progressive disease (11 subjects [29.7%]) was the most frequently documented reason for discontinuing treatment. One subject (2.7%) ended treatment due to excessive toxicity, and one subject (2.7%) ended treatment due to a reason in the category of Other.

## 2.2.8.10. Post marketing experience

There are no post-marketing data for  131 I-omburtamab.

## 2.2.9. Discussion on clinical safety

The heterogenous nature and quality of the safety data was discussed in the Pre-submission meeting with Rapporteur teams on 23 November 2020. The MAA acknowledged that: ' Trials 03-133 and 101 have been initiated and conducted at different time periods. Therefore inevitably, there are differences in trial design, data capturing, and procedures between the two trials .' The Rapporteur team agreed with the presented strategy not to pool the clinical safety data from Trial 03-133 and Trial 101 for the MAA and that any similarities and differences across studies would be discussed as side-by-side comparisons.

<div style=\"page-break-after: always\"></div>

## Study population and exposure

Safety data were collected in two ongoing open-label, single-arm trials 03-133 and 101. The applicant initially presented interim report data of 109 and 24 paediatric neuroblastoma subjects, respectively, with CNS/LM metastasis expressing B7-H3 (CD276). An updated clinical interim report of study 101 with cut-off date June 2021 was submitted with the responses. Supportive serious adverse event data come from 37 paediatric non-neuroblastoma patients (03-133). The safety analysis population (SAF) of trial 03-133 consists of 109 enrolled neuroblastoma patients and the SAF of trial 101 includes all enrolled subjects who received at least one dose of  131 I-omburtamab.

Subjects in both Trial 03-133 and Trial 101 had received various types of prior treatments. In both trials, the  majority  had  received  a  combination  of  surgery,  chemotherapy,  irradiation  and  ASCT,  thus constituting a heavily pre-treated population. In the period between relapse and before initiation of  131 Iomburtamab administration, the same treatments with similar frequencies were applied suggesting that all available treatment options were exhausted.

Trial 03-133 employed a two-part dosing regimen: In Part 1 (dose-escalation part) patients received an icv infusion of  131 I-omburtamab ranging from 10 to 80 mCi administered at week 2 by icv infusion preceded by a 2 mCi  124 I-omburtamab or  131 I-omburtamab dosimetry dose of 2mCi. In part 2 (cohort expansion part) all subjects were treated at 50 mCi icv at week 2 and 7, also preceded by a 2 mCi  124 Iomburtamab or  131 I-omburtamab. This Part 2 dosing regimen was also applied in trial 101 and is the intended posology for the claimed indication. Age-dependent dose reductions were performed for infants.

In trial 03-133, the mean exposure was lower than in trial 101; patients had fewer treatment cycles and a lower mean dosage (70 vs. 75.4 mCi).

## Treatment-emergent Adverse Events

In  both  trials,  almost  every  patient  experienced  treatment-emergent  as  well  as  treatment-related adverse events across all administered doses, and the majority had events ≥Grade 3. Serious adverse events were common, and about a third had treatment-related serious adverse events.

In trial 03-133 ,  most study subjects experienced TEAEs in SOCs Investigations (71.6%), Blood and lymphatic  system  disorders  (66.1%),  Gastrointestinal  disorders  (55.0%),  Respiratory,  thoracic  and mediastinal disorders (37.6%) and Nervous system disorders (33%).

The most frequent PTs were lymphopenia (64.2%), platelet count decreased (54.1%), and WBC count decreased  (46.8%),  suggesting  a  myelosuppressive  side  effect,  an  anticipated  risk  of  omburtamab treatment. Moreover, vomiting was reported by 34.9% and Headache by 24.8% as central nervous secondary effects . 69.2% of all TEAEs were ≥CTCAE Grade 3/4 with a similar distribution across SOCs as listed above. Grade 4 TEAEs were of similar quality, furthermore myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) were diagnosed in 2.8% and 1.8% of the patients, respectively. TEAE intensity seemingly increased with doses &gt;50 mCi, however, in this dose group only 5 patients were included limiting significance of the results, thus, a treatment-by-subgroup effect is difficult to identify.

Throughout trial  101 ,  most  TEAEs  were  reported  in  SOCs  Investigations  (87.5%),  Gastrointestinal disorders (50.0%), Respiratory, thoracic and mediastinal disorders (50%), Nervous system disorders (45.8%),  and  General  disorders  and  administration  site  conditions  (45.8%).  The  most  frequently reported  PTs  were  platelet  count  decreased  (62.5%),  WBC  count  decreased  (50.0%),  lymphocyte

<div style=\"page-break-after: always\"></div>

decreased (41.7%), neutrophil count decreased (37.5%), and anaemia (33.3%), Nausea (33.3%), and Headache (33.3%). Thus, results were relatively similar across both studies.

Based  on  the  listing  of  concomitant  therapies  and  procedures,  only  one  patient  had  simultaneous radiotherapy and two concomitant chemotherapies, thus, it is likely that these observed effects were related to the IMP itself and to the extensive pre-trial treatments, respectively. Due to the lack of control groups, it is doubtful if any further data can substantially improve the understanding of whether pre-trial treatments  or  131 I-omburtamab  are  causing  the  adverse  reactions.  The  3-week  treatment  wash-out period  implemented  in  both  trials  hardly  excludes  pre-trial  treatments  as  causally  involved  in  the myelosuppression and its consequences.

The most frequently reported related TEAE was cytopenia with a similar incidence in both trials. Infusionrelated TEAEs were reported in about half of the patient population in both studies. Several cases with chemical  meningitis  occurred  throughout  both  studies,  an  adverse  reaction  already  known  to  be associated with intracerebroventricular injections.

## Serious Adverse Events

Proportions of patients that experienced SAEs were similar in both trials (48.6% vs. 41.7%), treatmentrelated SAEs had 32.1% vs. 41%, respectively. The SAE profile was broadly similar in studies 03-133 and  101,  and  as  described  above,  most  TEAEs  were  reported  in  SOC  Investigations  due  to myelosuppression and elevated liver enzymes. Apart from SOC Investigations, no specific SAE cluster is evident.

In trial 101 further SAEs were reported, i.e. lymphocyte count decreased, intracranial haemorrhage, and lymphopenia. One patient died due to intracranial haemorrhage. The cause is difficult to identify based on  the  narratives  and  may  have  been  associated  with  disease  progression  or  the  concurrent thrombocytopenia.

## Adverse Events of Special Interest

Only for trial 101 AESIs were predefined including myelosuppression ≥ Grade 4, liver and neurotoxicities ≥ Grade 3, device related infections, chemical meningitis, and worsening of performance test. These data were supplemented by investigations of AEs by organ systems for both trial 03-133 and 101 including general signs of myelosuppression, liver and neurotoxicities, thyroid suppression, anaphylactic reactions, secondary malignancies, infections and haemorrhage.

As described above, AESI associated with myelosuppression prevailed in both trials affecting all three haematopoietic cell lines. It is known that ionizing radiation impairs haematopoiesis, inter alia, through dose-dependent declines in circulating haematopoietic cells caused by reduced bone marrow production, redistribution and apoptosis of mature cells, in some cases resulting in leukaemia as long-term effect.

Secondary malignancies were reported for 5.5% of the patients in trial 03-133, 6 patients developed MDS (one of these was fatal after five years) and 4 AML and at least 3 cases were assessed as possibly related  to  omburtamab.  No  cases  occurred  in  trial  101.  Every  third  patient  had  TEAEs  related  to haemorrhage,  most  likely  due  to  decreased  platelet  counts,  and  2  cases  of  serious  haemorrhage occurred. A potential relationship between myelosuppression and infections cannot be ruled out, however the frequenc y of infections ≥Grade 3 was relatively low. Neurotoxic effects were common in both trials. Hepatic toxicities occurred in some patients without associated TEAEs.

The applicant  referred  to  earlier  studies  assessing  the  safety  and  complication  rate  associated  with ventricular access devices in patients receiving compartmental intraventricular radioimmunotherapy and concluded that minimal acute complications are observed, and long-term complications are rare.

Intracerebroventricular route of administration appears to be a safe and well-tolerated method of longterm drug delivery in both paediatric and adult patients. It is acknowledged that no short-term dose-

<div style=\"page-break-after: always\"></div>

limiting toxicities were reported. Long-term effects could not have been investigated. In addition, the safety  of  the  medical  device  used  seems  well  documented  (low  complication  rate,  low  long  -  term complications). Based on submitted data, the variability in the rates of Ommaya reservoir non-infectious complications is influenced by the improved neuroguidance for placement of an ICV device.

## Laboratory findings/Vital signs

The laboratory abnormalities recorded throughout the studies are consistent with the clinical condition of the patient population and treatment effects. No additional safety concern has been identified by analysing laboratory parameters, however, the assessment of related harmful therapeutic effects is only possible with restrictions as this population is heavily pre-treated and no comparative, but concomitant treatment was administered. Data on vital signs need to be prepared and presented differently.

## Immunogenicity

No immunogenicity results are hitherto available. In trial 03-133, two patients experienced each ≥Grade 3 and ≥Grade 4 Hypersensitivity assessed in both cases as related. However, causality assessment is hampered by the fact that immunogenicity detection is only part of ongoing trial 101.

## Discontinuation due to TEAEs

In study 03-133, the AEs leading to treatment discontinuation in 10 patients were decreases in platelet count (8/109 subjects; 7.3%), chemical meningitis (3/109 subjects; 2.8%), and immune thrombocytopenic purpura (1/109 subjects; 0.9%).

In study 101 a third of the study subjects discontinued omburtamab treatment. Decreased platelet count was the only TEAE leading to withdrawal that occurred in 7/24 (29.2%) patients, all other TEAEs were reported for single patient only.

Safety results included in the submitted updated interim report of clinical trial 101 are consistent with those of the primary safety analysis.

Long-term post-marketing safety data with a specific focus on neurocognitive adverse effects are deemed important  as  the  drug  has  potential  curative  intent.  Assessment  of  the  long-term  safety  of 131 IOmburtamab was not planned in both studies, however, some data on neurocognitive function will be available  when  trial  101  will  have  been  finalised.  The  inclusion  of  'long-term  safety  including neurocognitive development' as Missing Information in the Summary of Safety Concerns of the RMP was proposed by the applicant and is endorsed.

In conclusion, myelosuppression is an important identified risk, and the proposed PI provides advice regarding  suspension  of  treatment  until  acceptable  blood  counts  return.  Chemical  meningitis  is  an important identified risk, and the proposed PI provides advice regarding monitoring, pre-treatment with dexamethasone and permanent discontinuation in patients experiencing this adverse reaction. Adverse events related to hepatic toxicity were based solely on laboratory values; there were no clinical signs of impaired hepatic function. If a patient shows hepatic toxicity, it is recommended to suspend or delay the administration until toxicities return to acceptable levels. Neurotoxicity was observed in a small number of children; patients experiencing neurotoxicity CTCAE grade 4 should be permanently discontinued from the  treatment.  Thyroid  suppression  is  a  potential  risk  with 131 I-omburtamab  due  to  the  effects  of radioactive iodine on the thyroid. The risk is mitigated by treating all subjects with thyroid-blocking agents from one week before treatment until two weeks after the last therapeutic dose.  131 I-omburtamab may cause serious infusion reactions. In order to mitigate the risk of such reactions, the patient should prophylactically  be  given  dexamethasone  (or  equivalent)  and  an  oral  antihistamine,  moreover  131 Iomburtamab should be permanently discontinued in patients who develop serious infusion reactions including  CTCAE  Grade  3  or  higher  anaphylaxis.  Increased  susceptibility  to  infections  can  occur  in patients with myelosuppression. Thus, blood counts should be monitored in order to mitigate the risk of

<div style=\"page-break-after: always\"></div>

infections  as  stated  in  the  Product  Information.  Due  to  radiation  exposure  to  bone  marrow,  serious haemorrhage  is  a  potential  risk  with 131 I-omburtamab  due  to  low  platelet  counts.  In  the  Product Information, patients are advised to seek immediate medical attention if unexpected bleeding or other signs develop.

Due to the radioactive properties of the product,  131 I-omburtamab is only to be handled and administered by specialised health care professionals.

## 2.2.10. Conclusions on the clinical safety

Most  frequently  reported  related  TEAEs  were  consistent  with  myelosuppression,  neurotoxicity  and infusion  related  reactions.  Respective  risk-mitigation  measures  have  been  reflected  in  the  proposed Product Information. The summary of safety concerns in the RMP was amended accordingly.

Overall, the heterogeneous nature and quality of safety data issuing from differences in trial designs, data capturing, and procedures between the two trials render a comparison of safety results difficult. The  single-arm  designs  including  limited  patient  numbers  as  well  as  the  considerable  number  of treatment discontinuations impede the evaluation of the safety profile, especially in light of the fact that comparable treatments are lacking.

Long-term post-marketing safety data with a specific focus on neurocognitive adverse effects are deemed important  as  the  drug  has  potential  curative  intent.  Considering  the  unmet  medical  need,  a  postauthorisation study would be warranted (see section 2.3 Risk Management Plan). However, similar to the pivotal single arm trial the interpretation of data from a post-authorisation study would be challenging if the product is used as a second line treatment in patients having been exposed to first line treatments (radiation and cytotoxic drugs). Thus, only a study of infusion related reactions may be possible but considering the indication, it is questionable if this safety concern can be classified as important. Without controls only severe toxicities would be detected whereas mild ones would probably go undetected. However, even under the given circumstances, every effort should be made to characterise the safety profile as precisely as possible.

Safety data from this heavily pre-treated patient population were collected in the context of two openlabel and single-arm trials yielding data that are difficult to interpret. However, the described uncertainties related to data acquisition and interpretation may be tolerable if the efficacy of the product could have been clearly demonstrated.

The CHMP considers the following measures would be necessary to address issues related to safety:

A long-term, observational cohort study of children with neuroblastoma who are new users of Omblastys following other central nervous system (CNS)- directed multi-modal therapy for the treatment of CNS/leptomeningeal (LM) metastasis in the real-world setting.

## 2.3. Risk Management Plan

## 2.3.1. Safety concerns

Table SVIII.1: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns   |
|------------------------------|------------------------------|
| Important identified risks   | None                         |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                       |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | • Myelosuppression and prolonged cytopenia • Chemical meningitis. • Secondary malignancies                                                                                                                                       |
| Missing information          | • Use in patients who have received systemic chemotherapy and/or cranial or spinal irradiation less than 3 weeks prior to the start of the treatment. • Immunogenicity. • Long-term safety including neurocognitive development. |

## 2.3.2. Pharmacovigilance plan

Table Part III.3: On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                                                               | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                          | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                          | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                       | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Voluntary PASS                                                                                                                                                                                                             | A long-term, observational cohort study of children with neuroblastoma who are new users of Omblastys following other central nervous system (CNS)- directed multi-modal therapy for the treatment of CNS/leptomeningeal (LM) metastasis in the real-world setting. | Myelosuppression and prolonged cytopenia (and potentially associated (non- opportunistic infections and bleeds), Chemical meningitis Secondary malignancies                                                                | To be determined                                                                                                                                                                                                           | To be determine d                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 2.3.3. Risk minimisation measures

Table 62 Part V.3: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                           | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                        |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Important Potential Risks                                                                                                                                                           |
| Myelosuppression and prolonged cytopenia | Routine risk minimization measures: SmPC section 4.2 and 4.4 PL section 2 and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: • SmPC Section 4.2 and 4.4 and PL Section 3 where requirements are given for haematology tests before each administration and every week for four weeks after administration. • SmPC section 4.2 where criteria are given for dose modification based on haematology test results. • SmPC section 4.4 informing that severe myelosuppression may be treated with transfusions or growth factors in accordance with local medical practice. • SmPC section 4.4 instructing to withhold initial treatment or delay second treatment with Omblastys in patients with a grade 4 infection. PL Section 2 which informs patients to tell the doctor if having a life- threatening infection. • PL Section 2 which informs patients to immediately tell the doctor if experiencing | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing follow-up questionnaire. Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern      | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     | unexpected bleedings or severe headache. Additional risk minimization measures: None Legal status: Medicinal product subject to restricted medical prescription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                    |
| Chemical meningitis | Routine risk minimization measures: SmPC section 4.4 and 4.4 PL section 2 Routine risk minimisation activities recommending specific clinical measures to address the risk: • SmPC Section 4.2 and 4.4 where pre-medication with dexamethasone is described. • SmPC Section 4.2 where instruction is given to permanently discontinue Omblastys in event of chemical meningitis. • SmPC Section 4.4 where instructions are given to monitor blood counts and to not initiate or resume Omblastys until lab values are at acceptable ranges. • PL Section 2 which informs patients about early signs and symptoms of chemical meningitis and to | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing follow-up questionnaire Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern         | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                        |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        | immediately tell the doctor if such occur. Additional risk minimization measures: None Legal status: Medicinal product subject to restricted medical prescription                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                     |
| Secondary malignancies | Routine risk minimization measures: SmPC section 4.2 and 4.4 PL section 2 and 4 Routine risk minimisation activities recommending specific clinical measures to address the risk: SmPC Section 4.2 and 4.4 and PL Section 3 where treatment with potassium iodide and liothyronine sodium prior to and after Omblastys administration is described. • SmPC Section 4.4 where it is described that it must be ensured that the risks of the radiation exposure are less than the risks from the disease itself, especially for patients having received prior radiation/chemotherapy. Additional risk minimization measures: None Legal status: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing follow-up questionnaire. Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                                     | Risk minimisation measures                                                                                                                                                               | Pharmacovigilance activities                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                    | Medicinal product subject to restricted medical prescription                                                                                                                             |                                                                                                                                                  |
| Missing Information                                                                                                                                | Missing Information                                                                                                                                                                      | Missing Information                                                                                                                              |
| Use in patients who have received systemic chemotherapy and/or cranial or spinal irradiation less than 3 weeks prior to the start of the treatment | Routine risk minimization measures: SmPC section 4.4 PL section 2 Additional risk minimization measures: None Legal status: Medicinal product subject to restricted medical prescription | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Immunogenicity                                                                                                                                     | Routine risk minimization measures: SmPC section 4.4 Additional risk minimization measures: None Legal status: Medicinal product subject to restricted medical prescription              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Long-term safety including neurocognitive development                                                                                              | Routine risk minimization measures: None                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                               |

<div style=\"page-break-after: always\"></div>

| Risk minimisation measures              | Pharmacovigilance activities             |
|-----------------------------------------|------------------------------------------|
| Legal status: Medicinal product subject | Additional pharmacovigilance activities: |
| to restricted medical prescription      | None                                     |

## 2.3.4. Conclusion

The CHMP, having considered the data submitted in the application was of the opinion that due to the concerns identified with this application, the risk management plan cannot be agreed at this stage.

## 2.4. Pharmacovigilance

## 2.4.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.4.2. Periodic Safety Update Reports submission requirements

Not applicable

## 2.5. Product information

In light of the negative recommendation, a satisfactory summary of product characteristics, labelling and package leaflet cannot be agreed at this stage.

## 2.5.1. User consultation

In light of the negative recommendation, a satisfactory package leaflet cannot be agreed at this stage, therefore no user testing consultation has been assessed.

## 2.5.2. Labelling exemptions

A request of translation exemption of the labelling as per Art.63.1 of Directive 2001/83/EC has been submitted by the applicant and has been found acceptable by the QRD Group for the following reasons:

The Group accepted the proposed translation exemption to have English-only outer carton and vial label.

However, the Group didn't reach an agreement on the proposed translation exemption of the package leaflet.  Therefore,  the  applicant  is  requested  to  liaise  with  the  NCAs  to  discuss  requirements  and

<div style=\"page-break-after: always\"></div>

alternatives at national level. The applicant should explore the feasibility of including a QR code on the package leaflet to provide information in all EU official languages. Alternatively, a printed package leaflet in national language could be distributed alongside the supplies of the product, under the responsibility of the MAH.

The labelling subject to translation exemption as per the QRD Group decision above will however be translated in all languages in the Annexes published with the EPAR on EMA website, but the printed materials will only be translated in the language(s) as agreed by the QRD Group.

## 2.5.3. Additional monitoring

Not Applicable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The initially  sought  indication  for  131 I-omburtamab  is  'OMBLASTYS  is  indicated  for  the  treatment  of neuroblastoma with central nervous system (CNS)/leptomeningeal (LM) metastasis.'

Neuroblastoma is a rare paediatric cancer and is the most common extra-cranial solid tumour cancer in children. High-risk neuroblastoma is a life-threatening disease that is associated with poor long-term survival. For high-risk patients, 5-year overall survival (OS) rates have improved during the last two decades but are still below 50%.

Neuroblastoma  with  CNS/LM  metastasis  is  neuroblastoma  that  at  initial  staging  or  at  relapse,  has metastasised to the brain parenchyma and/or the leptomeninges. The clinical presentation of CNS/LM neuroblastoma  is  dependent  on  the  location  and  nature  of  the  lesion.  The  diagnosis  of  CNS/LM neuroblastoma is based on clinical symptoms and imaging.

## 3.1.2. Available therapies and unmet medical need

Surgery, chemotherapy, immunotherapy, differentiation therapy and radiotherapy techniques for newly diagnosed  patients  have  improved  the  prognosis  of  patients  with  stage  4,  high-risk  neuroblastoma. However,  recurrent  disease  occurs  in  many  patients  with  high-risk  neuroblastoma,  and  CNS/LM metastasis primarily occurs in the relapsed or recurrent setting.

Various treatment combinations comprise one or more of the following standard options for metastatic CNS/LM neuroblastoma, all with the aim of reducing symptoms, but with modest chance of cure:

- -Surgical debulking of tumour when feasible prior to irradiation, to reduce symptoms, oedema, and haemorrhage, or to correct cerebrospinal fluid (CSF) flow.
- -Focal, whole brain irradiation, or craniospinal irradiation (where feasible) to alleviate symptoms, obtain disease control, and correct CSF flow in cases of obstruction.
- -Systemic combination chemotherapy (e.g., irinotecan plus temozolomide).
- -Myeloablative therapy and stem cell transplantation.

Data obtained from the Central German Childhood Cancer Registry (CGCCR) which include the majority of neuroblastoma patients enrolled in clinical trials in Germany, show that the treatment modalities for CNS/LM neuroblastoma are not uniform, even on a nationwide level in Germany.

Currently there are no approved medicinal products for the treatment of neuroblastoma metastasised to the CNS/LM. There exists an unmet medical need for these patients as the prognosis with available therapies is still unsatisfactory. The current aim of treatment is prolongation of survival.

## 3.1.3. Main clinical studies

The  application  is  mainly  based  on  trial  03-133.  This  single  arm  trial  recruited  patients  with  a histologically-confirmed diagnosis of an omburtamab-reactive-malignancy with CNS/LM disease but the majority of patients had relapsed neuroblastoma with CNS/LM disease (n=109). The majority of patients received a total dose of 1850 MBq in one or two doses.

Trial 101 is a smaller trial in neuroblastoma with CNS/LM disease that is considered supportive (n=50).

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

The most important favourable effect to consider is the 3-year OS rate that is derived from the trial 03133. The 3-year OS rate (KM estimate) for the FAS was 0.56 (95%CI 0.46, 0.65). The median survival is estimated as 50 months (95% CI 27.4, not estimable).

Supportive information can be derived from the 12-month CNS/LM PFS rate. This is estimated as 0.59 (95%CI 0.48, 0.68).

To further support the conclusion of efficacy a propensity score model was developed. Using this model to compare OS in the trial population to the selected external control a final HR of 0.58 (95%CI: 0.31, 1.09) was derived.

In the supportive trial 7 objective responses have been observed resulting in an ORR of 35% if only patients with measurable disease at baseline (n=20) are used as the denominator.

## 3.3. Uncertainties and limitations about favourable effects

Data for efficacy are derived from an exploratory trial without pre-specified hypothesis or analysis plan. The trial was subject to many modifications. The supportive trial is too small to allow conclusions. There is no confirmatory element to the clinical development plan.

The chosen endpoints (landmark analyses of time related endpoints, e.g., 3-year OS rate, 12-month CNS/LM PFS) are unsuited to establish efficacy in single arm trials. Analysis and comparison to controls is indispensable in a complex disease with complex, non-standardised treatments. The tumour response to treatment was not analysed in the main dataset from trial 03-133.

As this was a single centre trial, many patients were referred after additional unspecified/non-explicit selection in the referring centres. The process that led to selection and referral of patients is unknown. Aside from selection bias, this also has impact on the external validity of the results.

Patients received additional treatments (irradiation, chemotherapy, surgery) in varying combinations and the impact of the different treatments on the endpoints cannot be differentiated. The population is heterogenous, also with respect to the presence or absence of CNS/LM disease at baseline, i.e., prior to the administration of the experimental therapy.

The population was selected based on clinical course and presence of stable disease. Comparison to an external control emphasised differences in treatments administered to patients prior to the administration of the experimental treatment. The performed comparison of OS between patients from trial 03-133 and the external CGCCR patients show important differences in the shape of the KM-plots that are not compatible with a treatment effect but point to prognostically distinct populations and an immortal time bias.

The use of subgroups from external controls to make the results comparable with the finalised study 03133 raise serious issues on the reliability of the results and their clinical relevance. In order to further explore the data and enable the use of the collected time-related endpoint a propensity score method was used. The employed advanced statistical methods do not allow the establishment of efficacy as they cannot address the fundamental uncertainties related to selection and unmeasured confounding. In any case,  even  despite  this  major  effort  in  the  development  of  the  model  the  obtained  results  are  not considered compelling.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

In  the  two  studies  03-133  and  101,  respectively,  using  the  recommended dosing  regimen  with ICV administration of  131 I-Omburtamab almost every patient (93.6%* and 100%) experienced treatmentemergent  adverse  events  (TEAEs).  The  most  frequent  TEAEs  were  cytopenia  such  as  decreased lymphocyte, platelet, WBC, and neutrophil count, as well as decreased haemoglobin, consistent with myelosuppression.  Further  frequently  reported  TEAEs  were  vomiting,  nausea,  cough,  headache  and pyrexia.

As to AESI, hepatic toxicities were experienced by 7.3% and 4.2% of patients, respectively for each of the two studies. Serious adverse events (SAEs) included elevated liver enzymes. Secondary malignancies were reported for 5.5% and 0% of patients respectively; overall, 6 patients developed MDS and 4 AML and at least 3 cases were assessed as possibly related to omburtamab. 6.4% and 12.5% of patients, respectively had symptoms of neurotoxicity such as seizures (2 were SAEs), meningitis (3/4 were SAEs) and sensory neuropathy. Worsening of performance was noted in 20.8% of the patients in trial 101. Overall,  18.3%  and  20.8%  reported  infections  in  each  of  the  two  studies,  6  patients  experienced unrelated serious infections and 3 thereof had reduced WBC. 29.4% and 33.3% of patients, respectively for each of the two studies, had TEAEs related to haemorrhage, and 2 cases of serious haemorrhage occurred (see above, 1 presented with serious thrombocytopenic purpura. Pooled data of both trials yielded a frequency of 2.3% for ≥Grade 3 haemorrhage.

Most patients (84.4% and 87.5% respectively for each of the two studies) experienced at least one severe (grade 3/4) AE. The most frequent severe AEs were related to myelosuppression, moreover, patients had elevated liver enzymes and some developed myelodysplastic syndrome and acute myeloid leukaemia.

SAEs were experienced by 48.6% and 47.7% of patients respectively for each of the two studies; the vast  majority  of  the  SAEs  was  assessed  as  treatment-related.  Most  TEAEs  were  reported  in  SOC Investigations due to myelosuppression and elevated liver enzymes. Apart from SOC Investigations, no specific SAE cluster is evident. As to PTs, reported SAEs for &gt;2 patients were WBC/platelet/neutrophil count decreased, haemoglobin decreased, ALT increased, vomiting, MDS and chemical meningitis.

In the whole safety database 5 deaths occurred, 2 due to haemorrhagic events possibly related to  131 Iomburtamab; 3 were the result of disease progression.

25.7% and 33.3% of patients respectively for each of the two studies, discontinued the study drug due to TEAEs such as progressive disease, excessive toxicity, low platelets with or without low neutrophils, medical events that required treatment cessation or investigator discretion for other treatments.

Data on long-term effects assessing the safety and complication rate associated with ventricular access devices in patients receiving compartmental intraventricular radioimmunotherapy are missing.

## 3.5. Uncertainties and limitations about unfavourable effects

The methodological issues described under 'uncertainties and limitations about favourable effects' also affect the data validity and interpretability of the safety profile.

The size of the safety database is currently limited with many withdrawals in both studies. As Study 101 is considered to have more prospective elements, this database could provide more reliable information, however,  effects  of  131 I-Omburtamab  treatment  cannot  be  determined  properly  on  the  basis  of  50 patients.

The  single-arm  trial  design  contributes  to  a  difficult  interpretation  of  safety  data  as  it  hampers conclusions on treatment-related AEs and especially the distinction between treatment-related TEAEs

<div style=\"page-break-after: always\"></div>

and disease-related events. Included patients seem not to have been standardised regarding the pretreatments and some patients received concomitant therapies which makes it difficult to disentangle side effects.

Lacking immunogenicity data hinder the characterisation of the safety profile as well as missing longterm safety data with a specific focus on neurocognitive and developmental adverse effects.

Inaccuracies relating to the data processing and presentation hamper the overall interpretation of the results. These findings lead to uncertainties on the safety profile, which is already difficult to determine in light of the fact that maximally 2 cycles in 6 weeks are administered in a heavily pre-treated patient population.

Thus, a full assessment of the safety profile is not possible.

## 3.6. EFFECTS Table

Table 63. Effects Table for  131 I-Omburtamab for the treatment of paediatric patients with central nervous system (CNS)/leptomeningeal metastasis from neuroblastoma (data cut-offs: 30 June 2019 for trial 03-133 and 01 June 2020 for trial 101).

| Effect                                      | Short Description                                  | Unit                              | Treatment 131 Omburta mab         | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                   | References                        |
|---------------------------------------------|----------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| Favourable Effects (study 03-133)           | Favourable Effects (study 03-133)                  | Favourable Effects (study 03-133) | Favourable Effects (study 03-133) | Favourable Effects (study 03-133)                                                                                                                                                                                                                                                                                                                                                                                     | Favourable Effects (study 03-133) |
| 3-year overall survival rate (trial 03-133) | KM estimate of OS rate three years after diagnosis |                                   | 0.56 95%CI (0.46, 0.65)           | Methodological: exploratory trial, single arm, no hypothesis, no pre- specified planning of data analysis; inherent difficulty to establish efficacy on the basis of time-related endpoint in single arm trial Data assessment: Selected population; external control not comparable with differing treatment intensity; possible immortal time bias; prior and concomitant treatments with possible effect on LM/PM. |                                   |

<div style=\"page-break-after: always\"></div>

| Effect                                         | Short Description                                            | Unit                 | Treatment 131 Omburta mab   | Uncertainties/ Strength of evidence                                           | References           |
|------------------------------------------------|--------------------------------------------------------------|----------------------|-----------------------------|-------------------------------------------------------------------------------|----------------------|
| 12month CNS/LM progressi on free survival rate | KM estimate of OS rate three years after diagnosis (FAS)     |                      | 0.59 (95% CI: 0.44, 0.68)   | See above, in addition magnitude of effect cannot be assessed without control |                      |
| Unfavourable Effects                           | Unfavourable Effects                                         | Unfavourable Effects | Unfavourable Effects        | Unfavourable Effects                                                          | Unfavourable Effects |
| TEAE                                           | Patients with at least 1 treatment- related TEAE of ≥Grade 3 | %                    | 81.7 1 83.3 2               | No control                                                                    |                      |
| TE-SAE                                         | At least 1 treatment- emergent serious AE                    | %                    | 48.6 1 41.7 2               | No control                                                                    |                      |
| Death                                          | TEAEs leading to death                                       | %                    | 1 1 4 2                     | No control                                                                    |                      |

Abbreviations: AE: Adverse event, TEAE: Treatment- emergent AE, SAE: Serious AE

Notes:  1 source: CSR 03-133,  2 source: CSR trial 101, 3: CSR 03-133, App.13.31, Pooled data

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

3-year OS rate is a clinically relevant endpoint as it could indicate longer term survival in patients with a malignant disease such as neuroblastoma. 12-month CNS/LM PFS is an unusual endpoint but could be accepted  in  these  specific  circumstances.  Nevertheless,  the  interpretation  of  OS  and  PFS  without  a comparator group is not possible. The original purpose of the pivotal study 03-133 was dose-finding and safety  of  an  experimental  targeted  radiotherapy.  From  a  confirmatory  perspective  the  insufficient planning and fundamental flaws in the trial design, the questionable choice of endpoints for the chosen single-arm trial, the changes in the conduct and the analysis while the trial was ongoing, are obvious concerns. The provided analyses to the external control cannot address the issues that were observed for the pivotal trial. Selection bias and confounders are likely to be present and comparability of the populations is not accepted.

Overall, the study design as well as the data processing of both trials prohibit any thorough assessment of the safety profile. The restricted sample size renders it difficult to detect rare adverse events, so nearly  every  treatment-emergent  adverse  event  is  considered  related  and  listed  as  adverse  drug reaction. Due to the relatively large number of treatment discontinuations the safety profile is difficult

<div style=\"page-break-after: always\"></div>

to characterise in an already small study population, even if it seems that 50% of TEAEs resolved in trial 101 (no information available as to trial 03-133). However, this aspect per se may be an expression of poor tolerance towards  131 I-omburtamab. Considering the dismal prognosis of the investigated study population, the described uncertainties related to data collection and interpretation could have been acceptable if the efficacy of the product was clearly demonstrated which is not the case with the data provided.  Taken  together,  more  prospective  and  unified  (long-term)  data  are  needed  to  provide meaningful results regarding the characterisation of a safety profile in the claimed indication. Currently, the quality of the data submitted merely enables a descriptive data interpretation.

## 3.7.2. Balance of benefits and risks

A favourable effect of  131 I-omburtamab has not been demonstrated and the safety profile cannot be sufficiently characterised for the reasons stated above. The benefit-risk balance of  131 I-Omburtamab is unfavourable.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

The overall benefit/risk balance of Omblastys is negative.

## 4. Recommendations

Based on the CHMP review of data on quality, safety and efficacy for Omblastys in the treatment of central nervous system (CNS)/leptomeningeal (LM) metastasis of neuroblastoma in patients, who have previously received CNS-directed multi-modal therapy for their disease, such as chemotherapy, surgery, or  radiation  therapy,  the  CHMP  considers  by  consensus  that the  safety  and  efficacy  of  the  abovementioned medicinal product is not sufficiently demonstrated, and, therefore recommends the refusal of the granting of the marketing authorisation  for Omblastys. The CHMP considers that:

- The trial design and subsequently conducted analyses do not allow to isolate a treatment effect that can be attributed to  131 I-omburtamab. In analyses of time related endpoints where trial data are compared to an external control in a post-hoc manner, it cannot be ascertained with reasonable certainty, that underlying prognosis in the respective groups is sufficiently similar. The response data  from  the  supportive  trial  are  not  considered  robust  enough  to  ameliorate  the  identified concerns concerning the pivotal data set. These concerns are based on confounding by additionally administered therapies and divergent imaging assessments.
- It should be noted that concerns remain regarding the stability of the  131 I-omburtamab drug product in  artificial  cerebrospinal  fluid  (aCSF)  as  well  as  human  plasma/human  serum.  Non-targeted delivery of  131 Iodine poses a risk to patient safety, therefore the stability of  131 I-omburtamab must be demonstrated.

Due  to  the  aforementioned  concerns  a  satisfactory  summary  of  product  characteristics,  labelling, package leaflet, pharmacovigilance system, risk management plan and post-authorisation measures to address other concerns as previously outlined in the list of outstanding issues cannot be agreed at this stage.

<div style=\"page-break-after: always\"></div>

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Omblastys is not similar to Qarziba within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## New active substance

Furthermore, following review of the available data in the context of the applicant's claim of new active substance status, the CHMP position at the time of this report is that  131 I omburtamab is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.